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   Man, he took his time in the sun 
   Had a dream to understand 
   A single grain of sand 
 
- from the Nightwish masterpiece 
The Greatest Show on Earth 
(lyrics by Tuomas Holopainen) 
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ABSTRACT 
Background and aims 
Polycystic ovary syndrome (PCOS) and type 1 diabetes are relatively common 
endocrinopathies, often manifesting across most of the lifespan. Cardiovascular risk is 
increased in both PCOS and type 1 diabetes, affecting patients’ quality of life and overall 
prognosis. Acute dynamic exercise is a widely used tool to examine an individual’s 
cardiovascular health. Particularly, peak pulmonary O2 uptake (V̇O2peak), measured 
during maximal incremental dynamic exercise and reflecting the highest achievable 
level of whole-body oxidative metabolism, is a strong and independent predictor of 
cardiovascular morbidity and mortality. This is because V̇O2 response to exercise 
consists of integrated serial steps of systemic O2 delivery (i.e., pulmonary function, 
cardiac pump function, blood O2 carrying capacity), peripheral O2 delivery (i.e., 
skeletal muscle blood flow), and peripheral O2 extraction and utilization (i.e., muscle 
O2 diffusion and metabolism). Early identification of potential disease-related 
derangements in these integrated organ systems would provide important information 
on clinical manifestations of PCOS and type 1 diabetes; however, studies examining the 
issue from the integrated perspective have been sparse. Little evidence also exists on 
effects of long-term exercise training on the signs of the derangements related to type 
1 diabetes. 
The aim of this thesis was to study O2 delivery and utilization during acute dynamic 
exercise in both healthy individuals and individuals with PCOS or type 1 diabetes. The 
adaptations induced by long-term exercise training were also examined in individuals 
with type 1 diabetes and compared with those in healthy individuals. Acute exercise 
was thus used as a physiological probe to identify early signs of cardiovascular 
dysfunction related to the disease states of PCOS and type 1 diabetes, whereas exercise 
training was employed to demonstrate whether it alleviates such early signs associated 
with type 1 diabetes. 
 
Subjects and methods 
Studies I-IV of this thesis belonged to a Canadian-Finnish research collaboration 
entitled “ARTEMIS – Innovation to Reduce Cardiovascular Complications of Diabetes 
at the Intersection of Discovery, Prevention and Knowledge Exchange”. Data on 22 
healthy adult men (Study I), 15 adult overweight or obese women with and 15 without 
PCOS (Study II), seven adult men with and 10 without type 1 diabetes (Study III), and 
eight adult men with and eight without type 1 diabetes (Study IV) were included in the 
final analyses. The groups of Studies II-IV were matched for age, anthropometry, and 
leisure-time physical activity (II, III) or baseline V̇O2peak (IV). Neither PCOS women 
(II) nor men with type 1 diabetes (III, IV) had clinically overt cardiovascular disease. 
The subjects performed either maximal incremental treadmill (I) or cycling (II-IV) 
exercise tests, and in Study IV the subjects did so both before and after a 1-year 
individualized exercise training intervention. Integrated data were collected during the 
exercise tests; alveolar gas exchange (volume turbine and mass spectrometry) (I-IV), 
arterial O2 saturation (pulse oximetry) (I-IV), heart rate (electrocardiography) (I-IV), 
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cardiac pump function (PhysioFlow impedance cardiography) (II, III), and active leg 
muscle deoxygenation (I, III, IV) and blood flow (III) (near-infrared spectroscopy 
[NIRS]), were monitored. In Study I, less active arm muscle and cerebral 
deoxygenation were also monitored (NIRS). In Study IV, peak O2 pulse was calculated 
to indirectly reflect cardiac pump function. Total hemoglobin mass (I) and blood 
volume (III) were also determined (carbon monoxide rebreathing method), and blood 
samples were drawn particularly to measure hemoglobin concentration (I-IV) and to 
evaluate glycemic control (glycosylated hemoglobin A1c) (III, IV). 
 
Results 
I: Deoxygenation profiles, reflecting local imbalance between O2 delivery and 
utilization, in the tissues of interest were linked to alveolar gas exchange (i.e., whole-
body) responses during maximal incremental treadmill exercise in healthy men. II: 
Reduced V̇O2peak, reduced peak systemic O2 extraction, and a pronounced cardiac 
response to increasing V̇O2 but otherwise intact systemic O2 delivery were observed in 
overweight and obese PCOS women. III: Reduced peak cardiac pump function, being 
associated with reduced blood volume, and independently deteriorated peak active leg 
muscle blood flow led to reduced V̇O2peak and were suggested to be associated with 
glycosylated hemoglobin A1c in men with type 1 diabetes. IV: The 1-year training 
intervention improved V̇O2peak and peak O2 pulse similarly in men with and without 
type 1 diabetes but had no effect on NIRS-derived local active muscle O2 extraction or 
glycosylated hemoglobin A1c in men with type 1 diabetes. In addition, consistent 
associations between training dose and responses were observed in healthy men but 
not in those with type 1 diabetes. 
 
Conclusions 
The findings of this thesis overall highlight the integrated nature of O2 delivery and 
utilization responses to acute dynamic exercise. The following conclusions on disease-
related early signs of cardiovascular dysfunction can be drawn: In women with excess 
weight, PCOS per se is linked to alterations in peripheral adjustments to acute dynamic 
exercise rather than to limitations of systemic O2 delivery. In type 1 diabetes, both 
systemic and peripheral cardiovascular impairments, being affected by glycemic 
control, limit O2 delivery during acute dynamic exercise. Furthermore,  regular exercise 
training improves V̇O2peak and probably cardiac pump function, and hence, improves 
the overall prognosis of cardiovascular morbidity in type 1 diabetes. However, exercise 
training, at least to the extent in Study IV, is not able to alleviate diabetes-related 
defects within active muscle microvasculature or to improve patients’ glycemic control. 
The lack of dose-response associations in men with type 1 diabetes may highlight the 
need for more individualized exercise regimens in individuals with type 1 diabetes. 
These conclusions lead future multi-disciplinary research to identify more detailed 
mechanisms behind, the clinical significance of, and treatment for the observed 
disease-specific early signs of cardiovascular dysfunction.  
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TIIVISTELMÄ (ABSTRACT IN FINNISH) 
Tausta ja tavoitteet 
Munasarjojen monirakkulaoireyhtymä (PCOS) ja tyypin 1 diabetes ovat yleisiä tauteja 
ja vaikuttavat potilaiden elämään usein koko elinkaaren ajan. Molempiin tauteihin 
liittyy kohonnut sydän- ja verenkiertoelimistön sairastavuuden riski, mikä vaikuttaa 
sekä potilaiden elämänlaatuun että ennusteeseen. Sydän- ja verenkiertoelimistön 
terveyden tutkimiseen yleisesti käytetty menetelmä on akuutti dynaaminen kuormitus; 
erityisesti maksimaalinen hapenottokyky (V̇O2peak), joka mitataan maksimaalisen 
portaittain nousevan dynaamisen kuormituksen aikana ja joka kuvaa koko kehon 
maksimaalista O2-kulutuskykyä, on sydän- ja verenkiertoelimistöön liittyvää 
sairastavuutta ja kuolleisuutta vahvasti ja itsenäisesti ennustava muuttuja. Näin siksi, 
että V̇O2peak muodostuu toisiinsa kokonaisvaltaisesti integroituneiden systeemisen O2-
jakelun (keuhkojen toiminta, sydämen pumppaustoiminta, veren O2-
kuljetuskapasiteetti), perifeerisen O2-jakelun (verenvirtaus luustolihaksissa) sekä 
perifeerisen O2-ekstraktion ja -käytön (O2-diffuusio ja -käyttö luustolihaksissa) 
yhteistyön tuloksena. Näihin hengitys-, sydän- ja verenkiertoelimistön osatekijöihin 
liittyvien tautikohtaisten häiriöiden varhainen tunnistaminen tarjoaisi tärkeää tietoa 
PCOS:n ja tyypin 1 diabeteksen kliinisten ilmentymien osalta; tutkimustieto 
kokonaisvaltaisesta näkökulmasta on tältä tieteen alueelta kuitenkin vähäistä. Myös 
pitkäaikaisen liikuntaharjoittelun vaikutuksia tyypin 1 diabetekseen liittyviin hengitys-
, sydän- ja verenkiertoelimistön häiriöihin on tutkittu vähän.  
Tämän tutkimuksen tavoitteena oli tutkia O2-jakelua ja -käyttöä akuutin 
dynaamisen kuormituksen aikana sekä terveillä henkilöillä että PCOS- ja tyypin 1 
diabetes -potilailla. Myös pitkäaikaisen liikuntaharjoittelun vaikutuksia tyypin 1 
diabetes -potilaisiin tutkittiin ja verrattiin niitä terveissä henkilöissä havaittuihin 
vaikutuksiin. Akuuttia kuormitusta käytettiin täten tunnistamaan PCOS:ään ja tyypin 
1 diabetekseen liittyviä sydän- ja verenkiertoelimistön sairastavuuden varhaisia 
ennusmerkkejä, kun taas liikuntaharjoittelulla testattiin, pystytäänkö sillä 
vaimentamaan kyseisiä tyypin 1 diabetekseen liittyviä varhaisia ennusmerkkejä.  
 
Aineisto ja menetelmät 
Osatutkimukset I-IV kuuluivat suomalais-kanadalaiseen tutkimusyhteistyöhön 
(ARTEMIS – Innovation to Reduce Cardiovascular Complications of Diabetes at the 
Intersection of Discovery, Prevention and Knowledge Exchange). Lopullisiin 
analyyseihin sisällytettiin 22:n aikuisen miehen (osatutkimus I), 15:n PCOS:ää 
sairastavan ja 15:n PCOS:ää sairastamattoman ylipainoisen tai lihavan aikuisen naisen 
(osatutkimus II), seitsemän tyypin 1 diabetesta sairastavan ja 10:n tyypin 1 diabetesta 
sairastamattoman aikuisen miehen (osatutkimus III), ja kahdeksan tyypin 1 diabetesta 
sairastavan ja kahdeksan tyypin 1 diabetesta sairastamattoman aikuisen miehen 
(osatutkimus IV) tutkimustulokset. Osatutkimusten II-IV ryhmät kaltaistettiin 
keskenään iän, antropometrian, ja fyysisen aktiivisuuden (II, III) tai V̇O2peak:n (IV) 
suhteen. PCOS:ää (II) ja tyypin 1 diabetesta sairastavilla (III, IV) ei ollut diagnosoituja 
sydän- ja verenkiertosairauksien ilmentymiä. Koehenkilöt suorittivat maksimaalisen 
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portaittain nousevan kuormituksen joko juoksumatolla (I) tai polkupyöräergometrillä 
(II-IV). Osatutkimuksessa IV koehenkilöt tekivät näin sekä ennen vuoden mittaista 
yksilöllistä liikuntaharjoitteluinterventiota että sen jälkeen. Kuormitusten aikana 
kerättiin kokonaisvaltaista tutkimustietoa: Alveolaarista kaasujenvaihtoa 
(tilavuusturbiini ja massaspektrometria) (I-IV), valtimoveren O2-kyllästeisyyttä 
(pulssioksimetria) (I-IV), sydämen sykettä (elektrokardiografia) (I-IV), sydämen 
pumppaustoimintaa (PhysioFlow-impedanssikardiografia) (II, III) sekä aktiivisen 
luustolihaksen mikroverenkierron O2-tasapainoa (I, III, IV) ja verenvirtausta (III) 
(lähi-infrapunaspektroskopia [NIRS]) monitoroitiin. Myös vähemmän aktiivisen 
luustolihaksen ja aivojen mikroverenkierron O2-tasapainoa monitoroitiin (NIRS) (I). 
Sydämen pumppaustoimintaa arvioiva maksimaalinen O2-pulssi laskettiin (IV). 
Kokonaishemoglobiinimassa (I) ja veritilavuus (III) määritettiin (hiilimonoksidin 
takaisinhengitysmenetelmä) ja verinäytteistä erityisesti hemoglobiinipitoisuus (I-IV) 
sekä pitkäaikaista veren glukoositasoa kuvaava glykoitunut hemoglobiini A1c (III, IV) 
mitattiin. 
 
Tulokset 
I: Tutkittujen kudosten O2-tasapainoprofiilit, jotka kuvaavat paikallista O2-jakelun ja -
käytön välistä epätasapainoa, olivat yhteydessä alveolaarisen kaasujenvaihdon ja siten 
koko kehon tason vasteisiin maksimaalisen portaittain nousevan 
juoksumattokuormituksen aikana terveillä miehillä. II: Ylipainoisilla ja lihavilla PCOS-
naisilla havaittiin alentunut V̇O2peak, alentunut systeeminen O2-ekstraktio 
maksimikuormituksessa ja korostunut sydämen pumppaustoiminnan vaste suhteessa 
kuormituksen aikana kasvaneeseen O2-kulutukseen. III: Tyypin 1 diabetesta 
sairastavilla miehillä havaittiin alentunut sydämen pumppaustoiminta, joka oli 
yhteydessä heidän alentuneeseen veritilavuuteensa, ja sydämen 
pumppaustoiminnasta riippumattomasti alentunut aktiivisen luustolihaksen 
verenvirtaus. Nämä tekijät johtivat tyypin 1 diabetes -miesten alentuneeseen 
V̇O2peak:yyn ja olivat yhteydessä glykoituneen hemoglobiini A1c:n tasoon. IV: Vuoden 
liikuntaharjoitteluinterventio paransi V̇O2peak:ä ja maksimaalista O2-pulssia yhtä 
paljon terveillä ja tyypin 1 diabetesta sairastavilla miehillä mutta sillä ei ollut 
vaikutusta NIRS-johdannaiseen aktiivisen luustolihaksen kuormituksenaikaiseen O2-
ekstraktioon eikä myöskään glykoituneen hemoglobiini A1c:n tasoon tyypin 1 diabetes 
-miehillä. Lisäksi havaittiin, että liikuntaharjoittelun annoksen ja vasteen välillä oli 
johdonmukainen suhde terveillä miehillä mutta ei tyypin 1 diabetesta sairastavilla. 
 
Johtopäätökset 
Tulokset korostavat kokonaisuudessaan, kuinka O2-jakelu ja -käyttö reagoivat 
akuuttiin dynaamiseen kuormitukseen systeemisellä ja perifeerisellä tasolla yhteen 
integroituneesti. Tautikohtaisten sydän- ja verenkiertosairastavuuden varhaisten 
ennusmerkkien osalta voidaan vetää seuraavat johtopäätökset: Ylipainoisilla naisilla 
PCOS itsessään on yhteydessä mieluummin perifeerisen O2-jakelun ja/tai -käytön kuin 
systeemisen O2-jakelun häiriöihin akuutin kuormituksen aikana. Tyypin 1 diabetesta 
sairastavilla miehillä O2-jakelu on akuutin kuormituksen aikana rajoittunut sekä 
systeemisellä että perifeerisellä tasolla, ja nämä rajoitteet ovat yhteydessä 
pitkäaikaiseen veren glukoositasoon. Säännöllinen liikuntaharjoittelu parantaa 
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V̇O2peak:ä, mahdollisesti sydämen pumppaustoimintaa ja siten sydän- ja 
verenkiertoelimistön sairastavuuden ennustetta tyypin 1 diabetesta sairastavilla 
miehillä. Pitkäaikainenkaan liikuntaharjoittelu, ainakaan sellaisena kuin se toteutui 
osatutkimuksessa IV, ei kuitenkaan paranna aktiivisen luustolihaksen 
mikroverenkierron häiriöitä eikä pitkäaikaista veren glukoositasapainoa tyypin 1 
diabeteksessa. Liikuntaharjoittelun annos-vastesuhteen puuttuminen tyypin 1 
diabetesta sairastavilla miehillä lisäksi korostaa, että liikuntaharjoittelun tässä 
potilasryhmässä tulee olla yksilöllisesti äärimmäisen räätälöityä suotuisien vasteiden 
aikaansaamiseksi. 
Nämä tulokset ja johtopäätökset ohjaavat tulevaisuuden poikkitieteellistä 
tutkimusta tunnistamaan havaittujen tautikohtaisten sydän- ja verenkiertoelimistön 
sairastavuuden varhaisten ennusmerkkien yksityiskohtaisempia mekanismeja, 
kliinistä merkittävyyttä ja hoitoa.  
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1 INTRODUCTION 
PCOS is a complex endocrinopathy characterized by hyperandrogenism, chronic oligo- 
or anovulation, and polycystic ovaries (1-3). Depending on the population studied and 
the diagnostic criteria applied, PCOS affects approximately 6-20% or even more of 
women (4-7), making it one of the most common human disorders and the most 
common single endocrinopathy in reproductive-aged women (1). Diabetes mellitus, 
henceforth referred to as diabetes, is characterized by a chronic state of hyperglycemia. 
While 382 million people worldwide were estimated to have diabetes in 2013 and the 
prevalence is expected to reach 592 million people by 2035 (8), autoimmune-mediated 
type 1 diabetes accounts for 5-10% of all diabetes patients (9). Type 1 diabetes is 
typically diagnosed before the age of 15 years (10) and is one of the most common 
chronic diseases of childhood. Interestingly, type 1 diabetes has its highest incidence 
in Finland (~64/100 000/year below the age of 15) (11). 
PCOS has important long-term health implications related to reproductive and 
hormonal, psychosocial, and metabolic and cardiovascular disturbances, with excess 
weight being a common factor contributing to all of these derangements (1-3,12). 
Insulin resistance (IR) has an essential role in the pathogenesis of PCOS, hence driving 
different phenotypic features of women with the syndrome (1-3), and also significantly 
increases patients’ risk of metabolic disturbances such as type 2 diabetes (13). 
Accordingly, vast evidence suggests that lifelong metabolic dysfunction in women with 
PCOS results in exaggerated risk of cardiovascular disease (1,2,14). In diabetes, clinical 
manifestations include well-known microvascular (i.e., retinopathy, nephropathy, and 
neuropathy) and macrovascular complications (i.e., coronary artery, cerebrovascular, 
and peripheral artery diseases). In addition, chronic hyperglycemia can also lead to 
diabetes-specific myocardial dysfunction known as diabetic cardiomyopathy (15-17), 
which has recently been shown to increase the risk of early development of heart failure 
already in relatively young adults with type 1 diabetes (18). Taken together, a common 
feature of PCOS and type 1 diabetes is that both are characterized by an increased risk 
of cardiovascular disease. 
An individual’s cardiovascular risk and its magnitude can strongly and 
independently be predicted by V̇O2peak (19). V̇O2peak reflects the highest achievable level 
of whole-body oxidative metabolism and is typically measured during a maximal 
incremental cardiopulmonary exercise test (CPET) involving dynamic exercise, such 
as running or cycling, that features repetitive contractions of large muscle groups (20-
22). V̇O2 response to such acute dynamic exercise consists of an integrated pathway 
for O2 from the atmosphere to the skeletal muscle mitochondria. The pathway contains 
serial steps of alveolar ventilation (V̇A), alveolar-to-capillary diffusion, circulation 
(including cardiac pump function, blood O2 carrying capacity, muscle blood flow), and 
muscle O2 diffusion and utilization. In consequence, as V̇O2peak reflects the highest 
achievable outcome of the integrated pathway and depends on all of the serial steps 
mentioned, acute dynamic exercise is an excellent physiological probe to identify 
possible disease-related defects in the serial organ systems responding for appropriate 
adjustments of O2 delivery and subsequent mitochondrial O2 utilization (23-30). 
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As overall cardiovascular risk is increased in PCOS and type 1 diabetes and 
performing acute dynamic exercise is able to reveal detailed signs of organ dysfunction, 
possibly limiting O2 delivery and utilization, it is reasonable to examine responses to 
acute dynamic exercise in these patient groups. However, existing data on responses 
to acute dynamic exercise in women with PCOS are sparse. V̇O2peak itself has been 
observed to be either reduced or intact in PCOS and is likely to depend on the 
magnitude of IR (31-35). By contrast, little is known of more specific adjustments of 
systemic O2 delivery (i.e., pulmonary function, cardiac pump function, blood O2 
carrying capacity) or peripheral O2 delivery (i.e., muscle blood flow) and utilization to 
exercise in women with the syndrome. Current literature on responses to acute 
dynamic exercise in type 1 diabetes is understandably more extensive than that in 
PCOS. While several studies have reported reduced V̇O2peak in type 1 diabetes, it has 
also been well acknowledged that individuals with the disease are capable of attaining 
a similar V̇O2peak to that of healthy individuals but this most likely depends on them 
maintaining good glycemic control (36). Meanwhile, numerous studies have observed 
separate systemic and peripheral determinants of V̇O2 response to exercise in patients 
with type 1 diabetes but no studies have simultaneously examined the integrated 
contribution of these systemic and peripheral derangements to V̇O2peak. 
Exercise training is a planned form of physical activity. Ever since Greek physicians, 
with Herodicus and Hippocrates leading the way, around 400 B.C. began using 
exercise training as a therapy for various diseases (37), extensive scientific evidence 
has verified that exercise training is truly an important behavior for individual and 
population health (38). Hence, adherence to regular exercise training has also become 
a generally recommended part of overall treatment of patients with type 1 diabetes 
(39). Particularly endurance-type exercise training leads to various adaptations in the 
different components of the integrated O2 pathway, thus increasing V̇O2peak (40,41). 
However, such adaptations to long-term (i.e., >4-5 months) exercise training 
interventions have been sparsely studied in type 1 diabetes. Moreover, evidence of the 
effect of exercise training on glycemic control of type 1 diabetes patients is inconclusive, 
and long-term training intervention studies have not even been conducted to examine 
the issue. 
The purposes of this thesis were 1) to study O2 delivery and utilization during acute 
dynamic exercise in both healthy individuals and individuals with PCOS or type 1 
diabetes, and 2) to examine the adaptations induced by long-term 1-year exercise 
training in individuals with type 1 diabetes. The large-scale aims were thus to identify 
early signs of cardiovascular dysfunction in the two patient groups and to examine 
whether long-term exercise training alleviates the early signs related to type 1 diabetes. 
The scientific infrastructure, including the integrated noninvasive methodology 
employed, was provided by a Canadian-Finnish research collaboration supplemented 
by Finnish research collaborations. 
A reader of this thesis is first introduced to the topic through a narrative literature 
review. The literature review has been outlined so that it has its focuses on dynamic 
whole-body exercise, endurance-type exercise training, and data on human studies 
with some occasional complementary examples from animal models. The literature 
review is then followed by the integrative presentation of the methods, results, 
discussion, and conclusions of the four original studies. 
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2 REVIEW OF THE LITERATURE 
2.1 OXYGEN DELIVERY AND UTILIZATION DURING ACUTE 
DYNAMIC EXERCISE 
 
Oxidative phosphorylation within mitochondria of mammalian cells is the 
fundamental energy-producing biochemical process utilizing O2 and making life 
possible. The basic equation describing mitochondrial regeneration of adenosine 
triphosphate (ATP), containing the high-energy bonds that are transduced into energy, 
is as follows (23): 
 
(1) 3 ADP + 3 Pi + ½ O2 + NADH + H+ ? 3 ATP + NAD+ + H2O 
 
where ADP is adenosine diphosphate, Pi is inorganic phosphate, H+ is a hydrogen 
ion, H2O is water, and NADH and NAD+ are the reduced and oxidized forms of 
nicotinamide adenine dinucleotide, respectively. 
At rest, whole-body O2 utilization in humans, traditionally measured as V̇O2, 
averages 3-4 mL/min/kg body weight, corresponding to resting V̇O2 of 0.15-0.4 L/min 
in young healthy humans weighing 50-100 kg. Most (~80%) of the O2 utilized in a 
resting human is used by the brain, heart, liver and kidneys (22,41,42). 
Dynamic exercise, such as walking, running, cycling, or different ball games, 
features skeletal muscle contractions performed over and over again (22). Acute 
dynamic exercise leads to elevated ATP turnover particularly within active skeletal 
muscles, thus increasing overall O2 utilization according to Equation 1. In detail, during 
maximal exercise, henceforth referred to as peak exercise, V̇O2 can increase 10- to 15-
fold, reaching 30-50 mL/min/kg in young untrained subjects and near 60 mL/min/kg 
in young trained subjects (22). Furthermore, a peak V̇O2 (V̇O2peak) of 70-85 mL/min/kg 
(or ~5.0-6.5 L/min) is typically reported in elite male endurance athletes (43-45). As 
muscle O2 and high-energy phosphate stores are small, any sustained elevation of 
muscle ATP turnover requires that O2 is delivered to the muscle mitochondria at a rate 
precisely matched to mitochondrial O2 requirements (46). Consequently, acute 
dynamic exercise presents a great physiological challenge to the pulmonary, 
cardiovascular, and muscular systems, which strive to meet the increased 
requirements for O2 delivery and subsequent mitochondrial O2 utilization. 
A pathway for O2 from the atmosphere to the mitochondria has been detailed in 
several scholarly reviews (e.g., 23,26,28-30). The pathway contains an integrated 
series of steps: Pulmonary function comprises adequate V̇A and gas exchange being 
responsible for diffusing O2 from the environment to the blood, cardiac pump function 
delivers O2 to the periphery within the limits of blood O2 carrying capacity, and 
diffusion of O2 then transfers O2 from the microcirculation to the mitochondria within 
the peripheral tissues (i.e., particularly active skeletal muscles during acute dynamic 
exercise). 
At the systemic whole-body level, the presented pathway for O2 is mathematically 
distilled into the Fick principle (47): 
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(2) V̇O2 = Q̇ × C(a-v)O2 
 
where Q̇ is cardiac output and C(a-v)O2 is systemic arterial-venous O2 difference. 
For Q̇ at rest, textbook values in young healthy males weighing around 70 kg are 
around 5 L/min, which is achieved as a product of heart rate (HR) of ~70 bpm and a 
stroke volume (SV) of ~70 mL (48-51). At the same time, while ~50 mL O2/L (i.e., C(a-
v)O2) is extracted from the peripheral circulation at rest, resting V̇O2 is ~250 mL/min 
or 3.5 mL/min/kg in a 70-kg human (22), as approximated above. 
Regarding acute dynamic exercise and adaptations to exercise training, the 
different components of the Fick principle will be thoroughly covered in the following 
sections examining systemic and peripheral O2 delivery as well as peripheral O2 
extraction and utilization during acute dynamic exercise along with V̇O2peak and effects 
of endurance-type exercise training on these integrated adjustments. Figure 1 
simplifies how the text flows in Sections 2.1.1-2.1.2 towards the integrated concept of 
V̇O2peak, presented in Section 2.1.3. 
 
 
 
 
Figure 1 Simplified flow of Sections 2.1.1-2.1.2 towards the integrated concept of V̇O2peak, presented in 
Section 2.1.3. 
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2.1.1 SYSTEMIC OXYGEN DELIVERY DURING ACUTE DYNAMIC EXERCISE 
 
The components determining systemic O2 delivery (i.e., circulatory O2 convection for 
the body as a whole) can be recognized by compartmentalizing the Fick principle 
(Equation 2) (23): 
 
(3) V̇O2 = Q̇ × C(a-v)O2 = Q̇ × (CaO2 – CvO2) = Q̇ × CaO2 – Q̇ × CvO2 
 
where CaO2 is arterial O2 content and CvO2 is mixed venous O2 content. 
The minuend (Q̇ × CaO2) of Equation 3 refers to systemic O2 delivery. In detail, 
CaO2 is a product of arterial O2 saturation (SpO2), hemoglobin concentration [Hb], and 
1.34, which is the physiological O2 binding coefficient of hemoglobin (Hb) (1.34 mL/g 
(52); range of reported values of nonsmokers: 1.30-1.39 mL/g (53)). Notably, ~98.5% 
of O2 delivered from the lungs to the periphery is carried by Hb, while the remaining 
~1.5% is transported in the dissolved state in the water (51). Taken together, according 
to the chronological order of the O2 pathway, systemic O2 delivery is determined by 
pulmonary function (approximated by SpO2), cardiac pump function (quantified as Q̇), 
and blood O2 carrying capacity (reflected by [Hb]) (23,26,28-30). 
 
 
2.1.1.1 Pulmonary function 
 
V̇O2 increases linearly as a function of intensity during acute dynamic exercise (54,55). 
Eventually, V̇O2 may or may not reach an observable plateau at peak exercise (56-58). 
V̇O2 here refers to pulmonary O2 uptake but closely reflects O2 utilization of active leg 
muscles over the broad range of cycling intensities, from moderate to severe (54,55). 
In other words, V̇O2 is tightly coupled with aerobic energetics according to Equation 1 
and particularly reflects the increasing energetic demand of the exercising musculature 
in the limbs during acute dynamic exercise (46). It is notable that as a sign of their 
pronounced O2 demand, respiratory muscles themselves may also receive a substantial 
amount of Q̇ at peak exercise (59). However, it is not fully elucidated whether this 
affects blood flow to and O2 utilization within the exercising limb musculature (see 
Section 2.1.2.1). 
In addition to the rise in V̇O2, pulmonary CO2 output (V̇CO2) also rises with exercise 
intensity due to the increased activation of metabolic pathways (particularly 
glycolysis). Furthermore, V̇CO2 even accelerates if exercise intensity exceeds a certain 
threshold (60-62). This acceleration is due to an anaerobic component of muscle 
metabolism reflected by increased lactate and reduced bicarbonate concentrations in 
the blood (62,63). The threshold at which V̇CO2 begins to accelerate in relation to V̇O2 
is termed an anaerobic threshold (AT) (60,61). 
V̇A and diffusive gas exchange across the alveolar membrane to the erythrocytes are 
the pulmonary components responsible for appropriate exercise-induced increases in 
V̇O2 and V̇CO2. Pulmonary ventilation is quantified as minute ventilation (V̇E), which 
reflects the volume of expired air exhaled from the lungs in one minute. V̇E increases 
linearly when plotted against exercise intensity (or V̇O2) until reaching the respiratory 
compensation point (RC). Above RC, V̇E rises more rapidly in order to compensate 
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acidosis caused by the anaerobic component of energy metabolism (60). Consequently, 
this hyperventilation results in decreases in partial pressure of arterial CO2 (PaCO2) 
and its surrogate (end-tidal pressure of CO2 of respired gases [PETCO2]) at exercise 
intensities above RC (60,64). 
Regarding an interplay between V̇A and partial pressures of alveolar O2 and CO2, 
modest hyperventilation is also needed to reduce alveolar CO2 pressure so as to 
increase alveolar O2 pressure enough to raise a driving pressure for alveolar-to-
capillary diffusion of O2 (41). In the average individual exercising at sea level, the 
driving pressure for O2 diffusion (i.e., alveolar-arterial O2 pressure difference) 
commonly increases from 5-10 mmHg at rest to about 25 mmHg at peak exercise (41). 
This is sufficient to maintain partial pressure of arterial O2 (PaO2) and SpO2 near 
resting levels at light, moderate, severe, and even peak exercise intensities (65-68). 
Thus, the lungs of healthy nonathletes perform their tasks of both V̇A and alveolar-to-
capillary diffusion extremely well under normoxic conditions. 
Contrary to healthy nonathletes, fit athletes may undergo exercise-induced arterial 
hypoxemia (EIAH; SpO2 decreasing [far] below 95% (69)) at near peak or peak exercise 
(70), but even during intensities of 40-50% of V̇O2peak (70,71). Both an excessive 
alveolar-arterial O2 pressure difference and inadequate compensatory 
hyperventilation contribute to EIAH, as do acid- and temperature-induced rightward 
shifts of the O2 dissociation curve at any given PaO2 (69). In more detail, inadequate 
V̇A in relation to Q̇ (i.e., ventilation-perfusion [V̇A/Q̇] mismatch) and limited O2 
diffusion contribute equally to the excessive alveolar-arterial O2 pressure difference, 
whereas exercise hyperventilation may be limited by expiratory flow limitation set by, 
for instance, mechanical constraints of airway diameter and/or respiratory muscle 
force production (69). Interestingly, EIAH may be more frequent in women than in 
men (72). In fact, even some untrained women may develop EIAH (73). This sex 
difference is particularly due to pronounced mechanical constraints in women (72-74). 
Taken together, while pulmonary function does determine systemic O2 delivery, 
and thus V̇O2, during acute dynamic exercise, it rarely sets any limitation on these in 
healthy nonathletes. However, such pulmonary limitations may be evident in trained 
athletes, but also in some untrained women; each 1% reduction in SpO2 (or CaO2) leads 
to 1-2% reduction in V̇O2peak below the SpO2 level of 95% (69). 
 
 
2.1.1.2 Cardiac pump function 
 
Cardiac cycle 
Cardiac events occurring from the beginning of one heartbeat to the beginning of the 
next one constitute the cardiac cycle, which is presented in Figure 2. The cardiac cycle 
comprises a relaxation period called diastole, during which the heart fills with blood, 
followed by a contraction period called systole. Diastole begins with a period of 
isovolumic relaxation; the right and left intraventricular pressures decrease rapidly 
back to their low diastolic levels, while pulmonary, atrioventricular, and aortic valves 
are closed. The atrioventricular valves then open and the ventricles fill with blood 
during three phases (rapid inflow, diastasis, and atrial contraction) to reach their end-
diastolic volumes (EDV). After the ventricular filling, systole is initiated; the ventricles 
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begin contracting and the ventricular pressures rise, causing the atrioventricular valves 
to close. During the following period of isovolumic contraction, the ventricles build up 
sufficient pressures to push the pulmonary and aortic valves open against the pressures 
in the pulmonary artery and aorta. After the pulmonary and aortic valves have opened, 
blood is ejected from the ventricles until the elevated pressures of filled and distended 
large arteries lead to the closing of the pulmonary and aortic valves. The volume 
pumped towards the periphery during systole is SV, the ratio of SV to EDV is termed 
ejection fraction (EF), and the difference between EDV and SV reflects end-systolic 
volume. After the systolic ejection, the next cardiac cycle begins (50). 
 
 
 
 
Figure 2 Cardiac cycle for left ventricular function, demonstrating changes in left atrial pressure, left 
ventricular pressure, aortic pressure, ventricular volume, and electrocardiogram. Modified 
from Guyton and Hall (50). 
 
 
Cardiac pump function during acute dynamic exercise 
During acute dynamic exercise, Q̇, which is the product of HR and SV and has a key 
role in the Fick principle (Equation 2), rises in proportion to V̇O2. Reviews of extensive 
literature in the field have documented that Q̇ increases between 5 and 6 L for every 1 
L increase of V̇O2 in healthy individuals (41,75). Based on the data collected before 
modern obesity and inactivity epidemics, typical peak values of Q̇ of 20-year-olds are 
15-20 L/min in sedentary, 20-25 L/min in active, and 25-40 L/min in elite athlete 
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individuals (22). Since peak HR may increase up to ~200 bpm during acute dynamic 
exercise rather regardless of fitness level (22,48), these values indicate that peak SV in 
these groups is correspondingly around 70-100 mL, 100-125 mL, and 125-200 mL, 
respectively (22). Anecdotally, Q̇ of 42.3 L/min in a world-class orienteer is probably 
the highest published value of cardiac pumping capacity (45). 
The exercise-induced rise in Q̇ is mainly achieved through elevated HR (i.e., 
tachycardia), and to a lesser extent through increased SV (41,49). The relationship 
between HR and V̇O2 is linear (41,49). In humans, the rapid onset of tachycardia up to 
~100 bpm is mainly attributable to the withdrawal of parasympathetic vagal activation, 
whereas HR increases above the level of ~100 bpm are primarily due to sympathetic 
activation of cardiac β1-adrenoceptors (76,77). SV is raised partly through increased 
ventricular filling pressure, which increases EDV via the Frank-Starling mechanism, 
and partly through increased myocardial contractility and EF, which reduce end-
systolic volume (78-80); the former mechanism contributes ~2/3 and the latter ~1/3 
to the increase in SV from seated rest to upright exercise (80). The rise in filling 
pressure is brought about by sympathetically mediated venoconstriction in the 
splanchnic circulation and the skeletal muscle pump, which compresses veins in the 
exercising limbs, and thus, both provides optimal filling pressure for the heart at all 
levels of exercise and simultaneously prevents central venous pressure (CVP) from 
falling (41,49). The increase in myocardial contractility is due to increased stimulation 
of cardiac sympathetic nerves and also to a lesser degree to the increase in circulating 
adrenaline (41,49). 
The response of SV to incremental upright exercise was observed to be nonlinear as 
early as 1960 (78). Further observations of the SV response to acute exercise from the 
1960s (45,81,82) eventually led to the common acceptance that after increasing from 
rest, SV plateaus at 40-50% of V̇O2peak during incremental upright exercise. The first 
study to simultaneously measure pulmonary and systemic pressures and left 
ventricular volume in humans during upright exercise explained this as follows: at low 
intensities, SV increases via increases in ventricular filling pressures and EDV, whereas 
at high intensities, EDV decreases, possibly as a result of tachycardia, and SV thus is 
just maintained through a decrease in end-systolic volume (i.e., increase in 
contractility) (83). However, current evidence shows that SV response to incremental 
upright exercise varies between individuals depending on age, fitness level, genetics, 
and sex (84). In particular, a progressive increase in SV during exercise to V̇O2peak may 
be seen in endurance-trained individuals (85-88) due to their higher left ventricular 
diameter, wall thickness, and mass (89-93), larger ventricular compliance (89,94), 
more rapid diastolic filling (85-87), and possibly also due to greater contractility 
(95,96) and longer ventricular ejection time (86,87). However, since a decrease in SV 
and Q̇ at high exercise intensities has also been observed in fit individuals (97), no 
consensus on this issue has been reached. Figure 3 illustrates the interindividual 
variability of SV responses to increasing exercise intensity, detailed elsewhere by Vella 
et al. (84). 
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Figure 3 Different types of stroke volume (SV) responses to increasing exercise intensity (i.e., 
increasing pulmonary O2 uptake [V̇O2]). Modified from Vella et al. (84). 
 
 
Darcy’s law defines the systemic relationships between Q̇, mean arterial blood 
pressure (MAP), CVP, and systemic vascular resistance (SVR) (49): 
 
(4) Q̇ = (MAP – CVP) / SVR 
 
where MAP is calculated by the standard equation (MAP = [systolic arterial blood 
pressure + 2 × diastolic arterial blood pressure] / 3), and CVP is close to 0 mmHg from 
rest to peak exercise (97). 
Equation 4 assumes that blood flow from the left ventricle back to the right atrium 
is determined by the pressure difference between the two chambers, discounting the 
fact that the circuit is affected by the skeletal muscle pump, which also delivers energy 
to drive blood flow (41). However, as incremental exercise from rest to peak intensity 
causes only a modest rise in MAP (from 90 to 115 mmHg when measured from the 
aorta), the rise in Q̇ and vasodilatation in the exercising skeletal musculature, the latter 
of which reduces SVR, are well compensated by each other, in accordance with 
Equation 4 (81,98). 
Q̇ has a critical role in the Fick principle (Equation 2), thus being an important 
determinant of V̇O2. The following key observations support that at peak exercise, Q̇ 
(particularly SV) and hence systemic O2 delivery are main determinants of V̇O2peak: 
First, V̇O2peak is achieved by intense activation of only ~50% of the total muscle mass, 
and addition of more active muscle causes no further increase in Q̇ or V̇O2peak (22,41). 
Exceptions to this include cross-country skiers and rowers, who have highly trained 
arms, thus achieving 5-10% higher V̇O2peak when arm exercise is added to leg exercise 
(99,100). Even so, the heart cannot provide enough blood flow for all of the muscles. 
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In fact, with the aid of the development of the groundbreaking knee-extensor model to 
study an isolated exercising muscle in 1985 (101), Andersen and Saltin (102,103) and 
Richardson et al. (104) observed that the capacity of the skeletal muscles to receive 
blood flow is at least 2-3 times higher than the pumping capacity of the heart. Second, 
surgical opening of the pericardial sac of dogs has been shown to facilitate significant 
increases in their peak SV, peak Q̇, and V̇O2peak (105). This indicates that pericardium 
sets crucial mechanical constraints on ventricular filling and hence SV and the 
pumping capacity of the heart. Third, mitochondrial capacity to utilize O2 has been 
demonstrated to exceed V̇O2peak (106), although this may not always be the case (see 
Section 2.1.2.2). In summary, regarding the Fick principle (Equation 2), pronounced 
peak Q̇ and particularly pronounced peak SV rather consistently contribute to higher 
V̇O2peak more than pronounced peak C(a-v)O2, especially in younger men and women 
(107). However, this sort of interpretation actually incorrectly dismisses the integrated 
nature of V̇O2peak (see Sections 2.1.3.2 and 2.1.4.3). Taken together, Q̇ and systemic O2 
delivery are main (or at least highly important) determinants of V̇O2peak, although 
peripheral determinants may be at least equally important in unfit subjects (26), as 
discussed later (see Section 2.1.2.2). 
 
Methods to quantify cardiac pump function 
The “gold standard” methods to determine cardiac pump function are considered to be 
the direct Fick method and indicator dilution methods (i.e., dye- or thermodilution 
methods) (51,108). The direct Fick method requires invasive measurements of CaO2 
from any artery and CvO2 from mixed venous blood (a cardiac catheter with its tip in 
the pulmonary artery), along with a direct measure of V̇O2; hereby, Q̇ can be calculated 
according to the Fick principle (Equation 3) (51,108,109). Dye-dilution method is 
similar to the Fick method with the exception that, instead of measuring O2, the 
concentration of injected dye (usually indocyanine green) in serial samples of arterial 
blood is measured. Eventually, Q̇ is obtained by dividing the amount of injected dye by 
the average arterial dye concentration after a single circulation through the heart 
(51,108). Thermodilution method, for its part, is based on the same principle as dye-
dilution except that, instead of dye, cold saline is injected into the right atrium through 
one channel of a double-lumen catheter. The temperature change in the blood is then 
recorded in the pulmonary artery by a thermistor in the other, longer side of the 
catheter. Consequently, the amount of cooling of the blood is inversely proportionate 
to Q̇ (51,108). 
The “gold standard” methods described above are invasive by nature and while they 
have been widely shown to give accurate and reliable determinations of Q̇ at rest and 
during submaximal exercise their use during maximal exercise conditions is debatable 
due to the inherent risks and inaccuracy increasing along with exercise intensity (108). 
In consequence, several noninvasive methods, such as foreign gas (particularly 
acetylene (110,111)) rebreathing methods, Doppler echocardiography (112), and 
impedance cardiography, have been developed and are popular among clinicians and 
exercise scientists (108,113). 
As listed above, impedance cardiography is one of the noninvasive techniques to 
quantify cardiac pump function. It is based on the measurement of transthoracic 
changes in electrical bioimpedance during the cardiac cycle (113,114). A small 
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alternating current (1.8-4 mA, 75-100 kHz) is passed through the chest using two sets 
of two skin electrodes (i.e., two transmitting+receiving pairs), and registered changes 
in electrical impedance are assumed to represent changes in SV. The principle has been 
applied to estimate beat-to-beat changes in SV and Q̇ since 1966 (115). The original 
Kubicek equation (115) to calculate SV was further modified by Sramek et al. (116) and 
Bernstein (117). However, all of these three equations rely on an evaluation of basal 
thoracic impedance, which depends on multiple factors such as thorax morphology, 
homogeneity of thorax perfusion, and fluid and gas content (115-119). The three 
equations could thus be confounded by perspiration, subcutaneous adiposity, and poor 
electrical contact (118). Consequently, Warburton et al. (113) concluded in their review 
in 1999 that impedance cardiography would not be able to provide accurate or reliable 
data during exercise. 
A different approach to impedance cardiography was presented in 2000 and 2001, 
when a new impedance cardiograph device, PhysioFlow, provided valid and reliable 
estimates of SV and Q̇ at rest and from low to peak exercise (114,120). Charloux et al. 
(114) first observed in 40 normal-weight, overweight, or obese adults that mean 
differences and correlation coefficients between Q̇ estimated by PhysioFlow and Q̇ 
measured by the direct Fick method were 0.07 L/min (95% confidence interval -0.23 - 
+0.27 L/min) and 0.89, respectively, at rest, and 0.26 L/min (95% confidence interval 
-0.17 - +0.69 L/min) and 0.85, respectively, during dynamic submaximal supine leg 
exercise. Richard et al. (120) then reported in seven normal- or overweight adults that 
a mean difference and a correlation coefficient between Q̇ estimated by PhysioFlow 
and Q̇ measured by the direct Fick method were 0.58 L/min (95% confidence interval 
-4.04 - +2.89 L/min) and 0.94, respectively, during maximal incremental cycling 
exercise. 
From a methodological point of view, the most important advancement of the 
PhysioFlow method is that evaluation of basal thoracic impedance is not needed for 
the calculation of SV (114). Using four impedance electrodes (i.e., two 
transmitting+receiving pairs) and two electrocardiography electrodes (Figure 4A), the 
PhysioFlow device first evaluates SV during a calibration procedure based on 24 
consecutive heartbeats recorded at rest. This evaluation, called SVcal, retains the largest 
impedance variation during systole (Zmax - Zmin), and the largest rate of variation of the 
impedance signal (dZ/dtmax = contractility index [CTI]) (Figure 4B). Additionally, the 
SV evaluation depends on ventricular ejection time, which is reflected as thoracic flow 
inversion time. Thoracic flow inversion time is a time interval between the first zero 
value of dZ/dt following the beginning of systole and the first nadir after the peak 
ejection velocity (dZ/dtmax) (Figure 4B). As a result of the above concepts, SVcal is 
calculated as follows (114): 
 
(5) SVcal = k × [(dZ/dtmax) / (Zmax - Zmin)] × W(TFITcal) 
 
where k is a constant and W(TFITcal) refers to a weighted algorithm of thoracic flow 
inversion time obtained during the calibration procedure. Furthermore, during the 
data acquisition phase (i.e., during ongoing exercise), SV values are derived by 
combining fluctuations of dZ/dtmax (CTI) and thoracic flow inversion time (114): 
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(6) SV = SVcal × 3√(CTI / CTIcal × TFITcal / TFIT) 
 
where “cal” indicates the parameters measured during the calibration phase. 
Figure 4 combines the placement of PhysioFlow electrodes and waveforms obtained 
by PhysioFlow. 
Concomitantly, Q̇ is obtained by multiplying estimated SV by HR (114). The 
PhysioFlow device also provides estimates of EF and EDV: EF is calculated by an 
equation (EF = 0.84 – 0.64 × pre-ejection period / ventricular ejection time), where 
pre-ejection period refers to time between ventricular depolarization and ejection 
(121). This equation has been shown to correlate strongly with EF obtained by gated 
pool scanning (121). EDV is calculated by the ratio of SV to EF. Overall, the PhysioFlow 
method, similarly to the acetylene rebreathing method (108,113), meets the criteria of 
being noninvasive, easy to use, reliable, and valid for use also at peak exercise 
(114,120). 
 
 
 
 
Figure 4 Placement of PhysioFlow impedance (Z) and electrocardiography (ECG) electrodes (A), and 
waveforms obtained by PhysioFlow (B). Largest (Zmax) and smallest (Zmin) impedances, largest 
rate of variation of impedance signal (dZ/dtmax), and thoracic flow inversion time (TFIT) during 
systole are registered. See text for detailed interpretation. Modified from Tan et al. (122) (A) 
and Charloux et al. (114) (B). 
 
In addition to all of the methods described above, SV can also be estimated by 
calculating O2 pulse, which has its origins in the Fick principle (20,123): 
 
(7) V̇O2 = Q̇ × C(a-v)O2 = SV × HR × C(a-v)O2  ?  V̇O2 / HR = SV × C(a-v)O2 
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where the V̇O2/HR quotient is O2 pulse. The calculation of O2 pulse assumes that 
no anemia, lung disease, hypoxic conditions, or EIAH are present, and C(a-v)O2 is 
maximal (20,123). Thus, O2 pulse is mainly applicable to estimate SV at peak exercise. 
 
 
2.1.1.3 Blood oxygen carrying capacity 
 
Apart from pulmonary and cardiac pump functions, the third factor determining 
systemic O2 delivery is blood O2 carrying capacity, which is reflected by [Hb]. During 
acute dynamic exercise in thermally neutral circumstances, [Hb] may rise slightly 
above resting values since plasma water is lost to active myocytes and interstitial fluid 
as the concentration of osmotically active particles in the muscles rises (41,124). 
However, if no EIAH is present, CaO2 remains nearly constant (41) since SpO2 is 
maintained near resting levels at all exercise intensities (65-68). 
[Hb] is formed as a ratio of total hemoglobin mass (tHb-mass) and blood volume 
(BV). Both tHb-mass and BV in endurance athletes with high V̇O2peak are up to 50% 
higher than in sedentary subjects (125). Accordingly, cross-sectional (126,127) as well 
as longitudinal (128) studies have shown that tHb-mass and BV are closely related to 
V̇O2peak; a change in tHb-mass by 1 g causes a change in V̇O2peak by ~4 mL/min (129). 
However, due to the “coinciding” training-induced increases of both tHb-mass and BV, 
no association between [Hb] and V̇O2peak is evident in very heterogeneously trained 
groups (127) or within groups characterized by similar endurance levels (125). Thus, 
rather than [Hb] alone, the balance between tHb-mass (affecting blood O2 carrying 
capacity and BV) and BV (affecting diastolic filling and hence SV and Q̇ (86)) for its 
part determines V̇O2 response to acute dynamic exercise in nonanemic, normoxic 
conditions (129). 
The methods to quantify tHb-mass and BV are all indirect and based on dilution of 
tracers injected into the circulation (130). A method using radioactive chromium as a 
tracer has previously been regarded as the criterion method on the basis of its 
reliability, reproducibility, and ease of routine clinical use (131). Another method uses 
inhaled carbon monoxide (CO) as a tracer and is thus known as a CO-rebreathing 
method; the subject first adopts a consistent posture for at least 20 min, after which 
basal capillary carboxyhemoglobin concentration ([HbCO]) is determined. Then CO is 
inhaled for two minutes via a spirometer. Seven minutes after inhaling the CO bolus, 
[HbCO] is again determined to derive tHb-mass (132,133): 
 
(8) tHb-mass = CO dose / 1.34 / ∆[HbCO] 
 
where CO dose is a volume of pure CO added to a rebreathing circuit, 1.34 (mL/g) 
is the physiological CO binding coefficient of Hb, and ∆[HbCO] is a difference between 
[HbCO] seven minutes after inhaling the CO bolus and basal [HbCO]. BV is obtained 
by dividing tHb-mass by measured [Hb] (133). 
The principle of this CO-rebreathing technique has originally been introduced more 
than 100 years ago (134), and its optimized, contemporary version has proved to be 
valid and reliable (132). In fact, the mean error of the method (a coefficient of variation 
of 2.2%) has been demonstrated to be lower than that of other methods (including the 
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radioactive chromium method) (133). Herewith, the CO-rebreathing method is 
currently recommended for determinations of tHb-mass and BV (133). 
 
 
2.1.2 PERIPHERAL OXYGEN DELIVERY, EXTRACTION, AND UTILIZATION 
DURING ACUTE DYNAMIC EXERCISE 
 
2.1.2.1 Overview of blood flow distribution and regulation at the whole-body level 
 
Section 2.1.1.2 describes how Q̇ reflects systemic blood flow and increases during 
incremental dynamic exercise. Here, Figure 5 illustrates how the distribution of Q̇ in a 
normal human changes from rest to higher exercise intensities. Blood flow increases 
with exercise intensity in skeletal, cardiac, and respiratory muscles, and to a lesser 
extent in the brain. In other words, “blood goes where it is needed”, as postulated by 
Scottish anatomist and surgeon John Hunter already in the 18th century (135). By far 
the largest increases in blood flow occur in the exercising skeletal musculature, the 
increasing energetic demand of which thus dominates that of the rest of the body 
(22,41,42,46). Coronary blood flow of cardiac muscle increases three- to fivefold, from 
~250 mL/min up to 1.0 L/min (41,136). As a result, skeletal muscle and cardiac muscle 
together receive 85-95% of Q̇ at maximal exercise intensities (22,41,42). Being involved 
in the portion of the exercising (skeletal) musculature, respiratory muscle work may 
require up to ~15% of Q̇ at peak exercise (59). In fact, even evidence of competition for 
blood flow between the exercising limb muscles and the respiratory muscles has been 
presented (59,137). However, Romer et al. (138) have reported that at least in 
moderately fit subjects, neither inspiratory muscle work nor diaphragm fatigue limit 
performance during maximal incremental exercise. In addition, based on their 
simultaneous measurements of blood flow in both locomotor and intercostal 
respiratory muscles, Vogiatzis et al. (139) have suggested that at least intercostal 
muscles do not “steal” blood from the dynamically exercising limbs. The idea of 
respiratory muscles “stealing” blood from the exercising limb muscles is therefore 
questionable. Regarding the brain, cerebral blood flow increases with exercise intensity 
up to ~60% of V̇O2peak, after which it decreases towards baseline values (140-142); 
numerically, cerebral blood flow is between ~0.7 and -0.9 L/min during various 
exercise intensities. 
Blood flow to the above-mentioned more active tissues during acute dynamic 
exercise is redistributed from less active tissues such as skin, kidneys, splanchnic 
organs (22,41,42), less active muscles (143,144), and bones (145). Blood flow to the skin 
is reduced with the onset of mild-to-moderate exercise intensities (146,147) and also 
remains minimal unless the cutaneous vascular bed is forced to dilate for the purposes 
of thermoregulation as a response to elevated core temperature (41,42,148). In 
addition, blood flow of kidneys and splanchic organs can both fall to ~25% of their 
resting levels during acute dynamic exercise (149-152), albeit O2 utilization in these 
tissues is preserved by elevated O2 extraction (149-151). Moreover, after having initially 
increased, blood flow to less active muscles (143,144) and bones (145) levels off with 
increasing exercise intensities. 
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Figure 5 Effects of increasing exercise intensity (i.e., increasing percentage of peak pulmonary O2 
uptake [V̇O2peak]) on distribution of systemic blood flow (cardiac output [Q̇]) to all tissues (A) 
and to all tissues except skeletal muscles (B). Modified from Laughlin et al. (42). 
 
 
The key point in regulating this blood flow redistribution during acute dynamic 
exercise lies in a competition between two fundamental physiological needs (22,41,42). 
First, in an integrated manner, pulmonary, cardiovascular, and muscular systems 
strive for meeting the increased metabolic demands of the exercising musculature. 
Second, appropriate maintenance of MAP is simultaneously needed to ensure there is 
adequate perfusion pressure to all vital organs such as the brain. From a systemic point 
of view, these two coinciding challenges are faced by sympathetic nerve activity, which 
begins to rise when cardiac vagal withdrawal is nearly complete at an HR of ~100 bpm 
(148,153). A dramatic illustration of the importance of sympathetic activity in the 
integrated hemodynamic response to acute exercise in humans is the observation that 
cerebral hypoperfusion may evoke loss of consciousness within one minute of exercise 
in patients with autonomic failure since they cannot maintain their MAP (154). 
The origins of the increase in sympathetic activity are not firmly established, but 
likely involve the action and interaction of the following neural inputs: central 
command, arterial baroreflex, and reflex responses to activation of mechano- and 
metabosensitive afferents within the active skeletal muscle (41,153,155). Central 
command refers to the idea that volitional activation of motor systems causes parallel 
stimulation of brain stem cardiovascular regulatory centers, which causes changes in 
autonomic nerve activity (156). Interestingly, as early as 1893, Johansson (157) 
suggested that the cardiovascular response to exercise was partly caused by 
neurological activation of the heart in parallel with the central neural drive to the 
exercising muscles. Central command is a positive, feedforward reflex contrary to 
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negative feedback reflexes such as the arterial baroreflex (156). The arterial 
baroreflexes are stretch-sensitive afferent receptor systems located primarily in the 
aortic arch and carotid sinus, and they suppress sympathetic activity as part of the 
reflex MAP-lowering responses to the afferent signals (158). For a long time, the 
arterial baroreflex was thought to be turned off during exercise as both HR and MAP 
increase. However, a vast amount of evidence since the 1960s has shown that, instead 
of being turned off, it is reset to a higher pressure during exercise (159-161). The 
mechano- and metabosensitive afferents originating from skeletal muscles are group 
III and IV fibers sensing increases in tension as well as increases in the interstitial 
concentration of chemicals released during increased metabolism (162). Activation of 
these fibers can cause large increases in sympathetic output, MAP, HR, and Q̇ (41). 
Taken together, the central cardiovascular control mechanisms described above 
tune the autonomic nervous system so that the increased demands for blood flow and 
particularly O2 delivery to the exercising musculature can, for their part, be faced 
without a decrease in MAP. Importantly, they are employed simultaneously with local 
vascular control mechanisms, designed primarily for the maintenance of tissue 
homeostasis in the periphery (22,41,42). The following sections, also providing a brief 
insight into these local regulatory mechanisms, will cover blood flow, O2 extraction, 
and O2 utilization in skeletal muscles and cerebral tissue during acute dynamic 
exercise. NIRS, a method to evaluate tissue-specific (im)balance between O2 delivery 
and utilization, will also be presented. 
 
 
2.1.2.2 Skeletal muscle blood flow and oxygen extraction and utilization 
 
Skeletal muscle blood flow 
At rest, skeletal muscle O2 utilization and blood flow account for ~20% of whole-body 
O2 utilization and Q̇, respectively (22,42). However, as introduced in the previous 
section and illustrated in Figure 5, metabolic demands in the periphery and hence 
systemic O2 delivery along with blood flow to the exercising skeletal muscles increase 
considerably during acute dynamic exercise. Data from one-leg knee-extensor exercise 
have shown that blood flow can rise from a few mL/min/100 g muscle at rest to well 
above 300 mL/min/100 g muscle (103,104). Consequently, as skeletal muscle typically 
comprises ~50% of lean and ~35-40% of whole-body mass in normal-weight humans 
(22), it has been concluded that if all the muscles were activated maximally, their blood 
flow would be at least 2-3 times higher than the capacity of the heart to deliver blood 
(102-104). Particularly in terms of whole-body dynamic exercise, this numerical 
discrepancy has given rise to the notion that skeletal muscle is a “sleeping giant” whose 
blood flow must be under tonic vasoconstrictor constraint if hypotension is to be 
averted (163). While sympathetic vasoconstriction hereby invariably affects muscle 
blood flow during dynamic exercise, it must be, however, overcome by local vascular 
control mechanisms since blood flow within exercising muscles is able to increase 
along with the increased O2 demand (97,103,164). 
The local mechanisms participating in the control of skeletal muscle blood flow 
include mechanical effects of contraction, shear stress-induced vasodilatation, 
conducted vasodilatation, myogenic control, metabolic control, and erythrocyte-
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mediated vasodilatation (42,165). Particularly Laughlin et al. (42) have 
comprehensively reviewed the current knowledge of these mechanisms, and only the 
basics are presented here. First, mechanical contractions per se can lead to the local 
release of vasoactive compounds such as ATP (166) and nitric oxide (NO) (167). 
Second, blood flowing through a vessel applies a frictional force onto the endothelial 
cells lining the lumen of all blood vessels. This physical force, termed shear stress, leads 
to endothelial formation of NO and thus to vasodilatation particularly in large conduit 
arteries (168). Third, conducted vasodilatation refers to vasodilatation, which initiates 
at the microvascular level as a result of hyperpolarization of endothelial and smooth 
muscle cells and conducts to upstream arteries (42). Fourth, myogenic control is 
evidence of the autoregulatory ability of smooth muscle cells, particularly in resistance 
arteries, to constrict as a response to increased transmural pressure and to dilate when 
transmural pressure is reduced (169). Fifth, metabolic control refers to the effect of any 
compound (e.g., adenosine, ATP, CO2, hydrogen, NO, potassium) that mediates 
vasodilatation by acting on receptors of cells such as endothelial or skeletal muscle 
cells, leading to the formation of vasodilatators (e.g., NO, prostacyclin). This metabolic 
control is regarded as a major component in tight local matching of peripheral O2 
delivery to O2 demand (42). Sixth, erythrocyte-mediated vasodilatation is to date the 
only mechanism known to couple the need for O2 with vasodilatator formation; when 
erythrocytes off-load O2 to the tissue, they simultaneously release ATP and NO (170). 
Functional sympatholysis refers to a modulation of the effect of sympathetic activity 
induced by locally formed compounds (particularly ATP (171)), thereby reducing the 
effect of sympathetic vasoconstriction on contracting skeletal muscles (172). Joyner 
and Casey (22) have thoroughly presented the key findings on this over 50-year-old 
concept and concluded that functional sympatholysis does exist at high exercise 
intensities and classically demonstrates the interplay between the central and local 
cardiovascular control mechanisms: during near-maximal exercise conditions when 
80-90% of Q̇ is directed to contracting skeletal muscles, sympatholysis in the smallest 
arterioles ensures adequate flow to the most metabolically stressed muscle regions, 
while vasoconstriction is retained in larger blood vessels. However, all this must 
happen under the tight control of the central mechanisms (i.e., the neural reflexes) 
(22). 
Figure 6 summarizes the central and local cardiovascular control mechanisms that 
work in concert. As a consequence of the illustrated entity, blood flow to exercising 
skeletal muscles is closely matched to changing metabolic demands during acute 
dynamic exercise (97,103,164), as repeatedly mentioned here. However, at the 
microvascular level of exercising muscles (i.e., arterioles, capillaries, and venules) 
where vasodilatation and diffusional gas exchange occurs (173,174), the relationship 
between local blood flow and O2 utilization is not perfectly linear (175-177); muscle 
blood flow increases immediately after the first contraction reflected as a rapid increase 
in microvascular blood flow. This rapid increase results from increasing erythrocyte 
flux and velocity in muscle capillaries (178) and tissue pressure causing vascular 
smooth muscle relaxation and consequent vasodilatation after pressure release (179). 
After the first few contractions, metabolic vasodilatation takes over and accounts for 
most of the rise in muscle blood flow (179). If/when acute dynamic exercise leads to 
HR of near ~100 bpm, muscle sympathetic nerve activity begins to increase 
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(77,180,181). From this point onwards, the interplay between the sympathetic stimulus 
and local vascular control mechanisms determines muscle blood flow. The sympathetic 
activation is likely demonstrated as a period during which the flow increases only 
modestly, and this period is eventually followed by one in which the increase in 
microvascular blood flow is again accelerated (175-177). This final acceleration of blood 
flow is accompanied by a plateau in local muscle O2 extraction, highlighting that any 
observable increase in local O2 utilization necessitates rising blood flow (175-177,182-
186). The acceleration of active muscle blood flow may be due to increased sympathetic 
vasoconstriction in less active tissues (148) but also to functional sympatholysis (22). 
The above-described nonlinear profile of microvascular blood flow leads us to the 
following section dealing with skeletal muscle O2 extraction and utilization. 
 
 
  
 
Figure 6 Simplified summary of key relationships between cardiac pump function, local factors 
contributing to blood flow rise in contracting skeletal musculature, and need to regulate arterial 
blood pressure to guarantee perfusion of central nervous system and other vital organs. 
Modified from Joyner and Casey (22). 
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Skeletal muscle oxygen extraction and utilization 
The Fick principle shows that V̇O2 comprises of Q̇ and C(a-v)O2, the latter of which is 
the difference between CaO2 and CvO2 (Equation 3). During acute dynamic exercise, 
not only Q̇ but also C(a-v)O2 increases. However, the increase in C(a-v)O2 along with 
intensity is not linear, but hyperbolic; C(a-v)O2 rises until reaching ~40-60% of 
V̇O2peak, after which it begins to plateau (41,81,107,175). Eventually, C(a-v)O2 rises 
from ~50 mL O2/L at rest to peak values of ~140-150 mL O2/L (22,41,107,175). 
However, far higher values, over 180 mL O2/L, have been reported in cardiac patients 
with low Q̇ (187) and in physically trained individuals (188,189). When these are 
expressed as per-centage values of CaO2, C(a-v)O2 on average rises from 25% at rest to 
75-85% at peak exercise (22,148), while even 90% of CaO2 may be extracted by cardiac 
patients (187) and physically trained individuals (188,189). 
As already indicated, CaO2 remains nearly constant through various exercise 
intensities (41). Hence, the exercise-induced increase in C(a-v)O2 is mainly attributable 
to a decrease in CvO2. Two factors account for the decreasing CvO2. First, 
sympathetically mediated vasoconstriction diminishes blood flow in less active regions 
such as kidneys, splanchnic regions, and less active muscles (143,144,149-152), so that 
their local O2 extraction increases to guarantee adequate O2 utilization (41). Second, 
local O2 extraction rises within the exercising skeletal musculature. 
The widening of O2 extraction in the active muscle during acute dynamic exercise is 
likely explained by “longitudinal capillary recruitment”, presented by Poole et al. in two 
extensive reviews using the supporting-opposing approach (178,190). This theory lies 
on evidence that, in many preparations, a majority of the muscle capillaries are 
perfused already at rest. Thus, instead of recruitment of new flowing capillaries, 
capillary surface area available for O2 diffusion is widened via exercise-induced 
increases in erythrocyte flux and velocity and decreases in intramyocyte O2 pressure. 
Simultaneously, a rise in capillary Hb content substantially elevates O2 diffusion 
capacity (178,190). This theory of “longitudinal capillary recruitment” challenges the 
older idea of exercise-induced recruitment of new flowing capillaries presented by 
Nobel Prize recipient August Krogh in 1919 (191,192). The issue has been a matter of 
some debate in the paper of Clark et al. (193) and subsequent point-counterpoint 
discussion. 
Several studies using NIRS have shown that local microvascular O2 extraction 
within exercising skeletal muscles follows a nonlinear, S-shaped profile from low 
intensities to peak exercise: muscle O2 extraction remains relatively constant at low 
intensities, increases in a steeper manner during moderate exercise, and typically (but 
not always) reaches a plateau at higher intensities (175-177,182-186). This extraction 
profile reflects the nonlinear relationship between local microvascular blood flow and 
O2 utilization, described in the previous section, and is thus explained by changes in a 
dynamic balance between local O2 delivery and utilization (175-177). However, these 
responses are heterogeneous between exercising muscle groups: there is a rightward 
shift in the S-shaped O2 extraction profile in deeper muscles compared to more 
superficial ones (185,186), which is likely due to higher vascularization, blood flow, 
and/or proportion of oxidative muscle fibers in deep muscles (194). Nevertheless, little 
heterogeneity seems to exist in the ratio of regional V̇O2 and blood flow (164), 
indicating again that blood certainly goes where it is needed. 
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After traveling from the atmosphere to the myocytes of the exercising skeletal 
muscles, O2 is utilized in a mitochondrial process of oxidative phosphorylation to 
produce energy (i.e., ATP) in accordance with Equation 1 (23). Mitochondrial capacity 
to utilize O2 has been shown to exceed V̇O2peak achieved during whole-body dynamic 
exercise (106). This would explain why recruiting more active muscles at or near 
V̇O2peak does not typically lead to further increases in Q̇ or V̇O2 (22,41), as mentioned 
earlier, and thus supports the idea that systemic O2 delivery governs V̇O2peak. However, 
Gifford et al. (195) have recently demonstrated how mitochondrial capacity to utilize 
O2 does exceed whole-body V̇O2peak in trained but not untrained individuals. Thus, it is 
possible that, in certain circumstances, the heart can supply enough O2 to meet the 
maximal demands of the mitochondria for O2. In other words, muscular capacity to 
utilize O2 may determine V̇O2peak in such cases. This is definitely the case in patients 
with McArdle’s disease (196) or mitochondrial myopathies (197), in which intracellular 
metabolism sets detrimental limitations on V̇O2peak. Mitochondrial oxidative 
metabolism may determine V̇O2peak also in sedentary individuals without any specific 
myopathy. Their V̇O2 has been shown to increase nonlinearly along with increasing O2 
fraction of inspired air (198,199), contrary to trained individuals, in whom the 
corresponding increase is linear (200,201). This agrees with the above-mentioned 
recent findings of Gifford et al. (195). Such a peripheral limitation to V̇O2peak has also 
been suggested by studies in which reduced peak C(a-v)O2 has been observed in 
subjects with obesity (202) or type 2 diabetes (203). All of these findings emphasize 
the integrated nature of the Fick principle (Equation 3); each component of the 
principle truly affects the pathway for O2 from the atmosphere to the mitochondria. 
 
 
2.1.2.3 Cerebral blood flow and oxygen extraction and utilization 
 
Total cerebral blood flow is ~0.7-0.9 L/min during various exercise intensities, as seen 
in Figure 5. Some older studies, such as that of Scheinberg et al. from 1954 (204), 
suggested that the effect of exercise on cerebral blood flow is minimal. However, that 
particular study (204) compared cerebral blood flow during upright exercise with that 
at supine rest, thus ignoring the influence of the upright posture-induced decrease in 
cerebral blood flow (205,206). It is now known that the response of cerebral blood flow 
to acute dynamic exercise follows an intensity-dependent trend: cerebral blood flow 
rises until ~60% of V̇O2peak, after which it decreases towards baseline values (140-142). 
In detail, depending on the method used and the area examined, cerebral blood flow 
at its peak is ~10-50% higher during exercise than at rest (42,141). Thus, the magnitude 
of the increase is relatively modest in terms of the amount of systemic blood flow. It is 
of note that cerebral blood flow shows regional distribution, paralleling changes in the 
regional activity and metabolism of the brain, as initially suggested by Lassen et al. in 
the 1970s (207): For example, mean flow velocity rises only in the contralateral middle 
cerebral artery during one-side handgrip exercise (208) and only in the contralateral 
anterior cerebral artery during one-side foot movements (209). However, since 
cerebral blood flow decreases at high intensities as mentioned above, it must be 
regulated to a greater extent by other mechanisms than neuronal activity and 
metabolism (210,211). 
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NIRS, which will be closely examined in the following section, is a method to 
evaluate a regional balance between tissue-specific O2 delivery and utilization. NIRS 
studies have collectively shown that regional microvascular blood volume in the 
prefrontal cerebral cortex increases from low to moderate exercise intensities, which is 
then followed by a decrease in untrained individuals, but an increase in trained ones 
(212). Accordingly, regional microvascular O2 extraction within the prefrontal cortex 
follows different profiles in untrained and trained subjects; in untrained subjects, 
prefrontal O2 extraction first increases from low to moderate intensities, then plateaus, 
and again rises at high intensities. Contrarily, in trained subjects, prefrontal O2 
extraction remains relatively constant at low intensities, increases in a steeper manner 
during moderate exercise, and then begins plateauing at higher intensities (212). 
Hence, fitness status seems to affect regional cerebral O2 delivery (~blood flow) and 
utilization. However, from a methodological viewpoint, it must be recognized that 
when no light-absorbing tracers are used, only regional blood volume but not flow can 
be estimated by NIRS. 
Different mechanisms participating in the regulation of cerebral blood flow aim at 
maintaining MAP so that cerebral perfusion pressure remains adequate at any exercise 
intensity (22,41,42). Cerebral blood flow during acute dynamic exercise is strongly 
regulated by PaCO2 and cerebral autoregulation. Increasing PaCO2 leads to cerebral 
vasodilatation, whereas decreasing PaCO2 causes cerebral vasoconstriction (213). The 
following offers a potential explanation for the above-mentioned difference in exercise-
induced blood volume response between untrained and trained individuals: lower 
chemosensitivity and lower submaximal V̇E of trained individuals attenuate PaCO2 
reduction at high intensities thus resulting in less cerebral vasoconstriction (214). The 
respiratory chemoreflex interacts with cerebrovascular CO2 reactivity so that they 
together strive to maintain cerebral CO2 homeostasis during exercise (215). Cerebral 
autoregulation is a term describing the ability of the cerebral circulation to maintain 
cerebral blood flow within a narrow range over the MAP range of 60-150 mmHg (216). 
It has been demonstrated that cerebral autoregulation is maintained during dynamic 
exercise and seems to compensate for exercise-induced hemodynamic and CO2 
responses (217). However, acute exercise may also impair this autoregulatory ability to 
regulate cerebrovascular tone, but this area warrants further investigation (211). In 
addition to PaCO2 and autoregulation, a variety of other factors, such as PaO2, Q̇, the 
arterial baroreflex, and endothelium-mediated mechanisms, may take part in the 
regulation of cerebral blood flow during exercise, but integrative physiological research 
exploring the complex interactions of these mechanisms is lacking (42,210,211). 
 
 
2.1.2.4 Near-infrared spectroscopy (NIRS) as a method to evaluate tissue-
specific (im)balance between oxygen delivery and utilization 
 
When O2 has bound to Hb, the Hb molecule is more reddish. Instead, the color of Hb 
without O2 is more bluish. This “oxygenation vs. deoxygenation” effect on the color of 
Hb was observed in 1875 by German physician Karl von Vierordt (218). About 50 years 
later Glenn Millikan began metering blood oxygenation in vitro and was the first 
person to coin the term “oximeter” (219). In 1977, Frans Jöbsis reported that a 
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relatively high degree of biological tissue transparency in the range of NIR light (700-
1300 nm) enables real-time noninvasive detection of Hb oxygenation using 
transillumination spectroscopy (220). Jöbsis’s observations made him the founder of 
in vivo medical NIRS and launched the development of NIRS methodology, which 
enables noninvasive metering of tissue-specific oxygenation status. In other words, 
NIRS is a method to evaluate local tissue-specific (im)balance between O2 delivery and 
utilization. In clinical research, NIRS was first used to transilluminate the newborn 
head in 1985 (221). 
As a result of its broad applicability, in vivo NIRS has been validated by numerous 
studies focusing on different tissues and using varied experimental modalities as 
presented by the comprehensive review of Ferrari et al. (222). While there is no other 
method quantifying exactly the same variables as NIRS does, the validation studies 
regarding NIRS have largely been based on examining correlations between NIRS 
variables and other methods. For example, Wilson et al. (maximal incremental cycling 
exercise) (223) and Vogiatzis et al. (submaximal graded cycling exercise) (164) have 
observed very strong correlations (e.g., r = -0.97 with a range of -0.97 - -0.98 in the 
study of Wilson et al.) between NIRS-derived (de)oxygenation status in the active 
vastus lateralis muscle and directly measured venous O2 saturation. However, NIRS 
truly has inherent methodological weaknesses that must always be considered when 
one performs NIRS experiments or interprets NIRS data. These methodological issues 
will be detailed at the end of this section, after first presenting the physico-
mathematical principles of NIRS in the following paragraphs. 
The physical principles of NIRS are based on the propagation of light through 
biological tissue. The propagation depends on reflection, absorption, and scattering. 
Reflection is determined by the angle of the light beam in relation to the tissue surface. 
Absorption of light by tissue causes light attenuation and depends on certain 
compounds known as chromophores (224). Each chromophore has its absorption 
spectrum in which the specific extinction coefficient is expressed as a function of 
wavelength (224). At least the following oxygenation-dependent chromophores are 
present in biological tissue: oxygenated Hb (O2Hb), deoxygenated Hb (HHb), 
myoglobin (in muscle only), and cytochrome oxidase (222). Light attenuation is 
measured in optical density and can be quantified using the Beer-Lambert law (225): 
 
(9) OD = log (I0 / I) = α × c × d 
 
where OD is dimensionless optical density of the medium (e.g., biological tissue), 
I0 is incident light intensity, I is transmitted light intensity, α is the specific extinction 
coefficient of the chromophore, c is the concentration of the chromophore, and d is the 
distance between light entry and exit points. 
Scattering, which is the third factor affecting light propagation through biological 
tissue, is the deviation of the light beam straight trajectory due to particulate matter in 
the sample. Scattering results in an increased optical pathlength traveled by the light 
beam in tissue, thus causing light attenuation via increased light absorption; ~80% of 
the total attenuation of NIR light is due to scattering (224). Hence, scattering is the 
biggest problem when quantifying optical density, and since the Beer-Lambert law was 
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originally intended for use in a nonscattering medium, the law has been modified to 
take this issue into account (226): 
 
(10) OD = log (I0 / I) = α × c × d × DPF + G 
 
where DPF refers to the differential pathlength factor and G to the O2 independent 
light losses due to scattering in the medium. DPF depends on age and the tissue of 
interest (227-229) and accounts for the scattering-induced increase in the optical 
pathlength, whereas G is assumed to have the same value for any chromophore in the 
medium and thus cleared. Furthermore, as DPF and the geometrical distance d are 
known and remain constant during any measurement period, quantitative data on 
changes in the concentration of any chromophore can be derived as follows (224): 
 
(11) ∆c = ∆OD / (α × d × DPF) 
 
where ∆ refers to a difference between two time points during any measurement 
period. The basic idea of Equations 9-11 is illustrated in Figure 7. 
 
 
 
 
Figure 7 Incident (I0) and transmitted (I) light beams in a scattering medium (A) such as biological tissue 
(B), where transmitted light travels a banana-shaped pathway before reaching its receiving 
detector. Chromophores are symbolized by black dots. Light beam 1 is scattered and 
therefore travels a distance equaling differential pathlength factor times the geometrical 
distance d. Light beam 2 is absorbed completely after being scattered. Modified from User 
Manual Oxymon Mk III (Artinis Medical Systems, Zetten, The Netherlands) (A). 
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Several different techniques to physically carry out NIRS measurements have been 
developed, applied, and extensively described in numerous reviews (e.g., 
222,224,230). The main focus here is on continuous wave instruments and the 
parameters based on the measurement of O2Hb and HHb. 
Continuous wave NIRS instruments have been perhaps the most widely used NIR 
spectrophotometers to date. Continuous wave means that only changes in light 
intensity are measured, and the concentration changes of the chromophores of interest 
(e.g., O2Hb and HHb) are to be resolved based on Equations 9-11. The number of the 
chromophores of interest determines the number of required light wavelengths. This 
continuous wave method usually relies on the DPF method described above and only 
allows the continuous quantification of relative values (222,224,230). A source-
detector distance of >2.5 cm is recommended to achieve a nearly constant DPF in all 
tissues (228). The continuous wave method is inexpensive and relatively robust, 
although it assumes that coupling and light scattering over time are constant, and that 
changes in absorption are only due to blood (222,224,230). 
Other NIRS methods include spatially resolved spectroscopy and time resolved 
spectroscopy, among others (222,224,230). Spatially resolved spectroscopy, also called 
multidistance spectroscopy, is based on light intensity being measured at several 
different source-detector distances (231,232). This method assumes that the light 
coupling between the optodes and the tissue is the same for different source-detector 
distances, and, by measuring the light attenuation as a function of the distance, 
determines a parameter that is independent of the coupling (231). This allows the 
determination of an O2Hb/(O2Hb+HHb) ratio, which is known as the tissue saturation 
index (TSI). Time resolved spectroscopy, also known as time domain spectroscopy, is 
a technique measuring not only the light intensity but also the time the light takes to 
pass through the tissue. This eventually allows the measurement of absolute 
concentrations of the chromophores of interest (224,230,233). Time resolved 
spectroscopy usually requires large and expensive instrument, which limits its usability 
(224,230). 
NIRS evaluates tissue (de)oxygenation, reflecting the regional (im)balance between 
O2 delivery and utilization, as repeatedly noted here. It does so by monitoring either 
relative concentration changes or absolute concentrations of oxygenation-dependent 
chromophores within the microvasculature (i.e., arterioles, capillaries, and venules) of 
the examined tissue (222,234). Regional blood flow can also be quantified or assessed 
by NIRS: by using NIRS and a light-absorbing tracer, such as indocyanine green, tissue 
blood flow can be quantified by regionally applying the Fick principle (139,164,235). 
Furthermore, blood flow in the vastus lateralis muscle can be mathematically assessed 
without tracers by a method also relying on the regional application of the Fick 
principle (see Section 5.1.5.3 for details) (175-177). In addition, regional blood volume 
but not flow can be evaluated by total Hb (tHb = O2Hb + HHb) (222,234). Altogether, 
NIRS can provide important information regarding the profiles of regional vascular 
responses and fractional O2 extraction within the skeletal muscle (175-177,182-
186,233,236-238) and/or cerebral (236,239-242) tissue, for example, during acute 
dynamic exercise. 
The following methodological issues have to be considered with NIRS: First, Hb 
and myoglobin have similar absorption spectra within the range of NIR wavelengths, 
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thus being indistinguishable with NIRS. In fact, muscle myoglobin may occupy from 
~10% (243,244) to ≥50% (245) of the NIRS light absorption signal. However, Davis 
and Barstow (245) have summarized existing data on similar kinetics of muscle 
deoxygenation (Hb and myoglobin) and muscle arterial-venous O2 difference ((a-v)O2) 
and have suggested that, despite its potentially great contribution to the NIRS signal, 
myoglobin does not invalidate the interpretation that particularly HHb data reflect 
regional O2 (im)balance also in muscle tissue. Second, muscle measurements may be 
confounded by subcutaneous adipose tissue; the maximum measurement depth of 
NIRS is approximately half the source-detector distance in muscle tissue (246) as well 
as in the cerebrum (247), meaning that an exceptionally thick layer of fat (and/or skin) 
prevents a substantial amount of light from passing through the muscle tissue. This 
further leads to the underestimation of muscle O2 metabolism as adipose tissue is 
metabolically more passive (248). Third, NIRS experiments may be affected by local 
changes in skin blood flow when performed under conditions inducing cutaneous 
vasodilatation (e.g., local warming, high-intensity or prolonged exercise). According to 
the most recent literature, this is likely the case when monitoring O2Hb or tHb in 
muscle (249-251) and cerebral (252,253) tissue. On the contrary, the same studies have 
consistently shown that HHb and TSI responses are highly insensitive to changes in 
skin blood flow (249-253). Fourth, the spatial heterogeneity of local blood flow and O2 
extraction profiles between deep and superficial muscles (185,186,194), described 
earlier, must be considered when interpreting NIRS data in muscle experiments. 
 
 
2.1.3 PEAK OXYGEN UPTAKE (V̇O2peak) 
 
2.1.3.1 V̇O2peak as a concept 
 
V̇O2peak represents the highest achievable level of whole-body oxidative metabolism 
(Equation 1) and is formed according to the Fick principle (Equation 2). The highest 
pulmonary O2 uptake, typically measured during a maximal incremental CPET 
involving large muscle groups (20,21), is traditionally expressed as V̇O2max referring to 
maximal V̇O2. This “max” term refers to almost 100-year-old observations of an 
English Nobel Prize physiologist Archibald V. Hill and his colleagues, who made 
careful experiments of V̇O2 on one subject running around a grass track (254,255). Hill 
et al. (255) found that the highest V̇O2 attained was similar at the speed of 243 m/min 
and at higher speeds of up to 282 m/min. Based on these findings of plateauing V̇O2 
(254,255), Hill et al. stated that, “…however much the speed (or work rate) be increased 
beyond this limit, no further increase in oxygen intake occur” (254). Later, these 
observations about body’s maximal ability (or rate) to utilize O2 were confirmed, for 
example, in the classic studies by Taylor et al. (256) and Åstrand and Saltin (257). 
However, only up to ~50% of individuals demonstrate a V̇O2 plateau before symptom 
limitation when stressed to maximal effort (56-58). Consequently, the term V̇O2peak is 
often used as an appropriate estimate of V̇O2max to describe the absence of the plateau 
phenomenon (21,258). 
Since plateauing of V̇O2 may or may not be demonstrable in any given individual, 
different end criteria for verifying maximal effort have been presented (56,259) and 
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used widely for several decades (258). These alternative criteria particularly include a 
respiratory exchange ratio (RER = V̇CO2 / V̇O2) and blood lactate concentration 
(56,259). The rises of RER and lactate concentration at high exercise intensities are 
due to an imbalance between the formation and elimination of acids, particularly lactic 
acid, induced by increases in anaerobic energy metabolism (260). Recently, a study on 
a large random Norwegian population has presented recommended age- and sex-
related reference values of RER and lactate concentration to be used when defining 
maximal physical effort (56). 
Before presenting V̇O2peak as an integrated physiological model, three important 
aspects, providing a framework for the interpretation of any V̇O2peak observations, are 
noteworthy. First, the heritability of V̇O2peak, even when adjusted for age, sex, and 
anthropometrics, is at least 40% (261). Second, V̇O2peak has a relatively low day-to-day 
variability of 2-4% (41). Third, V̇O2peak and its components are important, but by no 
means the only factors determining endurance exercise performance; for example, 
motivation, tolerance for pain and dyspnea, development of neuromuscular fatigue, 
and the intensity of exercise that can be attained before a significant rise in lactate 
concentration, all fundamentally affect endurance performance (25,28). 
 
 
2.1.3.2 V̇O2peak as an integrated model 
 
The integrated nature of the pathway for O2 from the atmosphere to mitochondria has 
been repeatedly emphasized here. Furthermore, the pathway, containing serial steps 
of V̇A, alveolar-to-capillary diffusion, circulation, and muscle diffusion, has been 
detailed step by step together with references to the Fick principle (Equation 2). 
Eventually, V̇O2peak truly forms as an integrated model and depends on all of the serial 
steps presented (23-30). In addition to its serial nature, this model, which has mainly 
been theorized by Peter D. Wagner over the last three decades (23-27), relies on a 
principle that O2 throughput at each step must conserve O2 mass. The model ends up 
replacing the standard question of “what limits V̇O2peak?” with the more precise 
question of “how important are various independent variables to V̇O2peak?” 
The conceptual basis for the integrated pathway for O2 from the atmosphere to the 
mitochondria is illustrated by Figure 8. Figure 8 describes the coexistent processes of 
circulatory O2 convection (~blood flow) to and diffusion within muscle; these can be 
explained by two equations. The first equation is the previously mentioned Fick 
principle (Equation 3), and the second equation underlies the Fick law of diffusion (23-
25,27): 
 
(12) V̇O2 = D × (PcapO2 – PmitO2) 
 
 where D is muscle O2 diffusional capacity (or conductance), PcapO2 reflects mean 
capillary O2 pressure between the artery and vein and in effect serves to integrate O2 
diffusion along the capillary length, and PmitO2 refers to mitochondrial O2 pressure. 
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Figure 8 Conceptual basis for the coexistent processes of circulatory O2 convection (i.e., blood flow 
provided by cardiac output [Q̇]) and O2 diffusion from erythrocytes to muscle mitochondria. O2 
mass must be conserved through these processes; therefore, the convection must obey the 
Fick principle (V̇O2 = Q̇ × (CaO2 – CvO2)), and the diffusion must obey the Fick law of diffusion 
(V̇O2 = D × (PcapO2 – PmitO2)). In the latter equation, D is muscle O2 diffusional capacity, 
while PmitO2 refers to mitochondrial O2 pressure. See text for details. Modified from Wagner 
(27). 
 
 
Mean capillary O2 pressure is ~40-50 mmHg (262), whereas mitochondrial O2 
pressure must be less than 3-4 mmHg, which is the measured value of the O2 pressure 
associated with myoglobin in the cytoplasm during strenuous exercise (263). In 
consequence, as mitochondrial O2 pressure is very low relative to mean capillary O2 
pressure, it is taken to be zero and hence neglected. With these approximations, 
Equation 12 may be rewritten as follows (23-25,27): 
 
(13) V̇O2 = D × PcapO2 = D × k × PvO2 
 
where k is a constant and PvO2 is partial pressure of muscle venous O2. 
The Fick principle (Equation 3) and Equation 13 embody the same undisputed law: 
O2 mass is conserved during the pathway for O2 from the atmosphere to the 
mitochondria. Herewith, both equations must yield the same V̇O2 and PvO2. Since both 
Equations 3 and 13 relate V̇O2 to venous O2 levels, they can be plotted on one diagram 
with V̇O2 on the y-axis and PvO2 on the x-axis. In this diagram, which is shown in 
Figure 9A, the intersection point of two plots is the only point where conservation of 
O2 mass exists, therefore indicating the value of V̇O2peak for the given values of Q̇, CaO2, 
and muscle O2 diffusional capacity. This is where the integrated, in-series nature of 
V̇O2(peak) is etched; if any of Q̇, CaO2, or diffusional capacity is changed, the plots in 
Figure 9A will shift, yielding a different intersection point (i.e., different V̇O2peak) (23-
25,27). Figures 9B-F detail how such changes in independent key variables would affect 
V̇O2peak and PvO2; changing inspired O2 pressure and therefore PaO2, SpO2, and CaO2 
will produce a linear and proportional relationship between V̇O2peak and PvO2 (Figure 
9B) (201,262). Figures 9C and 9D contrast the effects of reduced Q̇ (and/or muscle  
  
 43 
 
 
Figure 9 Plot of pulmonary O2 uptake (V̇O2) against partial pressure of muscle venous O2 (PvO2) 
showing the two mass conservation equations describing circulatory O2 convection into the 
muscle microcirculation (Fick principle), and subsequent O2 diffusion from the microcirculation 
to the mitochondria (Fick law of diffusion) (A). Effects of progressive reduction of partial 
pressure of arterial O2 (B), reduced cardiac output (Q̇) (and/or muscle blood flow) (C), reduced 
muscle O2 diffusional capacity (D), high (E) and low (F) mitochondrial metabolic capacities to 
utilize O2 on V̇O2peak are described. See text for further details. Modified from Wagner (27). 
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blood flow) versus impaired muscle O2 diffusional capacity, respectively; the former 
reduces PvO2 as V̇O2peak is lowered, whereas the latter reduces V̇O2peak but increases 
PvO2 (23,25,27). Furthermore, Figures 9E and 9F illustrate the effects of mitochondrial 
metabolic capacity to utilize O2 on the model; metabolic capacity to utilize O2 has been 
demonstrated to exceed whole-body V̇O2peak (Figure 9E) (106), but as already 
mentioned earlier, this is not necessarily the case (Figure 9F) in sedentary/untrained 
individuals (195,198,199), let alone patients with McArdle’s disease (196) or 
mitochondrial myopathies (197). 
 
 
2.1.3.3 V̇O2peak as a predictor of cardiovascular disease and mortality 
 
In 1859, Charles Darwin published his theory of evolution as a constant struggle among 
individuals with different degrees of fitness within a species (264). In this regard, 
studies on a wide range of biological organisms have to date shown that oxidative 
metabolism has strong associations with overall physical capacity and health, which 
presumably is a product of the pivotal role of O2 in our evolutionary history (265). 
V̇O2peak represents the highest achievable level of whole-body oxidative metabolism, 
thereby reflecting so-called cardiorespiratory fitness. Today, over 150 years after 
Darwin’s writings, in the era of evidence-based medicine and rigorous scientific 
methods, when V̇O2peak is measured and study subjects are followed for years, the data 
supporting Darwin’s concept of “survival of the fittest” are strong and compelling. 
Some of the most essential findings on V̇O2peak and its associations with 
cardiovascular disease and mortality, mainly published over the last three decades, are 
briefly presented here. Blair et al. (266) published a seminal study in the field in 1989: 
After measuring V̇O2peak in 13 344 individuals (77% men) and then following them for 
over eight years, Blair et al. concluded that the higher the initial level of V̇O2peak, the 
lower the subsequent death rate from cardiovascular disease and cancer. These 
findings closely paralleled an earlier follow-up study among 4276 asymptomatic and 
clinically healthy men, in which a lower physical fitness, estimated by exercise time and 
submaximal HR responses, was reported to be associated with a higher risk of death 
from cardiovascular causes (267). More recent studies have substantiated these 
findings in asymptomatic women (268,269). Furthermore, these observations have 
been confirmed in numerous clinical populations such as in patients with clinically 
proven cardiovascular disease (270-272), overweight or obesity (273), diabetes (270), 
or impaired fasting glucose (274). A carefully adjusted meta-analysis, involving 33 
studies and nearly 103 000 individuals, has numerically demonstrated that each 1-
MET (i.e., a metabolic equivalent corresponding the resting V̇O2 of 3.5 mL/min/kg) 
increment in V̇O2peak is independently associated with 13% lower risk of cardiovascular 
event or mortality and 15% lower risk of all-cause mortality (19). In addition, 
individuals with low V̇O2peak of <7.9 METs have 56% and 70% higher risks of 
cardiovascular event/mortality and all-cause mortality, respectively, than those with 
higher V̇O2peak of ≥10.9 METs (19). Herewith, V̇O2peak is certainly an independent 
predictor of cardiovascular health and mortality (19). 
The above-mentioned findings are accompanied and/or characterized by a few 
important details. First, the greatest health benefits, such as a reduction in risk of 
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cardiovascular disease, have consistently been observed between the least fit and the 
next least fit groups (Figure 10B) (266,270,272,274,275). Second, the degree of health 
risk associated with low V̇O2peak is similar to or in some reports even stronger than 
(270,272) that associated with more traditional cardiovascular risk factors such as 
smoking, hypertension, lipid profile, or blood glucose. Additionally, some studies have 
shown low V̇O2peak to be a more powerful predictor of cardiovascular or all-cause 
mortality than exercise-induced ST-segment depression (268,270) or arrhytmias 
(270). In consequence, Myers et al. (276) have recently stated that “… no matter what 
an individual’s health status (i.e., the traditional cardiovascular risk factors), higher 
levels of physical activity and cardiorespiratory fitness improve the overall 
cardiovascular risk profile”. Figure 10A illustrates this statement. Third, compared 
with physical activity, cardiorespiratory fitness is likely a more powerful, and thus, 
more clinically meaningful prognostic measure of cardiovascular risk (Figure 10B) 
(275). In summary, these observations support the previous conclusion; in terms of 
overall risk stratification, V̇O2peak is a strong and independent predictor of 
cardiovascular health and mortality. 
 
 
 
 
Figure 10 Illustration of essential roles of physical activity and peak pulmonary O2 uptake (V̇O2peak ~ 
cardiorespiratory fitness) in relation to traditional risk factors in determining cardiovascular 
disease risk (A). Decrease in relative cardiovascular risk along with percentiles of increasing 
physical activity or V̇O2peak (B). See text for more detailed interpretation. Modified from Myers 
et al. (276) (A), and Franklin and McCullough (277) and Williams (275) (B). 
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2.1.4 EFFECTS OF ENDURANCE TRAINING ON OXYGEN DELIVERY AND 
UTILIZATION DURING ACUTE DYNAMIC EXERCISE 
 
More than 100 years ago, the effect of exercise training on peak Q̇ was perhaps first 
described by Henschen (278), who used only a basic physical examination with careful 
percussion to identify enlargement of the heart due to athletic activity in cross-country 
skiers. Current knowledge of the effects of regular exercise training on the various 
organ systems participating in O2 delivery and utilization is mainly based on scientific 
observations made since the 1960s (40,41). The focus of the following Sections 2.1.4.1-
2.1.4.2 is on endurance-type exercise training and adaptations in both the different 
components of systemic O2 delivery and skeletal muscles. Section 2.1.4.3 will then 
cover these adaptations in light of the Fick principle and the Fick law of diffusion 
(Equations 2, 3, and 13), describing the integrated pathway for O2 from the atmosphere 
to the mitochondria. 
 
 
2.1.4.1 Effects of endurance training on systemic oxygen delivery 
 
Endurance training reduces V̇E at a given submaximal V̇O2 level (214,279). This lowers 
the percentage of the total exercise O2 cost attributable to pulmonary function and may 
thus be beneficial for two reasons. First, fatiguing exercise effects on ventilatory 
musculature (280) are reduced, which attenuates the vasoconstrictive influence of 
reflexly increased sympathetic activation on skeletal muscle vasculature (281). Second, 
any O2 freed from use by the ventilatory muscles becomes available to the exercising 
skeletal muscles (137). In terms of integrated exercise responses at peak exercise, 
problems may be caused by the fact that training has little effect on lung structure 
(282): positive training adaptations outside the lungs (i.e., particularly in the heart and 
the skeletal musculature) enable higher endurance performance, and thus, lead to 
increasing ventilatory requirements at peak exercise, concomitantly leading to 
increased peak pulmonary blood flow facilitated by a training-elicited rise in peak Q̇ 
(41). This can result in V̇A/Q̇ mismatch, which may at least partly cause EIAH, hence 
setting limitations on increases in peak systemic O2 delivery and V̇O2peak (41,69). 
Consequently, trained athletes in particular may undergo EIAH during exercise (69-
71), as mentioned earlier. 
Dynamic endurance training elicits both structural and functional cardiac 
adaptations. The findings presented here are mainly based on observations of the left 
ventricle, acknowledging that at least structural remodeling of the right ventricle 
resembles that of the left one (283). Both cross-sectional and longitudinal studies have 
shown training-induced structural adaptations to include increases in left ventricular 
diameter (90,91,93), wall thickness (89-91), and mass (89,90,92,93). Importantly, 
training also leads to enhanced ventricular compliance, resulting in larger EDV via a 
greater use of the Frank-Starling mechanism (89,94). Functionally, endurance training 
leads to more rapid diastolic filling (85-87), whereas data on changes in early diastolic 
relaxation rate are controversial (92,284). Collectively, the diastolic (and structural) 
adaptations lead to increased EDV and hence larger SV during acute exercise. 
Contrarily, systolic function, typically evaluated by EF, has a minor role in training-
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induced functional cardiac remodeling (283), although occasional cross-sectional 
studies have reported both greater contractility (95,96) and longer ventricular ejection 
time (86,87) in individuals with pronounced SV. Likely secondary to the training-
induced increase in SV, resting and submaximal HR lower after endurance training 
(40), whereas training has little effect on peak HR (22,48). Thus, the training-elicited 
rise in peak Q̇, which further leads to increases in peak systemic O2 delivery and 
V̇O2peak, is due to the adaptations enabling increased peak SV (40,41). 
Both BV and tHb-mass may be up to 50% higher in endurance athletes with high 
V̇O2peak than in untrained individuals (125). By contrast, [Hb], formed as a ratio of 
“coincidingly” increased BV and tHb-mass, has no associations with V̇O2peak (125,127). 
Endurance training leads to the hypervolemic expansion of BV mainly via three 
mechanisms: first and second, an aldosterone-sodium retention mechanism together 
with increasing plasma albumin content lead to expanded plasma volume (285). This 
expansion of body water begins immediately after a single exercise session mainly due 
to the activation of a renin-angiotensin-aldosterone cascade as a response to acute 
exercise-induced reduction of plasma volume (41,124,285). Third, erythrocyte volume 
and therefore tHb-mass begin increasing BV after ~10-14 days of training, or in other 
words, after the plasma volume expansion has first peaked and then plateaued above 
the initial level (286). The exact mechanisms of such training-induced erythropoiesis 
under normoxic conditions are not fully understood (287). Importantly, the training-
induced expansion of BV does not stimulate a feedback diuresis, as CVP is reset to a 
higher operational range allowing greater intravascular volume (288). Overall, both 
studies employing acute BV expansion by intravenous colloid infusions (86) and 
studies re-establishing BV to a pretraining level by phlebotomy after a training 
intervention (289) have demonstrated the importance of expanded BV; increased BV 
increases cardiac preload, ventricular filling, and SV, thereby increasing peak systemic 
O2 delivery and V̇O2peak. 
 
 
2.1.4.2  Effects of endurance training on skeletal muscle blood flow and oxygen 
extraction and utilization 
 
In individuals with no vascular dysfunction at the onset of any training period or 
intervention, endurance training seems to lead to lower blood flow within the 
exercising skeletal musculature during submaximal dynamic exercise (40). This is 
mainly allowed by a training-induced increase in absolute local O2 extraction (290). At 
peak exercise, skeletal muscle blood flow rises as a consequence of endurance training 
(22,40). The rise in peak muscle blood flow is partly due to increased peak Q̇ and an 
increased proportion of that peak Q̇ to be distributed to active muscles (41). In 
addition, endurance training results in several adaptations within both the skeletal 
muscle vasculature and the mitochondria, which underlies the above-mentioned local 
changes in submaximal and peak responses. 
Vascular adaptations to endurance training are both structural and functional. 
Training constitutes a powerful stimulus for capillary proliferation, and hence, the 
elevation of muscle capillary density (291). This importantly leads to increased mean 
blood transit time (102), during which more O2 can be extracted (290) and diffused 
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from the microvasculature to the myocytes, allowing the above-mentioned reduction 
of muscle blood flow during submaximal exercise. Local O2 extraction may further be 
enhanced by training-induced decreases in blood flow heterogeneity (290), possibly 
demonstrated as improved matching of local O2 delivery and utilization during acute 
dynamic exercise (292). Endurance training also enlarges the luminal diameters of 
arterioles as well as their respective conduit arteries, which is favorable in terms of 
increasing blood flow and O2 delivery capacity throughout the arterial vasculature 
(293). This enlargement particularly occurs in response to elevated blood flow, which 
first increases flow-mediated shear stress on the endothelium, thereby stimulating 
both NO production and bioavailability in the endothelial wall. Further, the increase 
in functional NO bioactivity leads to the vessel enlargement if exercise training 
continues. Arterial vessels in other words grow in size to normalize shear stress 
(293,294). Accordingly, NO has a substantial role in structural and functional vascular 
adaptations, although it is not the sole local factor mediating beneficial health effects 
on the vasculature (295); Hellsten and Nyberg (40) have recently presented other 
training-induced functional adaptations of the vasculature in their extensive review.   
Endurance training also improves the oxidative capacity of the skeletal 
musculature. This occurs via increases in mitochondrial content (296,297), 
mitochondrial inner membrane surface (297), and activities of mitochondrial oxidative 
enzymes (296,298). In addition, the mitochondrial adaptations are accompanied by 
selective muscle fiber hypertrophy and fiber type transformation to a more oxidative 
direction (299). If an individual’s metabolic capacity to utilize O2 exceeds O2 delivery 
capacity and thus whole-body V̇O2peak as earlier illustrated in Figure 9E, its further 
training-induced increase does not further improve the individual’s V̇O2peak but does 
have beneficial influences on overall endurance performance: for example, improved 
oxidative metabolism delays the prominence of anaerobic metabolism during 
submaximal exercise (300), in addition to which muscle glycogen is spared longer as 
energy production can rely more on β-oxidation of free fatty acids (301). This 
demonstrates that while V̇O2peak and its components are important, they are by no 
means the only factors determining endurance exercise performance, as pointed out 
earlier. 
The vascular and mitochondrial adaptations mentioned in this section are revealed 
in the NIRS profiles of local muscle microvascular O2 extraction during maximal 
incremental dynamic exercise. A cross-sectional study has suggested that training 
leads to a rightward shift of the profile, when microvascular O2 extraction during 
maximal incremental dynamic exercise is examined in relation to maximal extraction 
capacity (177); in other words, relative muscle O2 extraction remains constant longer 
at low intensities, begins increasing later during moderate exercise, and also reaches a 
plateau later at higher intensities. Another cross-sectional study described how NIRS-
derived microvascular O2 extraction is higher from submaximal to peak exercise in 
trained individuals than in less trained persons when extraction is interpreted as “more 
absolute” units (i.e., μmol/L) not related to maximal extraction capacity (182). To 
verify this, a longitudinal study recently showed that aerobic training leads to an 
increase in NIRS-derived microvascular O2 extraction (not related to maximal 
extraction capacity) from submaximal to peak exercise (302). 
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2.1.4.3 Endurance training effects in the context of Fick’s theories 
 
In 1968, Saltin et al. (188) published their landmark “Dallas Bedrest” study describing 
the alterations in V̇O2peak resulting from two sequential interventions, which were 20 
days of bed rest and almost eight weeks of training. In terms of training adaptations 
and the Fick principle (Equation 2), Saltin et al. (188) concluded that their observation 
of training-induced increase in V̇O2peak (+18.5%) was explained by increases in both 
peak Q̇ (+14%) (or actually peak SV) and peak C(a-v)O2 (+4.5%). This kind of 
interpretation fails, however, to acknowledge the integrated relationship between 
training-induced elevations of systemic blood flow (i.e., peak Q̇) and increased muscle 
O2 diffusional capacity. Such a failure was recently highlighted by Wagner (303), who 
reanalyzed the data of the “Dallas Bedrest” study in light of the Fick law of diffusion 
(Equation 13). Wagner (303) observed that the great majority of the improvement of 
V̇O2peak was actually attributed to the increase in muscle O2 diffusional capacity 
(+23.4%), and only a small amount due to elevated peak Q̇. This reanalysis of 
demonstrates that the only way to observe training-induced increases simultaneously 
in both peak blood flow (~peak Q̇) and peak C(a-v)O2 is when muscle O2 diffusional 
capacity increases relatively more than peak Q̇. In other words, if peak Q̇ was increased 
without any change in diffusional capacity, peak C(a-v)O2 would be compromised by 
the reduction in mean blood transit time through the microcirculation. Unfortunately, 
Wagner had no data to identify whether the elevation of muscle diffusional capacity 
stems from increased muscle capillarity, greater subsarcolemmal mitochondrial 
content, or some other factor (303). It is noteworthy that this above-mentioned 
importance of the balance between increases in muscle O2 delivery and O2 diffusional 
capacity was interestingly expressed by Saltin himself (102) ~20 years after the 
publication of the “Dallas Bedrest” study. 
When interpreting endurance training effects and improved V̇O2peak in general but 
especially in light of Fick’s theories (Equations 2, 3, and 13), one must recognize three 
important aspects. First, as the described reanalysis of Wagner (303) points out, when 
physically trained individuals are reported to reach either significant increases in 
V̇O2peak (188) or high peak C(a-v)O2 values (189), it is most likely due to the relative 
dominance of peripheral muscle adaptations, although endurance training obviously 
also elicits significant cardiac adaptations. Second, while the rise in muscle O2 
diffusional capacity (if greater than a simultaneous rise in peak systemic blood flow) 
leads to a decrease in peak CvO2 (188), the possible training-induced development of 
EIAH (69-71) is demonstrated as a decrease in CaO2 and thus affects the interpretation 
of C(a-v)O2 and the Fick principle. Third, time courses of different endurance training-
induced adaptations vary considerably; while cardiac and systemic circulatory changes 
(particularly structural adaptations in cardiac morphology) progress rather slowly, 
within months or years, peripheral muscle adaptations (particularly increased 
capillary density and functional flow-mediated vasodilatation) take place more rapidly, 
within the first three months of any training period/intervention (40,41). Eventually, 
regarding training-induced increase in V̇O2peak, cumulative evidence shows that the 
most prominent increase in V̇O2peak is seen within the first two or three months of 
training, after which it continues to increase but in a more moderate manner (40), 
given that training is executed appropriately. 
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2.2 POLYCYSTIC OVARY SYNDROME (PCOS) 
 
2.2.1 DEFINITION AND EPIDEMIOLOGY 
 
PCOS is a syndrome and as such no single diagnostic criterion is sufficient for clinical 
diagnosis. Ever since Stein and Leventhal first described a series of women with oligo- 
or anovulation and polycystic ovaries in 1935 (304), different definitions of PCOS have 
been widely used: In 1990, the National Institute of Health Conference recommended 
that the major criteria for PCOS should include clinical and/or biochemical 
hyperandrogenism and chronic oligo- or anovulation (305). In 2003, the Rotterdam 
consensus expanded the diagnosis of PCOS to be based on the presence of at least two 
of the following three features: clinical and/or biochemical hyperandrogenism, chronic 
oligo- or anovulation, and polycystic ovaries (306). In 2006, the Androgen Excess 
Society recommended that PCOS be defined by clinical and/or biochemical 
hyperandrogenism, with either chronic oligo- or anovulation or/and polycystic ovaries 
(307). All three diagnostic definitions also included the exclusion of other confounding 
endocrine disorders such as hypothyroidism, hyperprolactinemia, and 
hyperandrogenism of some other etiology (305-307). Today, several recent 
international clinical guidelines and reviews (e.g., 308-310) recommend using the 
Rotterdam 2003 criteria (306), which are also applied in Finland (311). 
Worldwide, depending on the population studied, PCOS approximately affects from 
6% to 15% of women according to the 1990 NIH criteria (4-6) and even twice as much 
according to the broader Rotterdam criteria (6,7). The prevalence of PCOS is in the 
middle of these two extremities, when the 2006 Androgen Excess Society criteria are 
applied (6). PCOS is consequently one of the most common human disorders and the 
most common single endocrinopathy in reproductive-aged women (1). Up to 70% of 
women with PCOS are either overweight (25 kg/m2≤ body mass index [BMI] <30 
kg/m2) or obese (BMI ≥30 kg/m2) (312), although the number varies along with the 
population studied and averages ~50% (313). 
 
 
2.2.2 PATHOGENESIS 
 
PCOS is a complex endocrinopathy, and both genetic and environmental factors and 
possibly also epigenetic changes in fetal life contribute to its pathogenesis. However, 
the pathophysiology of the syndrome is not fully understood. Hence, while several 
scholarly papers have reviewed the accumulated evidence in the field (e.g., 1-3), only 
the most important and well-defined links between pathogenesis and clinical 
manifestations are presented here. 
IR drives different phenotypic features of women with PCOS, and thus, has an 
essential role in the syndrome (1-3). Recently, the first study to use the “gold standard” 
method of the hyperinsulinemic-euglycemic clamp to define the prevalence of IR 
among PCOS women indicated that 75% of lean and 95% of overweight PCOS women 
have pronounced IR (314), whereas earlier studies using non-clamp techniques had 
suggested somewhat lower prevalences of ~50-70% (315). A recent meta-analysis of 
clamp studies further verified that PCOS does involve intrinsic syndrome-specific IR 
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in addition to well-identified extrinsic BMI-related IR of overweight and obese women 
(316). 
IR interacts with hyperandrogenism, and this interplay largely forms the basis of 
the PCOS pathophysiology. The molecular mechanisms underlying IR in women with 
PCOS remain elusive (1). However, primary defects in insulin signaling pathways 
particularly in skeletal muscle (317-319) but also in adipose tissue (320) have been 
reported. In addition, pronounced hepatic glucose production has been observed in 
obese PCOS women (320). Subsequently impaired glucose metabolism leads to 
compensatory hyperinsulinemia, which strives to maintain normal glucose levels. 
Hyperinsulinemia contributes to hyperandrogenism particularly via direct stimulation 
of ovarian androgen secretion and inhibition of hepatic sex hormone-binding globulin 
production (SHBG); the inhibition of SHBG production worsens hyperandrogenism by 
increasing the proportion of unbound, and thus, biologically active testosterone in the 
circulation. Androgen excess is also exacerbated by itself as it increases hypothalamic 
release of gonadotropin-releasing hormone, which leads to a rise in pituitary release of 
luteinizing hormone, and hence, to a further elevation of ovarian androgen secretion, 
but also to menstrual dysfunction. It is of note, however, that despite the major 
pathogenetic role of hyperandrogenism, “only” up to 80% of women with PCOS have 
elevated circulating androgen levels (1-3). The clinical manifestations of these 
mechanistic derangements are discussed in the following section. 
 
 
2.2.3 CLINICAL MANIFESTATIONS 
 
PCOS is a chronic condition manifesting across the lifespan (14). Women with PCOS 
exhibit clinical manifestations related to reproductive and hormonal, psychosocial, 
and metabolic and cardiovascular disturbances. Excess weight is an important 
environmental factor contributing to all of these derangements (1-3,12). 
Reproductive and hormonal abnormalities form the basis of the diagnostic criteria 
(305-307) and are primarily caused by IR-driven hyperandrogenism. First, 
hyperandrogenism particularly causes hirsutism but also acne and alopecia. Second, 
hyperandrogenism interacts with hyperinsulinemia to disrupt follicle growth, which is 
then demonstrated as menstrual irregularity, anovulatory subfertility, accumulation of 
small antral follicles within the periphery of the ovary (i.e., “polycystic ovaries” on 
ultrasound), and an increased risk of endometrial cancer (1-3). 
Psychosocial manifestations in PCOS are various: Women with PCOS face 
challenges in feminine identity and body image due to obesity, hirsutism, acne, and 
infertility (12), in addition to which their long-term health-related concerns 
compromise quality of life and adversely affect mood and psychological well-being 
(12,321). 
Metabolic and cardiovascular disturbances in women with PCOS involve increased 
risks of several health complications. With IR being a prominent feature of the 
syndrome, PCOS is associated with ~two- to fourfold increases in risks of impaired 
glucose tolerance, type 2 diabetes, and metabolic syndrome (13), as well as gestational 
diabetes (322). The risks of impaired glucose tolerance or diabetes may be evident 
already during adolescence (323). Vast evidence suggests that lifelong metabolic 
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dysfunction in women with PCOS results in exaggerated risk of cardiovascular disease 
with aging. Impaired glucose metabolism is accompanied by an adverse lipid profile, 
pronounced centralized adiposity, carotid intima-media thickening, coronary artery 
calcification, and an increased prevalence of obstructive sleep apnea, which rather 
consistently but not explicitly are dependent on the severity of hyperandrogenism and 
obesity. However, evidence of increased risk of cardiovascular morbidity and mortality 
in PCOS is surprisingly limited and remains to be established (1,2,14). A few other 
subclinical cardiac and vascular defects observed in women with PCOS are integrated 
in the following section covering acute exercise responses and PCOS.  
 
 
2.2.4 PCOS AND EXERCISE 
 
2.2.4.1 Oxygen delivery and utilization during acute dynamic exercise in PCOS 
 
Since the above-mentioned clinical manifestations elevate cardiovascular and health 
risks in PCOS, and V̇O2peak is known to be an independent predictor of cardiovascular 
and all-cause mortality in women (268,269), it would be tempting to hypothesize that 
women with PCOS demonstrate reductions in V̇O2peak and its subcomponents. 
However, responses to acute dynamic exercise have been sparsely studied in women 
with PCOS. Data on measured V̇O2peak in PCOS are slightly contradictory. The largest 
cross-sectional studies (i.e., 45-90 PCOS women vs. 45-90 non-PCOS women) in the 
field have been conducted in Italy and observed even 48-63% lower V̇O2peak in 
overweight and obese women with PCOS than in age- and BMI-matched healthy 
women (31-33). By contrast, smaller studies (i.e., 8-11 PCOS women vs. 6-14 non-PCOS 
women) from the Commonwealth countries have reported similar V̇O2peak between the 
groups with similar IR profiles (34,35). As the magnitude of IR has also been shown to 
have a strong inverse association with V̇O2peak in PCOS women (31), IR has been 
suggested to be the leading pathophysiological feature affecting V̇O2peak in overweight 
and obese women with PCOS. 
Little is known about the mechanisms affecting exercise responses of O2 delivery 
and utilization, and therefore, V̇O2peak in women with PCOS. At rest, both diastolic 
(324-326) and systolic (326,327) dysfunction, associated with IR (324-327), as well as 
normal cardiac pump function (328-330) have been reported in women with PCOS in 
case-control echocardiographic studies. Theoretically, greater exercise sweating 
observed in overweight and obese women with PCOS (331) may also have a negative 
impact on plasma volume, and thus, cardiac filling at least during prolonged exercise 
performed in a warm environment. Taken together, cardiac dysfunction and 
concomitantly impaired Q̇ and systemic O2 delivery are potential factors affecting V̇O2 
response to acute dynamic exercise in PCOS. 
Peripheral O2 delivery and utilization during exercise may also be influenced by 
PCOS. Women with PCOS exhibit endothelial dysfunction manifested as impaired NO-
mediated vasodilatation (35,332), which has the potential to impair muscle blood flow, 
and hence, exercise tolerance in disease (e.g., chronic heart failure) (333). While it 
remains to be elucidated whether endothelial dysfunction is associated with IR status 
in PCOS (332), it is well acknowledged that endothelial dysfunction and IR have a 
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reciprocal relationship in various diseases (334). An exaggerated systolic blood 
pressure response to maximal exercise has also been reported in PCOS women (335). 
This probably reflects exaggerated SVR and, on a larger scale, increased sympathetic 
nerve activity characteristic of PCOS (336). Defects in skeletal muscle insulin signaling 
pathways (317,318) and expression of genes involved in mitochondrial oxidative 
metabolism (319) have also been observed in PCOS women with pronounced IR, 
possibly reducing responsiveness to glucose and O2 utilization within the skeletal 
musculature. These findings provide some PCOS-specific evidence of mitochondrial 
dysfunction, which is on large scale linked with insulin-resistant metabolic 
derangements (337). However, any potential role of mitochondrial dysfunction behind 
reduced V̇O2peak of PCOS women is controversial since intact gene expression (338) 
and function (339,340) of skeletal muscle mitochondria have also been found in PCOS. 
In conclusion, slightly contradictory evidence suggests that V̇O2peak may be lower in 
women with PCOS than in age- and anthropometry-matched women without the 
syndrome. At least, this is likely the case in women with PCOS and pronounced IR. In 
more detail, appropriate V̇O2 response to exercise may potentially be affected by both 
systemic and peripheral limitations set by PCOS. However, responses of different 
components of systemic O2 delivery or peripheral O2 delivery and utilization to acute 
dynamic exercise have not yet been studied in this patient group. 
 
 
2.2.4.2 Effects of exercise training in PCOS 
 
Based on the limited data available, regular exercise has beneficial effects on overall 
health risks of PCOS women. Exercise-induced improvements in IR, menstrual 
cyclicity, ovulation, self-esteem, quality of life, depression, body composition, and 
V̇O2peak have been reported (341,342). Hence, regular exercise is recommended to be 
an essential part of healthy lifestyle of PCOS women, particularly in those with excess 
weight (308,309). 
 
 
2.3 TYPE 1 DIABETES 
 
2.3.1 DEFINITION AND EPIDEMIOLOGY 
 
Diabetes is a group of systemic conditions characterized by a chronic state of 
hyperglycemia. In ancient times, Greek and Roman physicians used the term 
“diabetes” to describe a finding of a large urine volume, whereas the words “diabetes 
mellitus” referred to the sweet taste of the urine (51); the word diabetes comes from 
the Greek word “diabainein” meaning “to pass through”, whereas the subsequent word 
mellitus originates from the Latin word “mel” referring to honey. The criteria for 
diabetes diagnosis are an increased fasting plasma glucose of ≥7.0 mmol/L or a 2-h 
plasma glucose of ≥11.1 mmol/L during an oral glucose tolerance test or glycosylated 
Hb A1c (HbA1c) of ≥6.5% (≥48 mmol/mol), or a random plasma glucose of ≥11.1 
mmol/L in conjunction with classic hyperglycemic symptoms of polyuria, polydipsia, 
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and weight loss, accompanied by life-threatening ketoacidosis in some cases 
(9,343,344). 
Diabetes is etiologically classified into four categories: type 1 diabetes, type 2 
diabetes, other specific types (e.g., types induced by genetic defects, pancreatic 
diseases, drugs, etc.), and gestational diabetes. The etiology of hyperglycemia in 
diabetes lies in either decreased production of insulin from the pancreatic β-cells or 
diminished effect of insulin on target tissues (i.e., IR), or in variable combinations of 
these two. Type 2 diabetes, which is the most common diabetes type accounting for 
~90-95% of those with diabetes, is caused by such a combination of relative insulin 
deficiency and IR, and has strong associations with genetic predisposition and 
sedentary lifestyle. By contrast, type 1 diabetes, previously encompassed by the terms 
juvenile-onset or insulin-dependent diabetes, is a type caused by a more total cellular-
mediated autoimmune destruction of the insulin-secreting pancreatic β-cells (9). 
Notably, significant overlap exists between these two types, which thus have been 
suggested to merely be different ends of the spectrum of one and the same disease 
(345,346). However, the lack of evidence of genetic overlap between type 1 and type 2 
diabetes (346) justifies the concept of two separate diseases.  
Worldwide, 382 million people were estimated to have diabetes in 2013, and the 
prevalence is expected to reach 592 million people by 2035 (8). Type 1 diabetes 
accounts for 5-10% of all diabetes patients (9), and is typically diagnosed before the 
age of 15 years (10), albeit immune-mediated diabetes can occur at any age, even in 
70–80-year-olds (9). Type 1 diabetes is one of the most common chronic diseases of 
childhood, and its incidence varies markedly depending on the population examined; 
the highest incidence is observed in Finland (~64/100 000/year below the age of 15) 
(11), while the incidence is at its lowest in Venezuela and China (0.1/100 000/year 
below the age of 15) (347). The incidence of type 1 diabetes has been increasing rapidly 
over the past decades; in Finland, the incidence rate doubled nonlinearly from the early 
1980s until 2005, after which it has shown signs of plateauing (11). 
 
 
2.3.2 PATHOGENESIS 
 
Type 1 diabetes is caused by an autoimmune attack directed against β-cells of the islets 
of Langerhans in the pancreas. The attack, mediated by T-cells, results in selective 
destruction of the insulin-secreting β-cells, eventually leading to a complete 
dependency on exogenous insulin (348). The rate of the β-cell destruction is variable, 
typically being rapid in childhood and slower in adults (9). Eventually, at least 80% of 
the β-cells have been estimated to be destroyed at presentation of clinical disease 
(348). As humoral markers of the autoimmune activity, diabetes-associated 
autoantibodies (i.e., antibodies to the 65 kD isoform of glutamic acid decarboxylase, 
insulin autoantibodies, and classical islet cell, protein tyrosine phosphatase-related IA-
2A, and zinc transporter 8 antibodies (349)) can be detected from the circulation in 
~90% patients with newly diagnosed type 1 diabetes (350). Persistent positivity for two 
or more of these autoantibodies is highly predictive of progression to clinical diabetes, 
whereas positivity for a single autoantibody may reflect harmless β-cell autoimmunity 
(348). 
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The cascade leading to the autoimmune activity and subsequent β-cell destruction 
in type 1 diabetes involves both genetic and environmental factors. The most essential 
genes contributing to disease susceptibility are located in the human leukocyte antigen 
region of chromosome 6. These genes explain ~50% of the susceptibility for the 
disease, whereas the other ~50% is caused by over 50 other polymorphisms (346,349). 
Nevertheless, only a relatively small portion (i.e., ~10%) of individuals with human 
leukocyte antigen-conferred diabetes susceptibility progress to clinical disease (348). 
Furthermore, it has been shown that only 2-17% of children with newly diagnosed type 
1 diabetes have family history of the disease (351). In addition, abundant scientific 
evidence from twin, incidence rate, and migrant studies support the view that 
additional environment-related factors are needed to both trigger and contribute to the 
β-cell destruction in genetically predisposed individuals (349). In fact, since the 
proportion of high-risk human leukocyte antigen genotypes has decreased among 
newly diagnosed type 1 diabetes patients, environmental factors have perhaps even 
increased their role in the disease development (352). Over time, environmental 
factors implicated in the etiology of type 1 diabetes have particularly included different 
viruses (e.g., Coxsackie B1 and other enteroviruses) and dietary factors (e.g., vitamin 
D deficiency, short duration of breastfeeding) (349), in addition to which the role of 
the intestinal microbiota in mediating the progression from autoantibody positivity to 
clinical disease has recently been under investigation (353). However, identifying the 
precise roles of known and unknown environmental factors in the pathogenesis of type 
1 diabetes is in its early beginnings and thereafter requires further research (349). 
It further warrants mention that in addition to the above-described factors 
contributing to the autoimmune β-cell destruction, the β-cells are also stressed by IR 
of variable magnitude, which may act as an environmental trigger or contributor, thus 
speeding up the pathogenesis of type 1 diabetes. This “accelerator hypothesis” has 
particularly been linked to excess weight, which especially nowadays may be a problem 
in type 1 diabetes as it is in type 2 diabetes (345). IR also has an influence on 
cardiovascular risk in type 1 diabetes (see Section 2.3.3.2). 
 
 
2.3.3 CLINICAL MANIFESTATIONS 
 
Clinical manifestations of diabetes can be categorized into micro- and macrovascular 
complications. The microvascular complications comprise diabetic retinopathy, 
nephropathy, and neuropathy. The macrovascular complications consist of coronary 
artery, cerebrovascular, and peripheral artery diseases. Simply put, while 
microvascular disease can lead to premature mortality but particularly to substantial 
morbidity diminishing the quality of life, by far the greatest cause of death in patients 
with diabetes is macrovascular disease. Chronic hyperglycemia can also lead to 
diabetes-specific myocardial dysfunction known as diabetic cardiomyopathy. 
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2.3.3.1 Microvascular complications 
 
Results from randomized controlled trials, such as the seminal Diabetes Control and 
Complications Trial (354), have demonstrated that the risk of all microvascular 
complications can be reduced by intensive glycemic control. In addition, other 
modifiable (e.g., blood pressure, lipid profile, smoking status) and nonmodifiable (e.g., 
male predominance, diabetes duration) risk factors also affect the development and 
progression of microvasculature-related manifestations (355-357), naturally adjusted 
by genetic traits. 
Diabetic retinopathy is characterized by gradually progressing alterations in the 
retinal microvasculature and can lead to severe and permanent visual loss. In type 1 
diabetes, retinopathy is present in some of its forms in at least 80% of patients with 
diabetes of 15 years’ duration (355). 
Diabetic nephropathy is clinically characterized by renal protein leakage to the 
urine, decreased glomerular filtration rate, and hypertension (358). Diabetic 
nephropathy has also been suggested to be a marker of overall (micro)vascular 
dysfunction (359), and accordingly, type 1 diabetes patients with nephropathy have a 
10-fold risk of cardiovascular disease relative to patients without nephropathy (360). 
Up to ~30% of type 1 diabetes patients develop diabetic nephropathy after 20 years of 
diabetes, albeit the incidence seems to be decreasing (356). 
Diabetic neuropathy can be divided into sensory polyneuropathies, focal/multifocal 
mononeuropathies, and autonomic neuropathy. Poly- and mononeuropathies 
manifest themselves as various sensorimotor symptoms. Manifestations of diabetic 
autonomic neuropathy particularly include cardiovascular autonomic neuropathy 
(e.g., exercise intolerance, orthostatic hypotension) but also several other disorders, 
the examples of which are gastroparesis and hypoglycemic autonomic failure. 
Prevalence of diabetic autonomic neuropathy depends on the tests used and the 
population studied, thus ranging widely from 1.6% to 90% within diabetes patients 
(357). 
 
 
2.3.3.2 Macrovascular complications 
 
Atherosclerosis is a common feature in individuals with diabetes and leads to severe 
macrovascular complications such as coronary artery, cerebrovascular, and peripheral 
artery diseases. These macrovascular complications are hence the predominant cause 
of death also in patients with type 1 diabetes (361). A study of Livingstone et al. (362) 
was one of the recent extensive population studies in the field and concluded that while 
the relative risks of macrovascular disease and total mortality seem to have declined in 
type 1 diabetes patients over time, the risks are still at least twofold compared to 
individuals without diabetes; findings in type 2 diabetes studies have recently been 
relatively similar (363). 
Risk factors for macrovascular disease include dyslipidemia, hypertension, 
nephropathy, obesity, and smoking, are largely modifiable, and overlap between 
diabetes types. In addition, female sex, IR, and inflammation increase the 
cardiovascular risk in both types (361). The potential of intensive glycemic control to 
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reduce macrovascular complications has been less clearly defined, suggesting that 
glycemic control may be more important for micro- than macrovascular disease (364). 
However, the 17-year follow-up results of the Diabetes Control and Complications Trial 
have demonstrated that, compared with conventional therapy, intensive 6.5-year 
glycemic treatment was able to reduce the incidence of macrovascular complications 
over 40% and it did so independently of nephropathy (365). 
 
 
2.3.3.3 Diabetic cardiomyopathy 
 
A concept of diabetic cardiomyopathy was first postulated in 1972 by Rubler et al. (17), 
who reported post-mortem data on four diabetes patients with glomerulosclerosis and 
dilated left ventricles, but without other common causes. Accordingly, diabetic 
cardiomyopathy is today defined as myocardial dysfunction in the absence of coronary 
artery disease, hypertension, and significant valvular disease (16). 
Prominent functional manifestations of diabetic cardiomyopathy progress 
gradually from diastolic to systolic dysfunction. Diastolic dysfunction is hence 
observed first and characterized by impairment of relaxation and passive filling of the 
left ventricle, whereas systolic dysfunction emerges at a later stage to accompany the 
diastolic derangements and is expressed as reduced EF. Hyperglycemia is regarded as 
a central driver in the pathophysiology of diabetic cardiomyopathy since it has the 
potential to trigger several adaptations characteristic of the phenomenon (15,16). In 
detail, Tillquist and Maddox (15) have summarized that the effects of chronic 
hyperglycemia on the myocardium can be mediated by micro- and macrovascular 
disease, lipotoxicity, inflammation, autonomic neuropathy, mitochondrial 
dysfunction, epigenetic changes, and advanced glycation end products causing 
myocardial stiffness. However, the pathogenesis is overall poorly understood (15). 
Data on the prevalence of diabetic cardiomyopathy are limited. Two small 
echocardiography studies involving 100 and 157 patients have shown that diastolic 
dysfunction was evident in 27% and 36% of type 1 diabetes adults, respectively, with 
no signs of other contributors such as coronary artery disease or hypertension 
(366,367). Importantly, a recent 8-year follow-up study of Rosengren et al. (18) showed 
that a cohort of 33 402 type 1 diabetes patients with a mean baseline age of 35 years 
had a fourfold increase in the risk of being admitted to hospital with heart failure when 
compared with 166 228 well-matched controls without diabetes. The risk was evident 
despite a near absence of other risk factors for the development of heart failure, and 
also with glycemic control within target or with no signs of nephropathy (18). 
Furthermore, this study (18) together with an earlier observational study (368) 
reported a steep increase in the risk of heart failure with worsening glycemic control. 
Taken together, these findings suggest that diabetic cardiomyopathy seems to have 
clinical consequences and may likely be modified by appropriate glycemic treatment.  
Related to diabetic cardiomyopathy, diabetes-specific defects in cardiac function 
along with diabetes-specific vascular dysfunction are discussed in an integrated 
manner in the following section (Section 2.3.4) covering acute exercise responses and 
adaptations to exercise training in type 1 diabetes. 
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2.3.4 TYPE 1 DIABETES AND EXERCISE 
 
2.3.4.1 Oxygen delivery and utilization during acute dynamic exercise in type 1 
diabetes 
 
As in the case of women with PCOS, it would be tempting to hypothesize that also type 
1 diabetes patients demonstrate reductions in V̇O2peak and its components due to both 
the disease-related cardiovascular manifestations and the ability of V̇O2peak to 
independently predict cardiovascular disease and mortality. Available cross-sectional 
data on V̇O2peak in type 1 diabetes are presented in Table 1. Table 1 shows that V̇O2peak 
is rather consistently 8-21% lower in children and adolescents with type 1 diabetes than 
in their matched counterparts without diabetes (369-374). By contrast, the data on the 
relation between type 1 diabetes and V̇O2peak in adults at first glance appear 
contradictory, but are consistent after strict interpretation; both reduced (236,375-
378) and similar (379-386) V̇O2peak have been observed in type 1 diabetes adults in 
comparison with healthy subjects. However, HbA1c of diabetes patients has been 6.4-
7.7% (i.e., glycemic control within or at least close to target HbA1c of 7.0%) in all studies 
reporting intact V̇O2peak (379,381-386) except for that of Benbassat et al. (380). 
Additionally, studies that have examined V̇O2peak separately in diabetes patients with 
good or poor glycemic control have repeatedly found V̇O2peak reduction only in the 
latter group (387-390). Moreover, several studies (369-371,385,391) have observed an 
inverse correlation between HbA1c and V̇O2peak, although the absence of such an 
association has also been reported in smaller studies (236,372,374,376,380,382). 
Stubbe et al. (378) recently published the largest study in the field, and, while they did 
report reduced V̇O2peak in type 1 diabetes adults, they did not detect a significant 
association between HbA1c and V̇O2peak. The latter may be explained by relatively good 
level and relatively narrow range of glycemic control in the population with diabetes 
(i.e., HbA1c of 7.4% with 25th and 75th percentiles of 6.7% and 8.1%, respectively) (378) 
and indicates that V̇O2peak is not severely affected by glycemic control until HbA1c 
attains levels (far) above 8.1%. Taken together, the studies referred to in Table 1 reflect 
two main points: First, children and adolescents with type 1 diabetes seem to have 
reduced V̇O2peak relative to individuals without diabetes, suggesting that the onset of 
the disease affects the integrated whole-body pathway for O2 rather rapidly. Second, 
adults with type 1 diabetes are capable of attaining V̇O2peak similar to that of healthy 
adults, but this most likely depends on them maintaining good glycemic control, as 
previously concluded by Baldi and Hofman (36). 
Defects in each component of systemic O2 delivery have been observed in type 1 
diabetes patients. Regarding pulmonary function, reduced peak V̇E, associated with 
V̇O2peak (370), as well as impaired lung diffusion capacity (378,382,389) have been 
reported in individuals with type 1 diabetes. In addition, reductions of tHb-mass and 
BV in type 1 diabetes (376) as well as lower BV also in type 2 diabetes (392) have been 
observed, reflecting impaired blood O2 carrying capacity. These derangements have the 
potential to set limitations on CaO2 and Q̇, and hence, on V̇O2peak. 
Cardiac response to acute exercise may be deteriorated via mechanisms associated 
with diabetic cardiomyopathy, thus limiting systemic O2 delivery. Reduced EDV during 
submaximal exercise (371) as well as limitations of exercise SV and Q̇  
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Table 1 Cross-sectional studies on V̇O2peak in type 1 diabetes. See text for interpretation. 
 
Authors Subjects Mean age 
(years) 
Mean 
diabetes 
duration 
(years) 
Sex Matched 
for 
physical 
activity 
V̇O2peak 
(or V̇O2max) 
Mean age <18 years:       
Austin et al. 1993 D: 59, C: 18 D: 16, C: 14 8 F and M No F: ↔, M: -21% 
Komatsu et al. 2005 D: 72, C: 46 D: 16, C: 16 5 F and M Yes -19% 
Gusso et al. 2008 D: 12, C: 10 D: 15, C: 15 6 F No -17% 
Nadeau et al. 2010 D: 12, C: 12 D: 15, C: 16 8 F and M Yes -19% 
Gusso et al. 2012 D: 53, C: 22 D: 16, C: 17 6 F and M Yes -8% 
Bjornstad et al. 2015 D: 69, C: 13 D: 16, C: 15 6 F and M Yes -14% 
Nguyen et al. 2015 D: 16, C: 8 D: 14, C: 14 5 F and M Yes ↔ a, -21% b 
Mean age >18 years:       
Tantucci et al. 1996 D: 20, C: 10 D: 42, C: 36 18 M No -26% c, -33% d 
Niranjan et al. 1997 D: 18, C: 14 D: 39, C: 31 21 F and M No ↔ a, -27% b 
Nugent et al. 1997 D: 8, C: 8 D: 33, C: 32 20 F and M No ↔ 
Veves et al. 1997 D: 19, C: 29 D: 34, C: 34 18 F and M Yes ↔ c, -18% d 
Benbassat et al. 2001 D: 15, C: 15 D: 40, C: 48 25 F and M No ↔ 
Peltoniemi et al. 2001 D: 12, C: 11 D: 24, C: 25 8 M Yes ↔ 
Baldi et al. 2010 D: 12, C: 10 D: 40, C: 33 ? F and M No ↔ 
Komatsu et al. 2010 D: 27, C: 24 D: 27, C: 26 15 ? Yes ↔ 
Item et al. 2011 D: 9, C: 29 D: 27, C: 24 13 F Yes ↔ 
Wheatley et al. 2011 D: 12, C: 18 D: 40, C: 34 ? F and M No ↔ 
Hägglund et al. 2012 D: 10, C: 11 D: 34, C: 31 11 M Yes -20% 
Peltonen et al. 2012 D: 10, C: 10 D: 33, C: 32 11 M Yes -19% 
Koponen et al. 2013 D: 12, C: 23 D: 33, C: 33 4 – 27 e M Yes -20% 
Tagougui et al. 2015a D: 18, C: 18 D: 28, C: 27 8 F and M Yes ↔ a, -14% b 
Tagougui et al. 2015b D: 23, C: 23 D: 26, C: 26 8 F and M Yes ↔ a, -16% b 
Stubbe et al. 2016 D: 73, C: 292 D: 50:, C: 51 ? F and M No -13% 
Waclawovsky et al. 
2016 
D: 14, C: 5 D: 30, C: 27 14 M Yes ↔ 
D, type 1 diabetes patients; C, healthy controls; F, female; M, male. 
a good glycemic control; b poor glycemic control; c no autonomic neuropathy; d autonomic neuropathy; e range. 
 
 
(371,372,385,389) have been observed in both adolescents and adults with type 1 
diabetes, while findings on faster active muscle deoxygenation in type 1 diabetes 
patients may also reflect limited ability to increase O2 delivery during increasing O2 
demand (236). Reduced BV is likely one component of diabetes-related diastolic 
dysfunction as discussed earlier (see Sections 2.1.1.3 and 2.1.4.1). Further, diastolic 
dysfunction may be partly due to prolonged isovolumic relaxation, decreased 
ventricular compliance, or their combination, since Regensteiner et al. (393) have 
observed pronounced ventricular filling pressure during incremental exercise in adults 
 60 
with uncomplicated type 2 diabetes. To highlight the significance of glycemic control, 
HbA1c has been shown to have inverse relationships with these exercise SV and/or Q̇ 
responses in type 1 diabetes (371,384,385), indirectly being in line with the earlier 
referenced registry studies (18,368) reporting pronounced heart failure risk in patients 
with poorer glycemic control. 
Diabetes-specific deterioration of cardiac pump function both at rest and during 
exercise is associated with cardiovascular autonomic neuropathy and nephropathy. 
Reduced peak HR has been reported in type 1 diabetes (370,372,391), pronounced in 
individuals with autonomic neuropathy (391). In detail, the attenuated peak HR 
response may be explained by a reduction of β-adrenoceptor sensitivity (394). 
Furthermore, Pop-Busui et al. (395) have shown an association between autonomic 
neuropathy and diastolic dysfunction and also observed compensatorily elevated 
resting HR and Q̇ in the type 1 diabetes patients of their study. To summarize this, Baldi 
(396) presented a “vicious cycle hypothesis”, according to which diminished cardiac 
volumes would lead to exaggerated resting/exercise sympathetic activity, which in the 
long run would particularly desensitize cardiac β-adrenoceptors, diminishing cardiac 
reserve and attenuating cardiac response to exertion, thereby predisposing diabetes 
patients to heart failure. Baldi et al. (397) have very recently reviewed this cascade in 
more detail by focusing mainly on existing evidence on type 2 diabetes. Nephropathy 
may also have a role in these complex interactions since significant associations 
between renal function and V̇O2peak have been reported in type 1 diabetes patients 
(373,398), and renal function has been shown to be diminished in patients with 
autonomic neuropathy (395). However, while the role of renal function in determining 
cardiovascular risk is highly pronounced in type 1 diabetes (361), underlying 
pathophysiological mechanisms shared by nephropathy and overall cardiovascular 
dysfunction remain largely unclear. 
Defects in not only systemic but also peripheral O2 delivery are evident in type 1 
diabetes. Type 1 diabetes is characterized by vascular dysfunction manifested as 
endothelial dysfunction (399), reduced arterial compliance (374,400,401), decreased 
capillary-to-muscle fiber ratio (402,403), and impairments in microvascular muscle 
blood flow and O2 diffusional capacity (403-405). All of this evidence emerging from 
both animal and human studies shows potential limitations on peripheral O2 delivery 
also during acute dynamic exercise. During exercise, defects in both systemic and 
peripheral O2 delivery are tried to be compensated by pronounced local active muscle 
O2 extraction and utilization if type 1 diabetes is in good glycemic control (236). 
However, patients with poor glycemic control exhibit blunted exercise-induced active 
muscle O2 extraction (387), possibly owing to exaggerated O2 affinity of highly 
glycosylated Hb (406). In terms of O2 extraction at the whole-body level, no reductions 
of exercise C(a-v)O2 have been observed in patients with type 1 diabetes (372,384). 
In summary, type 1 diabetes may affect several steps of the integrated pathway for 
O2 from the atmosphere to the muscle mitochondria, and overall the diabetes-related 
derangements are dependent on glycemic control. However, the contribution of the 
different integrated steps to V̇O2 response to acute dynamic exercise has not 
simultaneously been studied in this patient group. 
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2.3.4.2 Effects of exercise training in type 1 diabetes 
 
After the discovery of insulin in the early 1920s, fundamental exogenous insulin 
treatment has transformed type 1 diabetes from a fatal illness into a chronic systemic 
disease. While optimal insulin treatment in combination with smoking cessation, and 
dietary and medical treatment of other modifiable risk factors (i.e., blood pressure, 
lipid profile) strive for better glycemic control and reduction of diabetes-related 
cardiovascular manifestations, it is generally recommended that patients with type 1 
diabetes also engage in regular physical activity (39). Physical activity importantly 
improves insulin sensitivity (407-410), lipid profile (407,408,411-414), and also well-
being (415) in those with the disease. However, the main focus is here on current 
evidence of effects of physical activity and exercise training on glycemic control, micro- 
and macrovascular complications, and acute exercise responses in type 1 diabetes, 
which is briefly covered below. 
Existing literature on effects of physical activity and exercise training on glycemic 
control is inconclusive. Epidemiological evidence has shown mainly favorable effects 
of physical activity. A large cross-sectional study reported a beneficial association 
between physical activity frequency and HbA1c in 23 251 ≤18-year-old type 1 diabetes 
patients (416). In addition, physical activity was shown to be beneficial with respect to 
HbA1c in a recent cross-sectional study involving 18 028 adults with type 1 diabetes 
(417). Wadén et al. (418) furthermore showed with their cross-sectional analyses of the 
Finnish Diabetic Nephropathy (FinnDiane) Study that low levels of leisure-time 
physical activity (LTPA) were associated with poor glycemic control in women with 
type 1 diabetes but not in men. Meta-analyses, in turn, have provided more conflicting 
results. A recent meta-analysis, including only randomized controlled trials, indicated 
an absolute -0.85% reduction in HbA1c in ≤18-year-old type 1 diabetes patients after 
physical activity interventions (419). In adult patients with type 1 diabetes, an absolute 
-0.78% decrease in HbA1c was observed after exercise interventions by another meta-
analysis, involving only randomized controlled trials but being substantially affected 
and possibly biased by a single study with a relatively large population (420). By 
contrast, a meta-analysis that included both randomized and nonrandomized 
controlled trials was unable to reveal any significant glycemic benefits of exercise 
training in children, adolescents, or adults with type 1 diabetes (421). In addition, Table 
2, which presents effects of exercise training interventions on V̇O2peak but also on 
HbA1c, shows that evidence for glycemic benefit of exercise in type 1 diabetes is not 
consistent at all. This uncertainty in the existing evidence has been speculated to be 
due to  excessive energy consumption around the time of physical activity (to meet 
energetic requirements but particularly to avoid hypoglycemia) and/or training-
induced reduction of insulin requirements (415). In conclusion, while physical activity 
conclusively has a beneficial influence on glycemic control in type 2 diabetes (422), it 
remains unresolved whether this is the case in type 1 diabetes. 
Since effects of physical activity on glycemic control remain inconclusive in type 1 
diabetes as described above, but the magnitude of hyperglycemia is a major risk factor 
for cardiovascular disease (18,354,365,368), it is not surprising that current literature 
only barely supports physical activity-related benefits for micro- and macrovascular 
complications. The Pittsburgh IDDM Morbidity and Mortality Study suggested an 
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inverse association between physical activity and the occurrence of microvascular 
complications (423), whereas results of the Diabetes Control and Complications Trial 
indicated no such benefit (424). Regarding macrovascular complications and 
mortality, prospective (425,426), retrospective (427), and cross-sectional (425) 
settings have all suggested (but not fully proved) a favorable influence of physical 
activity. The results of the FinnDiane Study have further specified that health benefits 
of physical activity in type 1 diabetes likely depend on its intensity level and frequency 
of performance: low intensity has been shown to be associated with both micro- and 
macrovascular disease (cross-sectional analysis) (428), whereas high intensity and 
high frequency have been suggested to prevent development and progression of 
diabetic nephropathy (429) and to reduce the risk of adverse cardiovascular events 
(430) (longitudinal analyses). However, prospective randomized controlled trials 
examining effects of exercise training intervention on micro- and macrovascular 
complications in type 1 diabetes patients are lacking. The Look AHEAD Trial was such 
a randomized controlled trial observing the issue in type 2 diabetes, but concluded that 
one year of intensive lifestyle (diet+exercise) intervention had no effect on 
cardiovascular or all-cause mortality during a ~10-year follow-up of 2570 type 2 
diabetes patients despite several other health-promoting effects (431). It may thus be 
that, at least in terms of “hard” end points, cardiovascular adaptations to recreational-
like, low-to-moderate intensity exercise training are somewhat deficient in individuals 
with diabetes, as suggested by the review of Baldi et al. (397) as well as the most recent 
and above-mentioned findings of the FinnDiane Study (430). 
Table 2 details effects of exercise training interventions on V̇O2peak. Aerobic training 
programs of six weeks to five months have consistently resulted in 5-27% increases in 
V̇O2peak in both youth (410,411,432-434) and adults (407-409,412-414,435-439) with 
type 1 diabetes. Furthermore, Table 2 shows that a reduction of HbA1c is not directly a 
prerequisite for or a consequence of an improvement of V̇O2peak, although vast evidence 
from cross-sectional studies suggests an obvious association between V̇O2peak and 
glycemic control, as discussd earlier (see Section 2.3.4.1). Three studies that have 
compared training-induced increases in V̇O2peak between individuals with and without 
type 1 diabetes have observed no differences in V̇O2peak improvements between the 
groups (411,435,436). With respect to integrated subcomponents of V̇O2peak, 
endurance-type exercise training has been shown to improve cardiac pump function in 
animal models of type 1 diabetes (440,441), whereas human studies examining training 
effects on systemic O2 delivery in type 1 diabetes are sparse. A 10% increase in peak O2 
pulse (i.e., a surrogate for peak SV (20,123)) has been reported after three months of 
aerobic training in type 1 diabetes adults (412). In addition, studies on type 2 diabetes 
patients have produced contradictory findings; both training-induced improvements 
(442,443) and no improvements (444,445) in echocardiography parameters 
describing myocardial function have been observed, with high training intensity 
possibly leading to more pronounced effects (443). In terms of peripheral O2 delivery, 
aerobic endurance training enhances endothelial function (434,439) and leads to 
muscle capillary neoformation (407) in type 1 diabetes patients, and has also been 
reported to increase the expression of pro-angiogenic genes in mice with type 1 
diabetes (402). However, animal (402), cross-sectional (401), and short-term training 
intervention (436) studies have showed that these vascular adaptations are deficient 
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compared with those on individuals without diabetes. Instead, subjects with and 
without type 1 diabetes have displayed similar training-induced rises in enzymatic 
capacity to utilize O2 (435,436). 
In summary, evidence of favorable effects of physical activity and exercise training 
on glycemic control and microvascular complications is inconclusive. Instead, 
epidemiological data more consistently support benefits of regular exercise for 
macrovascular complications, albeit the strongest evidence provided by large 
prospective randomized controlled trials is fully absent. As regards the integrated 
pathway for O2 from the atmosphere to the mitochondria, three small and short-term 
studies (411,435,436) suggest that V̇O2peak increases “normally” in individuals with 
type 1 diabetes. However, no adaptations of the integrated O2 pathway to long-term 
(i.e., >4-5 months) exercise training interventions have been studied in type 1 diabetes. 
In addition, type 1 diabetes studies of any duration examining training-induced 
adaptations of different components of systemic O2 delivery are almost completely 
lacking, while peripheral vascular adaptations, which seem to be deficient in type 1 
diabetes, have also been sparsely studied. 
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3 AIMS OF THE STUDY 
The main aim of this thesis was to study O2 delivery and utilization during acute 
dynamic exercise in both healthy individuals and individuals with PCOS or type 1 
diabetes. In addition, a particular interest was in the adaptations induced by long-term 
exercise training in individuals with type 1 diabetes. Acute dynamic exercise was hence 
used as a physiological probe to identify early signs of cardiovascular dysfunction in 
the patient groups of interest (i.e., PCOS and type 1 diabetes), whereas exercise training 
was employed to demonstrate whether it alleviates such early dysfunctional signs 
associated with type 1 diabetes. 
 
Specific aims of the study in accordance with four original publications were as follows: 
 
I To simultaneously investigate alveolar gas exchange and imbalance 
between local O2 delivery and utilization within active muscle, less active 
muscle, and cerebral tissues during maximal incremental treadmill 
exercise in healthy adult men. Moreover, associations of blood O2 carrying 
capacity with both alveolar gas exchange and local tissue-specific O2 
delivery and utilization were examined. 
 
II To explore the contribution of systemic O2 delivery and C(a-v)O2 to whole-
body V̇O2 response during maximal incremental cycling exercise in adult 
overweight and obese women with and without PCOS. 
 
III To simultaneously examine the contribution of systemic O2 delivery and 
local active muscle O2 delivery and utilization to whole-body V̇O2 response 
during maximal incremental cycling exercise in adult men with and 
without type 1 diabetes. Furthermore, associations of BV with cardiac 
responses to exercise were determined. 
 
IV To investigate the adaptations of V̇O2peak, peak O2 pulse, local active 
muscle O2 extraction, and glycemic control to a 1-year individualized 
exercise training intervention in adult men with and without type 1 
diabetes. 
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4 SUBJECTS AND STUDY DESIGN 
Studies I-IV are part of a Canadian-Finnish research collaboration entitled “ARTEMIS 
– Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection 
of Discovery, Prevention and Knowledge Exchange”. ARTEMIS was designed to 
identify, prevent, and treat early markers of cardiovascular dysfunction in patients at 
risk for, or with, diabetes, and to develop best practices for the prevention and reversal 
of diabetes-related cardiovascular complications (446). 
 
 
4.1 STUDY I 
 
Study I was conducted as a collaborative effort between the Department of Sports and 
Exercise Medicine (University of Helsinki), the Clinic for Sports and Exercise Medicine 
(Foundation for Sports and Exercise Medicine), and the Centre of Excellence for 
Health and Work Ability (Finnish Institute of Occupational Health). The experiments 
were performed between February and May in 2009. 
Twenty-nine male volunteers were assessed for inclusion in Study I. The subjects 
aged 22-37 years, were nonathletes but physically active, nonsmoking, had no history 
of cardiovascular, endocrine, musculoskeletal, neurological, or respiratory diseases, 
and were free of medication. The subjects visited the laboratory twice: One visit 
consisted of CPET accompanied by a medical examination and supplementary pre-
exercise experiments, whereas another visit included the determination of tHb-mass 
and BV. Eventually, the data on 22 subjects were fully available, characterized by no 
artifacts, and thus included in final analyses. 
 
 
4.2 STUDY II 
 
Study II was a cross-sectional substudy of a collaboration between the Department of 
Sports and Exercise Medicine (University of Helsinki), the Clinic for Sports and 
Exercise Medicine (Foundation for Sports and Exercise Medicine), and the 
Department of Obstetrics and Gynecology (Helsinki University Hospital and Helsinki 
University). Study II combined data from two different study projects of the 
collaboration: “WEll-Being of WOMen during pregnancy: focus on individualized 
EXercise training” (WEBWOMEX) and “Autonomic Nervous System and EXErcise in 
gestational diabetes” (ANS-EXE) (ClinicalTrials.gov: NCT01675271). These projects 
have mainly been designed to identify effects of individualized exercise training on 
those cardiovascular, inflammatory, and autonomic nervous system functions that 
contribute to infertility in women with PCOS and predict, prevent, or promote 
gestational diabetes. The experiments of the two projects were performed between 
March 2010 and September 2015. However, the statistical analyses for Study II were 
finished in April 2015; therefore, data gathered until the end of March 2015 were 
evaluated to be included in Study II. 
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A total of 122 female volunteers were assessed for eligibility for Study II: all 62 
women from the WEBWOMEX population, and those 60 women from the ANS-EXE 
population who had reported to the project until the end of March 2015. Thirty of all 
122 women had met the European Society for Human Reproduction and 
Embryology/American Society for Reproductive Medicine criteria for a diagnosis of 
PCOS (i.e., Rotterdam criteria) (306). PCOS women were recruited from the patient 
population of the Department of Obstetrics and Gynecology (Helsinki University 
Hospital), whereas women without PCOS were mainly recruited among the employees 
and students of the University of Helsinki. The exclusion criteria of Study II were as 
follows: age of <18 or >40 years, BMI of <25 or >40 kg/m2, pregnancy, androgen-
secreting tumors, congenital adrenal hyperplasia, Cushing’s syndrome, anemia, 
current diabetes, hypertension, antiandrogen medication, β-blocker medication, 
medication influencing glucose homeostasis, use of oral contraceptives, substance 
abuse, physical disability, smoking, and other cardiovascular, endocrine, 
musculoskeletal, neurological, or respiratory diseases that could have affected any 
outcome of interest. Thus, four over 40-year-old women, 44 women with BMI <25 
kg/m2, one woman with BMI >40 kg/m2, five pregnant women, one woman with 
cortisone treatment for asthma, two women using oral contraceptives, two smokers, 
and one woman with hypothyroidism were excluded from the analyses. In addition, 
seven irregularly menstruating (i.e., menstrual period not occurring every 23-32 days 
(447)) women without PCOS, two women with no North European background, and 
three women showing artifacts in their PhysioFlow data (i.e., impedance cardiography 
data on cardiac pump function), were not included in the analyses. Furthermore, one 
woman stopped her CPET at submaximal work rates, and 19 women withdrew prior to 
the commencement of any study experiments. Thus, a final sample of 30 women, 15 of 
whom had a diagnosis of PCOS, were included in the eventual analyses of Study II. 
The data for Study II were collected during two visits to the laboratory. One visit 
comprised CPET along with a medical examination and supplementary pre-exercise 
experiments, and the other visit consisted of drawing fasting venous blood. For the 
women who moved on to the lifestyle interventions of the WEBWOMEX or ANS-EXE 
projects, the data collected before any intervention were used for the analyses of Study 
II. 
 
 
4.3 STUDY III 
 
Study III was a cross-sectional subanalysis of an “Exercise, Diet and GEnes in T1D” 
(EDGE) Helsinki project. The EDGE subjects with type 1 diabetes were recruited from 
the patient pool of the FinnDiane Study (418), whereas the subjects without diabetes 
were mainly recruited from the employees and students of the University of Helsinki. 
The EDGE experiments were performed between May 2009 and December 2013. 
In addition to the EDGE subjects, the subjects of Study III also included 
participants from a Finnish television series entitled Finnautti. In Finnautti, five 
individuals (one woman, four men) underwent a diverse set of space flight-related tests 
including CPET and determination of tHb-mass and BV in the Department of Sports 
and Exercise Medicine (University of Helsinki) and the Clinic for Sports and Exercise 
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Medicine (Foundation for Sports and Exercise Medicine). The Finnautti experiments 
were performed in May 2010. 
All 42 male volunteers participating in EDGE and four male volunteers taking part 
in Finnautti were assessed for inclusion in Study III. Fifteen EDGE subjects had type 1 
diabetes. The exclusion criteria of Study III were age of <18 or >45 years at baseline; 
previous diagnosis or previous clinical evidence of microvascular complications (i.e., 
retinopathy, nephropathy, neuropathy), hypertension, or any chronic disease other 
than diabetes for the diabetes patients; β-blocker medication; medication influencing 
glucose homeostasis except for multiple daily insulin injections of those with diabetes; 
physical disability; substance abuse; smoking; and elite athlete status. Eleven EDGE 
subjects with and 19 without diabetes, who were not excluded based on the exclusion 
criteria, went through all experiments both before (i.e., baseline) and after (i.e., post) 
individualized exercise training- or no training intervention, as shown in Figure 11, 
which details the design and flow of Study IV. However, one of the 19 subjects without 
diabetes had only completed baseline experiments by the time that the statistical 
analyses of Study III were performed in June and July 2013. In addition, four subjects 
with and two without type 1 diabetes performed experiments only at baseline, and 
three ≤45-year-old Finnautti men performed experiments just once. Furthermore, a 
PhysioFlow device (used for estimating cardiac pump function) was not available until 
January 2010, before which 10 eligible men with and 13 without diabetes had already 
performed their baseline experiments. In consequence, full data on 16 subjects’ 
baseline experiments (five with and 11 without diabetes) and 29 subjects’ post 
experiments (11 with and 18 without diabetes) were assessed for inclusion in Study III. 
After further exclusion of 15 CPETs showing artifacts in PhysioFlow data (six with and 
nine without diabetes), one diabetic man with hypertension medication during post 
experiments, and one nondiabetic man with anemic [Hb] during post experiments, all 
required baseline or post data of only seven men with type 1 diabetes were eventually 
available for Study III. A numerically convenient sample of 10 age-, anthropometry-, 
and LTPA-matched men without diabetes was included in Study III so that those 
included were subsequently checked to match for age, anthropometry, LTPA, and 
V̇O2peak with all eligible subjects without diabetes (0.255 < P < 0.925). Thus, final 
samples of seven men with and 10 without type 1 diabetes were eventually analyzed for 
Study III. 
Collecting the data for Study III required three visits to the laboratory per subject. 
One visit consisted of drawing fasting venous blood, one visit was composed of CPET 
along with a medical examination and supplementary pre-exercise experiments, and 
one visit included the determination of tHb-mass and BV. 
 
 
4.4 STUDY IV 
 
Study IV was a main part of EDGE (for details, see Section 4.3) and consisted of a 
prospective, nonrandomized, and controlled exercise training intervention. The 
exclusion criteria of Study IV were the same as those of Study III (see Section 4.3). 
The study flow chart presented in Figure 11 illustrates the design and flow of Study 
IV. After the enrollment, exclusions, nonrandomized allocation (i.e., training- or no 
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intervention), and discontinuations, eight adult men with type 1 diabetes and 13 
healthy subjects completed a 1-year individualized exercise training intervention. To 
completely match these two groups for baseline age, anthropometry, and V̇O2peak, five 
healthy subjects with the highest baseline V̇O2peak values were excluded from further 
analyses. Thus, eight men with and eight without type 1 diabetes were included in 
between-group analyses evaluating the effects of the training intervention. 
In addition, five healthy men served as Reference group. At baseline and after a 1-
year time period, they went through the same clinical experiments as the training 
groups, but were only instructed to maintain their lifestyle, particularly regarding diet 
and physical activity, during that period. Age and V̇O2peak differed substantially from 
those of the training groups (see Sections 6.1.4 and 6.2.4, respectively), and the sample 
size of Reference group was small (n = 5). Thus, to avoid confounding the between-
group analyses (i.e., the analyses between the training groups) but to demonstrate the 
repeatibility of clinical experiments, Reference group was analyzed separately from the 
training groups. 
For Study IV, the subjects with diabetes visited the laboratory twice both at baseline 
and after their 1-year training intervention, whereas the subjects without diabetes 
visited the laboratory once at baseline and twice after the 1-year periods of training or 
no interventions. The first visits comprised of drawing fasting venous blood, and the 
second visits consisted of CPET, a medical examination, and supplementary pre-
exercise experiments. 
 
 
 
Figure 11 Study IV flow chart. * Five trained healthy subjects with the highest peak pulmonary O2 uptake 
(V̇O2peak) values at baseline were excluded from further between-group analyses to match two 
training intervention groups also for baseline V̇O2peak. 
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4.5 ETHICAL APPROVAL 
 
All subjects gave written informed consent prior to their participation in the study. All 
study projects conformed to the Declaration of Helsinki and were approved by the 
Ethics Committee of the Hospital District of Helsinki and Uusimaa, Helsinki, Finland. 
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5 METHODS 
5.1 CLINICAL EVALUATION AND EXPERIMENTS 
 
5.1.1 MEDICAL EXAMINATION 
 
In Studies I-IV, a physician specialized or specializing in sports medicine examined the 
subjects before any CPETs to ensure their suitability for exercise testing. The 
examination comprised a personal health and medical history (including 
interpretation of a preliminary questionnaire), clinical status, and interpretation of a 
12-lead resting electrocardiography, resting blood pressure, and the other pre-exercise 
experiments described below. Regarding the preliminary questionnaire, those subjects 
with type 1 diabetes who participated in a 1-year training intervention of Study IV 
reported their insulin doses within a 3-day period around the performed experiments. 
 
 
5.1.2 PRE-EXERCISE EXPERIMENTS 
 
5.1.2.1 Anthropometry 
 
In Studies I-IV, the subjects’ weight and height were measured, and body composition 
(i.e., fat-free mass [FFM], body fat percentage) was determined using the 
bioimpedance method (InBody 720, Biospace Co., Ltd., Seoul, South Korea). Subjects’ 
waist and hip circumferences were also measured and waist-to-hip ratio was calculated 
in Studies II-IV. Furthermore, thickness of subcutaneous fat was measured with 
skinfold calipers at NIRS recording sites particularly in Studies III and IV, in which 
NIRS data were compared between men with and without type 1 diabetes. 
 
 
5.1.2.2 Flow-volume spirometry 
 
In Studies I-IV, flow-volume spirometry (Medikro Spiro 2000, Medikro Oy, Kuopio, 
Finland) was one part of the pre-exercise experiments. Levels of forced vital capacity 
(FVC) and forced expiratory volume in one second (FEV1) were evaluated as both 
absolute values and percentual values of the reference data on the Finnish population 
(448). 
 
 
5.1.2.3 Leisure-time physical activity (LTPA) 
 
In Studies II-IV, LTPA was registered as one part of the preliminary questionnaire 
concerning personal health and medical history and interpreted by a physician. For 
this, the following single question was asked: “If you think about your past three 
months and physical activity sessions lasting more than 20 min in all settings (e.g., 
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commuting, walking a dog, recreation, sport), how many times a week and how long at 
a time have you engaged in physical activity?” This question meets the general 
minimum recommendations (i.e., frequency, duration, all settings) for enquiring about 
LTPA (449). 
 
 
5.1.3 BLOOD SAMPLES 
 
At a separate visit, the subjects reported to the laboratory after overnight fast and their 
antecubital venous blood was drawn for measurement of either lipid profile (i.e., high-
density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides), 
plasma glucose, and serum insulin (Study II), or HbA1c (Studies III and IV). 
In Study II, fasting plasma glucose and serum insulin were determined by the 
hexokinase method and the immunochemiluminometric assay, respectively, and 
homeostasis model assessment of IR (HOMA-IR) was calculated as follows (450): 
 
(14) HOMA-IR = [fasting plasma glucose] × [fasting serum insulin] / 22.5 
 
where the concentrations of fasting plasma glucose and serum insulin are in 
mmol/L and μU/mL, respectively. 
Serum testosterone and SHBG concentrations of PCOS women were not 
determined separately for Study II, but as part of the patients’ clinical care by the mass 
spectrometry assay and the immunochemiluminometric assay, respectively. Free 
androgen index was determined as follows: 
 
(15) free androgen index = [serum testosterone] / [serum SHBG] × 100 
 
where the concentrations of serum testosterone and SHBG are in nmol/L. 
 
 
5.1.4 BLOOD OXYGEN CARRYING CAPACITY 
 
The components of [Hb] (i.e., tHb-mass [Study I] and BV [Study III]) were determined 
by the optimized CO-rebreathing method (132) (SpiCO, BloodTech, Bayreuth, 
Germany), previously described in Section 2.1.1.3. The experiments were performed at 
separate visits and preceded by abstinence from physical exercise for at least 12 h and 
alcohol for at least 24 h. Capillary blood was drawn from a fingertip to analyze [HbCO] 
and [Hb] by a blood gas analyzer (ABL725, Radiometer, Copenhagen, Denmark). [Hb] 
was similarly determined also in Studies II and IV. According to duplicate tests, a 
typical error (451) of the tHb-mass measurements in the laboratory of the Department 
of Sports and Exercise Medicine (University of Helsinki) has been reported to be 1.7% 
with a 95% confidence interval of 1.3-2.4% (376). 
In Study I, tHb-mass was examined as both absolute and body weight-adjusted 
values. In addition, the magnitude of change in V̇O2peak versus a given change in tHb-
mass was determined by plotting V̇O2peak values against tHb-mass values and 
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interpreting the slope of this linear regression line. In Study III, BV was examined as 
both absolute and FFM-adjusted values. 
 
 
5.1.5 CARDIOPULMONARY EXERCISE TEST (CPET) 
 
5.1.5.1 CPET protocols 
 
In Studies I-IV, the subjects performed CPETs and underwent a medical examination 
and the pre-exercise measurements described above. Before CPETs, the subjects 
reported to the laboratory 2-3 h after their ordinary meal. The CPET protocols used in 
Studies I-IV differed slightly from each other, as detailed below. However, all of the 
protocols were incremental and used 3-min steps, which was based on V̇O2 kinetics: 
the time constant of V̇O2 is ~30 s, implying that it takes ~30 s to reach 63% of the 
remaining difference between the V̇O2 value at each time point and steady-state V̇O2 
value. Thus, it takes 5-6 time constants (i.e., ~3 min) to reach a steady state after each 
transition from the previous intensity to the next one. Notably, at intensities above AT, 
the slow component of V̇O2 is added to comprise the overall response to reach steady 
state. The slow component is calculated to be 3-6 min after transition from the previous 
intensity to the next one, but since it is affected by exercise intensity and 
interindividual variability (e.g., V̇O2peak) it cannot be standardized (452). 
In Study I, each subject performed their CPET on a treadmill (Juoksumatto OJK-1, 
Telineyhtymä, Kotka, Finland). The following step incremental protocol was used: 3-
min rest, while the subjects stood on the treadmill, preceded 5-min baseline walking at 
a speed of 5 km/h, which was then followed by incremental exercise (+1 km/h / 3 min) 
initiated with a speed of 8 km/h. The subjects continued exercising until volitional 
exhaustion. The incline of the treadmill was 0.5° throughout the test to mimic air 
resistance during outdoor running. 
In Studies II-IV, CPETs were performed on a mechanically braked cycle ergometer 
(Monark Ergomedic 839E, Monark Exercise AB, Vansbro, Sweden). The tests began 
with 5-min rest, while the subjects sat on the ergometer. The rest period was followed 
by 5-min baseline unloaded cycling, after which a step incremental protocol (+30 W / 
3 min in women [Study II], +40 W / 3 min in men [Studies III and IV]) was initiated 
with a work rate of 30 W (Study II) or 40 W (Studies III and IV). The subjects continued 
exercising until volitional exhaustion. 
In Studies III and IV, capillary blood was drawn from a fingertip to analyze blood 
glucose concentration (Glucocard x-meter, Arkray Factor, Inc., Shiga, Japan) before 
CPET; subjects with diabetes had glucose levels of 5.6-16.7 mmol/L with no signs of 
ketosis, according to the published guidelines (39). 
All somatic measurements during CPETs are described in Sections 5.1.5.2-5.1.5.3. 
In addition, rating of perceived exertion was obtained in Studies II-IV using the Borg 
scale of 6-20 (453) at the end of each work rate. 
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5.1.5.2 Systemic oxygen delivery 
 
In addition to the determination of [Hb], information on systemic O2 delivery was 
obtained by measuring several parameters of pulmonary and cardiac pump functions. 
Equation 3 was applied to calculate and analyze systemic O2 delivery particularly for 
this thesis. 
 
Pulmonary function 
Breath-by-breath V̇E was measured by a low-resistance turbine (Triple V, Jaeger 
Mijnhardt, Bunnik, The Netherlands) to determine inspiratory and expiratory flows 
and volumes during each CPET. The turbine was calibrated prior to each CPET using 
a syringe of 3.00 L (Hans Rudolph, Inc., Kansas City, MO, USA). Inspired and expired 
gases were continuously sampled at the mouth and analyzed for concentrations of O2, 
CO2, N2, and Ar by mass spectrometry (AMIS 2000, Innovision A/S, Odense, 
Denmark) (21) after calibration with precision-analyzed gas mixtures. Breath-by 
breath data were collected as raw data, which were transferred to a computer to 
determine gas delays for each breath. The gas concentrations were herewith aligned 
with volume data, and the profile of each breath was built. Breath-by-breath alveolar 
gas exchange was thereafter calculated with the AMIS algorithms, a moving average of 
individual test data was calculated over 5-s periods to lessen inherent breath-by-breath 
variability, and the data was eventually interpolated to obtain second-by-second data. 
In Study I, AT and RC were determined using the V-slope method (60). RER was 
traditionally calculated as a ratio of V̇CO2 and V̇O2. 
To monitor SpO2 during CPETs, fingertip pulse oximetry (Nonin 9600, Nonin 
Medical, Inc., Plymouth, MA, USA) was employed. Furthermore, CaO2 was calculated 
(Equation 3). 
 
Cardiac pump function 
In Studies I-IV, the electrical activity of the heart and HR were continuously monitored 
by electrocardiography (PowerLab, ADInstruments, Oxford, United Kingdom) during 
CPETs. In Studies II and III, a PhysioFlow impedance cardiograph device (Manatec 
Biomedical, Paris, France) was employed to continuously evaluate cardiac pump 
function (i.e., particularly SV and hence Q̇ [Studies II and III], but also EDV and EF 
[Study III]). The PhysioFlow method has been extensively described in Section 2.1.1.2. 
In Study IV, peak O2 pulse was calculated as a quotient of V̇O2peak and peak HR to 
provide a surrogate for peak SV (Equation 7) (20,123). 
In Studies II-IV, systolic and diastolic arterial blood pressures were measured 
automatically (Tango+, SunTech Medical, Morrisville, NC, USA) from the left brachial 
artery at seated rest and at the end of each work rate. MAP was calculated by the 
standard equation: MAP = (systolic arterial blood pressure + 2 × diastolic arterial 
blood pressure) / 3. In Studies II and III, where PhysioFlow data on Q̇ were available, 
SVR was determined applying Darcy’s law (Equation 4) and assuming that CVP is ~0 
mmHg from rest to peak exercise (97). In Study II, peak cardiac power output (CPO), 
relating changes in systemic blood flow and afterload, was furthermore calculated from 
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the values of Q̇ and MAP at peak exercise to reflect the hydraulic power of the heart 
(454): 
 
(16) CPO = Q̇ × MAP × K 
 
where K is a conversion factor (2.22 × 10-3) into watts. 
 
Scaling of cardiopulmonary data 
In Studies I-IV, V̇O2 was expressed as values of L/min but also as values scaled to body 
weight (mL/min/kg) and particularly to FFM (mL/min/kg FFM) (455). The 
importance of the latter method is particularly highlighted when examining overweight 
and obese individuals (456). Similarly, to further avoid ignoring any between-group 
differences in body size or composition we scaled EDV, SV, Q̇, O2 pulse, and CPO to 
FFM (93), whereas SVR was multiplied by FFM. These scaled cardiovascular variables 
are referred to as the indices: EDVi, SVi, Q̇i, O2 pulsei, CPOi, and SVRi, respectively. 
In Study I, V̇O2 at AT and RC were examined as absolute values (L/min; 
mL/min/kg; mL/min/kg FFM), but also as relative values (% of V̇O2 reserve = 
[measured V̇O2 – resting V̇O2] / [V̇O2peak – resting V̇O2] × 100%). 
 
 
5.1.5.3 Peripheral oxygen delivery, extraction, and utilization 
 
NIRS experiments 
A continuous wave NIRS device (Oxymon Mk III Near-Infrared Spectrophotometer, 
Artinis Medical Systems, Zetten, The Netherlands) was employed to monitor exercise-
induced changes in tissue-specific (de)oxygenation in Studies I, III, and IV. Thus, data 
on local tissue-specific (im)balance between O2 delivery and utilization, or in other 
words, local fractional O2 extraction, were acquired. A methodological principle of 
NIRS has been comprehensively presented in Section 2.1.2.4. 
In Study I, local (de)oxygenation profiles were monitored simultaneously from 
active leg muscle, less active arm muscle, and cerebral tissue. In Studies III and IV, the 
interest was only in active leg muscle deoxygenation. For leg muscle monitoring, a 
NIRS probe was placed over the right vastus lateralis muscle at mid-thigh level and 
parallel to the long axis of the muscle. To monitor arm muscle, a NIRS probe was 
positioned longitudinally on the right biceps brachii muscle above the elbow joint and 
lateral to the middle line. For cerebral monitoring, a NIRS probe was placed over the 
right prefrontal cortex, about 2 cm above the right eyebrow and as laterally as possible 
to the longitudinal fissure of the cerebrum. This prefrontal site projects to the premotor 
cerebral areas, and thus, participates in planning (457) and pacing (458) strategies 
during voluntary movements. Oxygenation status of the prefrontal cortex has also been 
shown to reflect muscle force-generating capacity (459). The optically dense plastic 
NIRS probes were attached to the skin with double-sided adhesive tape and covered by 
an elastic tape. 
The NIRS probes consisted of three transmitting and one receiving optode 
operating at wavelengths of 860 and 765 nm corresponding to the specific extinction 
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coefficients of O2Hb and HHb (224), respectively. The interoptode distance was set to 
35-50 mm so that a good signal quality was achieved before any experiments. Relative 
concentration changes (∆μmol/L) from the resting baseline of O2Hb (∆[O2Hb]) (Study 
I) and particularly of HHb (∆[HHb]) (Studies I, III, and IV) were analyzed. In addition, 
TSI as well as a relative concentration change of tHb (∆[tHb]) were examined in Study 
I. The DPF values used were 5.51 and 4.16 for leg and arm (227), respectively, whereas 
DPF for cerebral tissue was calculated according to the manufacturer’s guidelines (i.e., 
DPF = 4.99 + 0.067 × age0.814). Sampling frequencies of 50 Hz (Study I) or 10 Hz 
(Studies III and IV) were used for collecting NIRS data. The obtained NIRS data were 
averaged to give values in second-by-second intervals and time-aligned with 
cardiopulmonary data. In Studies III and IV, the averaged ∆[HHb] data were further 
normalized (%∆[HHb]) so that 0% represents the mean steady-state value of the last 
30 s of unloaded cycling (Study III) or of any work rate (Study IV), while 100% 
represents the highest mean value of the last 30 s of any work rate. The rationale for 
this, instead of comparing values to resting values, was that muscle pump action, 
expelling blood from muscles towards the heart at the onset of exercise (460), is 
expected to induce rapid temporary changes in NIRS data (238). 
In Study I, particular tissue-specific NIRS inflection points (NIP) were determined 
as follows: 
 
1. Second-by-second data of ∆[O2Hb], ∆[HHb], and TSI were plotted against time 
starting from locomotion at 8 km/h until the end of exercise. The plottings were 
performed for all three tissues of interest (m. vastus lateralis, m. biceps brachii, 
prefrontal cerebral cortex) in every subject. 
2. The sizes and axes of the plotted figures were scaled to be similar and 
comparable with each other (see Appendix 1). 
3. Trend lines were drawn and adjusted to reflect trends throughout the scatter 
plots. 
4. When an angle of ≥15° was observed between consecutive trend lines, the 
intersection of the two trend lines was regarded as an NIP and included in 
further analyses. 
5. A vertical line cutting both the intersection and X-axis (time) was drawn to 
determine the timing of the NIP. 
6. V̇O2 at each NIP was determined as a 30-s average (i.e., time ± 15 s) from 
second-by-second V̇O2 data. 
 
Any determined NIP was included in further analyses on the following condition: 
an angle of ≥15° between consecutive trend lines had to be observed at the same time 
point in all three parameters (∆[O2Hb], ∆[HHb], and TSI). The change of this 
magnitude was interpreted to reflect permanent changes in tissue (de)oxygenation 
trend. In addition, as regards cerebral tissue, inflection points with a rise only in 
∆[HHb] were also included in further analyses. NIPs were named as follows: NIPLegAT 
(i.e., NIP observed in leg muscle and being the closest to AT), NIPLegRC, NIPArmAT, 
NIPArmRC, NIPCerAT, and NIPCerRC, respectively. 
In Study III, %∆[HHb] data were converted to reflect local microvascular blood flow 
in the active vastus lateralis muscle (Q̇VL) as previously described (175-177): local (a-
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v)O2 was estimated from the pattern of %∆[HHb] using published values for muscle 
(a-v)O2, which was hence assumed to equal 10 mL per 100 mL blood during unloaded 
cycling (461) and 18 mL per 100 mL blood at peak exercise (55). Subsequently, 
normalized change in %∆[HHb] was converted to peripheral (a-v)O2 as follows: 
 
(17) Peripheral (a-v)O2 = 10 + (%∆[HHb] / 100%) × 8 
 
where 10 corresponds to the assumption of (a-v)O2 during unloaded cycling and 8 
reflects the assumed change in (a-v)O2 from unloaded cycling to peak exercise. 
Second-by-second Q̇VL was then calculated for each subject of Study III as the 
quotient of V̇O2 (measured) and peripheral (a-v)O2 (Equation 17); this calculation was 
thus based on a regional application of the Fick principle. Notably, the V̇O2 values used 
in this context were time-aligned with %∆[HHb] data by left-shifting the V̇O2 signal by 
20 s to account for the circulatory transit delay between the muscle and the lungs (175). 
Although this 20-s value may not precisely match the circulatory time delay in every 
subjects, it represents a reasonable estimate for the subjects tested (462). 
 
Systemic arterial-venous oxygen difference 
In Studies II and III, where PhysioFlow data on Q̇ were available, C(a-v)O2 was derived 
according to the Fick principle (Equation 2). 
 
 
5.2 EXERCISE TRAINING INTERVENTION (STUDY IV) 
 
A 1-year individualized exercise training intervention in Study IV was performed in a 
real-world setting. After their baseline experiments, the subjects allocated to training 
groups (Figure 11) were given a 30-min lecture containing research-based justification 
for general principles and effects of endurance and resistance training, and general 
instructions  on adjusting carbohydrate and insulin consumption according to physical 
activity. The lectures were given by exercise physiologists to 1-3 subjects at a time and 
also included face-to-face discussions aimed at individual goal setting. The overall goal 
of the intervention was to increase and improve exercise training in real-world 
circumstances according to an individual’s desires and goals, which were set based on 
the individual results of the baseline experiments. 
Throughout the intervention, the subjects were instructed to use HR monitors 
(Suunto t6c, Suunto Oy, Vantaa, Finland; or Polar RS800CX, Polar Electro Oy, 
Kempele, Finland) to collect data on every exercise session in their individual training 
diaries. The collected data included information on duration, energy expenditure, 
exercise modes, and mean HR of the performed exercise sessions. The subjects emailed 
these individual training diaries monthly to the researchers, who subsequently emailed 
individual prescriptive feedback to the subjects. The monthly feedback focused on 
frequency, energy expenditure, duration, modes, intensity, and progression of 
performed exercise training. An exercise mode was considered 1) endurance training if 
it included various dynamic aerobic and/or anaerobic activities performed with a large 
mass of contracting muscles (e.g., walking, jogging, running, cycling, ball games) (22), 
and 2) resistance training if it aimed at improvements in or maintenance of muscular 
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strength, power, and/or endurance (463). Exercise intensity was examined as % of HR 
reserve (% of HR reserve = [mean HR – resting HR] / [peak HR – resting HR] × 100%) 
(463). In this regard, resting HR was the lowest nocturnal HR obtained by Firstbeat 
Bodyguard (Firstbeat Technologies Oy, Jyväskylä, Finland) during the night following 
the baseline CPET, whereas peak HR was the peak HR during the baseline CPET. 
 
 
5.3 STATISTICAL ANALYSES 
 
Data were computed with PASW Statistics 18.0 (IBM Corporation, Somers, NY, USA) 
(Studies I-III) or IBM SPSS Statistics 21 (IBM Corporation, Armonk, NY, USA) (Study 
IV). All data are expressed as mean ± standard deviation (SD), and statistical 
significance was set at P < 0.05. Shapiro-Wilk test was used to check normality and 
data were log-transformed where appropriate. Relationships between any key 
variables were examined by Pearson’s correlation coefficients. 
As regards CPET data, the mean values of the last 30 s at rest, during baseline 
walking (Study I) or unloaded cycling (Studies II-IV), at each speed (Study I) or work 
rate (Studies II-IV), and at peak exercise were included in further analyses. However, 
V̇O2peak was defined as the highest value of a 60-s moving averaging V̇O2 interval. 
Further details of the statistical analyses of Studies I-IV are presented below. 
 
 
5.3.1 STUDY I 
 
NIRS data obtained during CPETs were compared with the values during the last 30 s 
of the 5-min baseline walking. For this purpose, repeated-measures ANOVA with Sidak 
post hoc analysis was used. Temporal coincidence of NIPs with AT and RC was tested 
with paired samples t-test. In addition, particularly for this thesis, one-way ANOVA 
with Games-Howell post hoc analysis was used to compare the extent of exercise-
induced deoxygenation (i.e., exercise-induced change in ∆[HHb] from baseline 
walking to peak exercise) between leg muscle, arm muscle, and cerebral tissue. 
 
 
5.3.2 STUDY II 
 
One-way ANOVA was used to compare descriptive characteristics, cardiovascular 
function at seated rest, profile of glucose metabolism, lipid profile, and CPO between 
PCOS women and controls. Two-way repeated-measures ANOVA was used to evaluate 
whether there were differences in responses to CPET between PCOS women and 
controls: Group×Exercise interactions were assessed, while Group (i.e., PCOS women 
vs. controls) was a between-subjects factor, and Exercise (i.e., unloaded cycling [0 W], 
work rates accomplished by each subject [30 W, 60 W, 90 W, 120 W], peak exercise) 
was a within-subject factor. In a separate analysis, relative intensities (i.e., % of V̇O2peak 
during unloaded cycling [0 W], 25% of V̇O2peak, 50% of V̇O2peak, 75% of V̇O2peak, 100% 
of V̇O2peak) were used as a within-subject factor. Multivariate ANOVA with Bonferroni 
 79 
post hoc analysis was performed to further identify the differences in CPET responses 
between PCOS women and controls. 
The response of Q̇ to acute incremental exercise was determined as follows: the 
means of Q̇ and V̇O2 at six data points (i.e., unloaded cycling [0 W], 30 W, 60 W, 90 
W, 120 W, peak exercise) were calculated separately for PCOS women and controls, 
after which ∆Q̇/∆V̇O2 slopes (i.e., β coefficients) for both subject groups were 
determined by performing a linear regression of Q̇ over V̇O2 at the six data points. The 
∆Q̇/∆V̇O2 slopes were further compared between PCOS women and controls by using 
the method of dummy variables and interaction terms (464): a dummy variable named 
Syndrome was first created so that it took the value 0 for controls and 1 for PCOS 
women. To test whether PCOS influenced the linear regression of Q̇ over V̇O2, an 
interaction term Syndrome×V̇O2 was created and then included in an additional 
multiple linear regression model, where Q̇ was the outcome and Syndrome, V̇O2, and 
Syndrome×V̇O2 were the predictors. Eventually, the contribution of the 
Syndrome×V̇O2 interaction to the model indicated whether the ∆Q̇/∆V̇O2 slopes 
differed between PCOS women and controls. 
 
 
5.3.3 STUDY III 
 
Two-tailed independent samples t-test was overall used to compare men with and 
without type 1 diabetes. Repeated-measures ANOVA with Sidak post hoc analysis was 
used to compare the within-group values of %∆[HHb] and Q̇VL at each work rate with 
those during unloaded cycling. 
 
 
5.3.4 STUDY IV 
 
One-way ANOVA was used for between-group comparisons regarding descriptive 
characteristics and CPET responses at baseline as well as characteristics of exercise 
training. One-way repeated-measures ANOVA was used to evaluate whether within-
group changes from baseline to post occurred in two training groups or Reference 
group. Two-way repeated-measures ANOVA was used to assess whether there were 
between-group differences in changes from baseline to post between the training 
groups: Group×Time interactions were assessed with Group (i.e., men with type 1 
diabetes vs. men without diabetes) as a between-subjects factor and with Time (i.e., 
Baseline, Post) as a within-subject factor. t-test with Bonferroni post hoc analysis was 
then used, if a significant interaction was observed. In case of nonnormally distributed 
data despite log transformation, nonparametric Mann-Whitney U and Wilcoxon 
signed-rank tests were used for between-group and within-group analyses, 
respectively. To evaluate magnitudes of any observed within-group training-induced 
changes, standardized effect sizes (ES) were calculated with threshold values of ≤0.2 
trivial, >0.2 small, >0.6 moderate, and >1.2 large (465). 
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5.3.5 STATISTICAL POWER CALCULATION (STUDIES II-IV) 
 
The main outcome in Studies II-IV was V̇O2peak (mL/min/kg FFM), based on which the 
adequacy of statistical power was evaluated. Two Web-enabled interfaces were used 
for statistical power calculations: One was provided by Decision Support Systems, LP 
(Studies II and III) (466) and the other by Clinical & Translational Science Institute, 
University of California, San Francisco (Study IV) (467).   
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6 RESULTS 
6.1 DESCRIPTIVE CHARACTERISTICS AND BLOOD OXYGEN 
CARRYING CAPACITY 
 
Ages, anthropometric profiles, LTPA, hematologic variables, and flow-volume 
spirometry data of the subjects of Studies I-III are summarized in Table 3. Table 3 also 
presents the data on cardiovascular function at seated rest in Studies II and III. Table 
3 importantly demonstrates that in both Studies II and III PCOS women and men with 
type 1 diabetes, respectively, were matched with their healthy controls for age, 
anthropometry, and LTPA. In addition, no defects (Studies I-III) or between-group 
differences (Studies II and III) were observed in [Hb] or any flow-volume spirometry 
experiments. 
Sections 6.1.1-6.1.3 are complementary to Table 3 and detail the descriptive 
characteristics as well as blood O2 carrying capacity of the subjects of Studies I-III, 
whereas Section 6.1.4 presents the descriptive characteristics of Study IV subjects. 
 
 
6.1.1 STUDY I 
 
The subjects of Study I had a tHb-mass of 928 ± 105 g corresponding to 11.6 ± 1.2 g/kg. 
When individual V̇O2peak values were plotted against individual tHb-mass data and a 
linear regression line was fitted, a tHb-mass change of 1 g was associated with a 3.6 
mL/min change in V̇O2peak (r = 0.83, P < 0.001). 
 
 
6.1.2 STUDY II 
 
Of 15 PCOS women included, four had clinical (hirsutism) and/or biochemical (serum 
testosterone >2.0 nmol/L) hyperandrogenism, all showed oligo- or anovulation, and 
all showed polycystic ovaries on transvaginal ultrasound, in accordance with the 
diagnostic Rotterdam criteria (306). 
Waist (99 ± 6 vs. 95 ± 11 cm, P = 0.246) and hip (115 ± 6 vs. 114 ± 12 cm, P = 0.817) 
circumferences as well as waist-to-hip ratio (0.86 ± 0.07 vs. 0.83 ± 0.08, P = 0.279) 
were similar between PCOS women and controls, respectively. 
No differences between PCOS women and controls were observed for HR, SV, SVi, 
or systolic or diastolic arterial blood pressures at rest, whereas PCOS women had 
higher Q̇ but similar Q̇i at rest relative to controls (Table 3). 
Table 4 summarizes the profile of glucose metabolism and lipid profile of the Study 
II subjects: fasting glucose and insulin, HOMA-IR, low-density lipoprotein and total 
cholesterols, and triglycerides were similar between the groups, while PCOS women 
had lower high-density lipoprotein cholesterol than controls. 
Serum testosterone was 1.4 ± nmol/L, serum SHBG was 40 ± 17 nmol/L, and free 
androgen index was 4.3 ± 4.0 in PCOS women.
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Table 4 Metabolic profile and cardiovascular risk factors of the subjects of Study II. 
 
 PCOS (n = 15) Controls (n = 15) P 
Fasting glucose (mmol/L) 5.4 ± 0.4 a 5.5 ± 0.6 0.814 
Fasting insulin (μU/mL) 12.1 ± 6.9 a 10.0 ± 4.4 0.356 
HOMA-IR 3.0 ± 1.8 a 2.5 ± 1.3 0.442 
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.6 ± 0.4 0.043 
LDL cholesterol (mmol/L) b 3.0 ± 0.8 3.0 ± 0.9 0.764 
Total cholesterol (mmol/L) 4.6 ± 0.7 4.7 ± 0.9 0.604 
Triglycerides (mmol/L) 1.1 ± 0.5 1.0 ± 0.4 0.496 
Data are means ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein. For other abbreviations, 
see the Abbreviations section. 
a n = 14; b Log-transformed for statistical analysis due to nonnormally distributed data. 
 
 
6.1.3 STUDY III 
 
Diabetes duration was 15.0 ± 8.6 years (range: 6.0-28.0 years) in men with diabetes. 
Neither waist (89 ± 8 vs. 88 ± 8 cm, P = 0.776) and hip (101 ± 7 vs. 97 ± 7 cm, P = 
0.312) circumferences nor waist-to-hip ratio (0.88 ± 0.07 vs. 0.90 ± 0.07, P = 0.542) 
differed between men with and men without diabetes, respectively. Similar thickness 
of subcutaneous fat of the vastus lateralis muscle (8 ± 3 vs. 8 ± 3 mm, P = 0.984) was 
measured in men with diabetes and controls, respectively. In addition, men with 
diabetes had higher HbA1c than controls (Table 3). At seated rest, HR, SV, SVi, Q̇, Q̇i as 
well as systolic and diastolic arterial blood pressures were similar between men with 
diabetes and controls (Table 3). 
The difference in absolute BV between men with and without diabetes failed to 
reach statistical significance (6810 ± 382 vs. 7269 ± 904 mL, respectively, P = 0.175). 
However, when BV was scaled to FFM, men with diabetes had lower BV than controls 
(94.0 ± 5.8 vs. 103.0 vs. 5.0 mL/kg FFM, respectively, P = 0.004). 
 
 
6.1.4 STUDY IV 
 
Table 5 presents the descriptive characteristics of the training groups both at baseline 
and after the 1-year training intervention: at baseline, the presented characteristics 
were similar between men with diabetes and controls. Training decreased waist-to-hip 
ratio in controls, increased [Hb] in men with diabetes, increased absolute FVC in both 
groups, increased FVC (% of reference value) in men with diabetes, decreased 
FEV1/FVC in controls, and decreased systolic arterial blood pressure at rest in controls. 
However, no Group×Time interactions were evident (Table 5). 
In addition to the data in Table 5, thickness of subcutaneous fat of the vastus 
lateralis muscle (9 ± 4 vs. 13 ± 7 mm, P = 0.410) as well as resting nocturnal HR (51 ±  
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Table 5 Descriptive characteristics of the training groups of Study IV at baseline and after the 
intervention. 
 
          T1D (n = 8)     Controls (n = 8) P at 
 Baseline Post  Baseline Post Baseline a 
Age (years) 33.4 ± 6.3 34.3 ± 6.4  37.9 ± 7.1 38.9 ± 7.0 0.205 
Diabetes duration (years) 10.5 ± 6.8 
(range: 4.0-24.0) 
11.4 ± 6.9  - - - 
Anthropometry       
   Weight (kg) 80 ± 11 80 ± 12  86 ± 13 86 ± 10 0.340 
   Height (cm) 180 ± 11 180 ± 11  181 ± 6 181 ± 6 0.713 
   BMI (kg/m2) b 24.9 ± 2.8 24.7 ± 3.1  26.3 ± 3.8 26.2 ± 2.8 0.834 
   FFM (kg) 68 ± 10 67 ± 10  67 ± 7 68 ± 6 0.901 
   Body fat (%) 16 ± 5 16 ± 6  21 ± 9 20 ± 7 0.151 
   Waist (cm) 89 ± 6 88 ± 7  95 ± 11 93 ± 9 0.724 
   Hip (cm) 95 ± 10 97 ± 5  98 ± 10 102 ± 9 0.522 
   Waist-to-hip ratio 0.95 ± 0.07 0.91 ± 0.05  0.97 ± 0.07 0.91 ± 0.06* 0.640 
Hematology       
   [Hb] (g/L) 144 ± 6 150 ± 8**  146 ± 3 c 149 ± 10 c 0.661 
   HbA1c (%) 7.3 ± 0.9 c 7.5 ± 1.1 c ‡  - 5.3 ± 0.2 - 
   HbA1c (mmol/mol) 58 ± 10 c 59 ± 11 c ‡  - 34 ± 2 - 
Spirometry       
   FVC (L) 5.5 ± 0.9 5.6 ± 0.9*  5.6 ± 0.7 5.8 ± 0.6* 0.825 
   FVC (% of   
   reference value) 
97 ± 12 99 ± 11*  98 ± 12 102 ± 10 0.773 
   FEV1 (L) 4.5 ± 0.7 4.5 ± 0.7  4.6 ± 0.5 4.6 ± 0.4 0.626 
   FEV1 (% of  
   reference value) 
96 ± 13 96 ± 13  101 ± 11 100 ± 8 0.411 
   FEV1/FVC (%) 82 ± 7 79 ± 6  83 ± 6 80 ± 4** 0.731 
SAP at seated rest (mmHg) 133 ± 14 125 ± 16  128 ± 11 119 ± 10** 0.514 
DAP at seated rest (mmHg) 86 ± 7 84 ± 14  79 ± 16 80 ± 8 0.287 
Data are means ± SD. T1D, men with type 1 diabetes; SAP, systolic arterial blood pressure; DAP, diastolic 
arterial blood pressure. For other abbreviations, see the Abbreviations section. 
a Between-group difference at baseline is evaluated with Group (T1D vs. CON) as a between-subjects factor;                
b Nonnormally distributed data: Nonparametric tests are used to compare the groups at Baseline (Mann-
Whitney U) and Baseline vs. Post (Wilcoxon signed-rank); c n = 7. 
* Significantly (P < 0.05) different from Baseline, ** Significantly (P < 0.01) different from Baseline, ‡ 
Significantly (P < 0.01) different from Controls. 
 
 
9 vs. 47 ± 5 bpm, P = 0.251) were similar for men with diabetes and controls at baseline, 
respectively. 
In men with diabetes, training decreased basal (baseline: 0.35 ± 0.19 IU/kg/d; 
change: -0.06 ± 0.06 IU/kg/d, ES = 1.0, moderate, P = 0.049) but not rapid-acting 
(baseline: 0.30 ± 0.09 IU/kg/d; change: 0.06 ±  0.07 IU/kg/d, P = 0.114) nor total 
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(baseline: 0.65 ± 0.26 IU/kg/d; change: -0.01 ± 0.09 IU/kg/d, P = 0.867) daily insulin 
doses. 
Reference group, which did not participate in the exercise training intervention but 
underwent the same clinical experiments as the training groups, was 28.6 ± 1.0 years 
old, and hence, younger than the training group without diabetes (P = 0.017). Changes 
in anthropometry, hematology, or flow-volume spirometry were not observed in 
Reference group after one year (P > 0.05). 
 
 
6.2 OXYGEN DELIVERY AND UTILIZATION DURING ACUTE 
DYNAMIC EXERCISE 
 
6.2.1 RESPONSES TO CPET IN HEALTHY MEN (STUDY I) 
 
The data on speed and cardiopulmonary responses at peak exercise in the subjects of 
Study I are presented as part of Table 6. In addition, PETCO2 and RER at peak exercise 
were 37.2 ± 4.9 mmHg and 1.09 ± 0.04, respectively. 
The patterns of local (de)oxygenation during incremental exercise are presented in 
Figure 12. In terms of exercise-induced change in ∆[HHb] from baseline walking to 
peak exercise, ∆[HHb] increased 12.2 ± 5.8 μmol/L in leg muscle, 21.9 ± 12.7 μmol/L 
in arm muscle, and 6.2 ± 2.4 μmol/L in cerebral tissue. This implies that deoxygenation 
was greatest in arm muscle, then in leg muscle, and least in cerebral tissue (arm vs. leg, 
P < 0.01; arm vs. cerebral, P < 0.001; leg vs. cerebral, P < 0.001). 
An example of NIP determination is illustrated in Figure 13. For the 22 subjects of 
Study I, a total of 24 NIPs were observed in leg muscle, 36 in arm muscle, 64 in cerebral 
tissue. Of the 24 NIPs observed in leg muscle, seven reflected oxygenation (i.e., 
∆[O2Hb] ↑, ∆[HHb] ↓, and TSI ↑), one was indefinable (e.g., (∆[O2Hb] ↓, ∆[HHb] ↓), 
and 16 reflected deoxygenation (i.e., ∆[O2Hb] ↓, ∆[HHb] ↑, and TSI ↓). In arm muscle, 
six NIPs reflected oxygenation and 30 reflected deoxygenation. In cerebral tissue, 63 
NIPs reflected deoxygenation, while just one was indefinable. 
The data on six tissue-specific NIPs being the closest to AT and RC are presented in 
Table 7. Table 7 reveals no differences between the NIPs closest to AT and AT (P > 
0.05). In terms of the NIPs closest to RC, NIPLegRC did not differ from RC (P = 0.058), 
whereas NIPArmRC (vs. RC, P < 0.001) and NIPCerRC (vs. RC, P < 0.05) did. 
The NIP reflecting acceleration of arm deoxygenation was observed in 10 subjects 
during last two minutes of CPET (63 ± 42 s before exhaustion). In nine of these 
subjects, an accelerated rise also occurred in V̇E 60 ± 72 s before the observed 
acceleration of arm deoxygenation. 
Furthermore, a positive association (r = 0.64, P = 0.001) between the extent of 
exercise-induced leg muscle deoxygenation (i.e., exercise-induced change in ∆[HHb] 
from baseline walking to peak exercise) and tHb-mass was found. By contrast, no such 
association was evident in arm muscle or cerebral tissue.
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Table 7 Data on the six tissue-specific NIRS inflection points being the closest to anaerobic 
threshold (AT) or respiratory compensation point (RC) (Study I). See text for interpretation. 
 
 Subjects (n) V̇O2 (mL/min/kg)  Subjects (n) V̇O2 (mL/min/kg) 
AT 22 34 ± 5 RC 22 43 ± 5 
NIPLegAT 9 34 ± 5 NIPLegRC 9 46 ± 6 
NIPArmAT 6 33 ± 3 NIPArmRC 17 46 ± 6*** 
NIPCerAT 21 33 ± 4 NIPCerRC 19 45 ± 7* 
Data are means ± SD. NIPLegAT, NIRS inflection point observed in leg muscle and being the closest to AT. 
The other five NIPs are named according to the same logic as NIPLegAT. For other abbreviations, see the 
Abbreviations section. 
* Significantly (P < 0.05) different from RC, *** Significantly (P < 0.001) different from RC. 
 
 
 
Figure 12 NIRS recordings from leg muscle (m. vastus lateralis; A-C), arm muscle (m. biceps brachii; 
D-F), and cerebral tissue (prefrontal cortex; G-I) during maximal incremental treadmill 
exercise (Study I). Relative concentration changes in deoxygenated (∆[HHb]; A, D, G) and 
total hemoglobin (∆[tHb]; C, F, I), and tissue saturation index (TSI; B, E, H) as a function of 
locomotion speed (n = 22). * Significantly (P < 0.05) different from baseline walking. 
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Figure 13 Example of the determination of NIRS inflection points (Study I). Relative concentration 
changes in oxygenated (∆[O2Hb]) and deoxygenated hemoglobin (∆[HHb]), and tissue 
saturation index (TSI), as a function of time in cerebral tissue (n = 1). Baseline walking (5 
km/h) begins at 180 s (dash-dot line). In this case, one NIRS inflection point (solid line) has 
been found between the start of locomotion at 8 km/h (dotted line) and the end of exercise 
(dashed line).  
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6.2.2 RESPONSES TO CPET IN WOMEN WITH VERSUS WITHOUT PCOS 
(STUDY II) 
 
As regards Study II, the responses of the main components of the Fick principle 
(Equation 2) to maximal incremental cycling are illustrated in Figures 14A-C. 
Moreover, work rates as well as pulmonary and cardiovascular responses at peak 
exercise are detailed in Table 6. 
A significant Group×Exercise interaction was found for V̇O2 (P = 0.014; Figure 
14A). When scaled to FFM, both peak work rate and V̇O2peak were lower in PCOS 
women than in controls, whereas the differences in unscaled values failed to attain 
significance. At peak exercise, particularly RER (1.12 ± 0.05 vs. 1.12 ± 0.05, P = 0.845) 
but also rating of perceived exertion (20 ± 1 vs. 19 ± 1, P =0.346) were similar between 
PCOS women and controls, respectively, indicating that both groups similarly made 
their maximal effort during CPET (56). 
Table 6 shows how there were no differences between PCOS women and controls in 
variables comprising systemic O2 delivery at peak exercise. The groups attained 
equivalent peak levels of V̇E, and both SpO2 and CaO2 were similarly maintained in the 
groups throughout CPET. In addition, similar profiles of HR, SVi, Q̇i (Figure 14B), 
MAP, and SVRi as a function of work rate were seen in PCOS women and controls 
throughout CPET, while no significant Group×Exercise interactions in these analyses 
were observed. Neither were there between-group differences in HR, EDV, EDVi, SV, 
SVi, EF, Q̇, or Q̇i at peak exercise (Table 6). Accordingly, calculated systemic O2 delivery 
and systemic O2 delivery scaled to FFM were similar in PCOS women and controls at 
peak exercise (Table 6). Furthermore, peak CPO (4.3 ± 0.7 vs. 4.0 ± 0.8 W, P = 0.213) 
and CPOi (0.08 ± 0.01 vs. 0.08 ± 0.01 W/FFM, P = 0.733) were equivalent in PCOS 
women and controls, respectively. Systolic and diastolic arterial blood pressures, MAP, 
SVR, and SVRi were also similar in the groups (Table 6). 
Hyperbolic responses of C(a-v)O2 to CPET were seen in PCOS women and controls 
(Figure 14C). Group×Exercise interaction for C(a-v)O2 (P = 0.075; Figure 14C) 
suggested that there might be true group effects at single work rates regarding C(a-
v)O2. Consequently, peak C(a-v)O2 was lower in PCOS women than in controls (Table 
6). Moreover, the ∆Q̇/∆V̇O2 slope was steeper in PCOS women than in controls (β = 
5.84 vs. β = 5.21, P = 0.004; Figure 14D). 
In a pooled population including both women with and without PCOS, an inverse 
correlation between V̇O2peak (mL/min/kg FFM) and HOMA-IR was observed, but it did 
not reach statistical  significance (r = -0.29, P = 0.066). By contrast, there was a 
significant correlation between V̇O2peak and HOMA-IR in the pooled population (r = -
0.34, P = 0.037), when V̇O2peak was scaled to body weight. When examined separately 
in PCOS women and controls, the correlations between V̇O2peak (mL/min/kg FFM) and 
HOMA-IR were not significant (r = -0.29, P =0.155; r = -0.19, P = 0.247; respectively). 
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Figure 14 Responses of the main components of the Fick principle (i.e., pulmonary O2 uptake [V̇O2] [A], 
cardiac output index [Q̇i] [B], and systemic arterial-venous O2 difference [C(a-v)O2] [C]) to 
maximal incremental cycling (Study II), and linear regression lines showing mean responses 
of cardiac output (Q̇) to increasing V̇O2 during maximal incremental cycling (D) (Study II). 
White triangles (Δ) = PCOS women (n = 15), black triangles (▲) = controls (n = 15). Presented 
work rates include unloaded cycling, work rates accomplished by every subject, and mean 
peak work rate. The P values refer to either the results of two-way repeated-measures 
ANOVA (A-C; * Post hoc significantly [P < 0.05] different from PCOS women) or the 
significantly different ∆Q̇/∆V̇O2 slopes between PCOS women (β = 5.84) and controls (β = 
5.21) (D). See Section 5.3 for further statistical details. 
 
 
6.2.3 RESPONSES TO CPET IN MEN WITH VERSUS WITHOUT TYPE 1 
DIABETES (STUDY III) 
 
V̇O2 and cardiovascular responses to CPET in the subjects of Study III are illustrated 
in Figure 15. Additionally, the Study III data on work rates as well as pulmonary and 
cardiovascular responses at peak exercise are shown in Table 6. 
Men with type 1 diabetes attained lower peak work rate and V̇O2peak than controls. 
Similar RER (1.20 ± 0.06 vs. 1.16 ± 0.03, P = 0.072) between men with diabetes and 
controls, respectively, indicate that the groups similarly made their maximal effort 
 91 
during CPET (56). Peak rating of perceived exertion was also similar between the 
groups (20 ± 1 vs. 19 ± 1, P = 0.698). 
The responses of the variables describing pulmonary function did not differ 
between men with diabetes and controls. Peak V̇E was equivalent in the groups (Table 
6), in addition to which SpO2 and CaO2 were similarly maintained in both groups 
throughout CPET (Table 6, Figure 15B). 
At peak exercise, men with diabetes had lower SVi and Q̇i as well as higher SVRi 
than controls. Thus, calculated systemic O2 delivery scaled to FFM was also reduced 
in the group with diabetes (Table 6). By contrast, the differences in peak HR, EDV, 
EDVi, SV, EF, Q̇, systemic O2 delivery (when expressed as mL/min), systolic and 
diastolic arterial blood pressures, MAP, and SVR between men with diabetes and 
controls failed to reach significance (Table 6). Similar hyperbolic responses of C(a-v)O2 
were seen in the groups throughout CPET (Figure 15H, Table 6). 
BV (mL) correlated with peak EDV (r = 0.45, P = 0.036), peak SV (r = 0.85, P < 
0.001), and peak Q̇ (r = 0.78, P < 0.001) in a pooled population containing both men 
with and without diabetes. Peak EDV/BV (24 ± 5 vs. 23 ± 3 mL/L, P = 0.709) and peak 
SV/BV (16 ± 2 vs. 17 ± 1 mL/L, P = 0.816) quotients were similar for men with diabetes 
and controls, respectively. In men with diabetes, HbA1c correlated inversely with peak 
SVi (Figure 16A) and Q̇i (Figure 16B), whereas the association between HbA1c and 
V̇O2peak (mL/min/kg FFM) missed significance (r = -0.54, P = 0.107), and HbA1c had 
no association with BV scaled to FFM (r = 0.08, P = 0.433). 
Figure 17 illustrates the NIRS profiles of leg muscle deoxygenation and Q̇VL. Leg 
muscle %∆[HHb] increased from unloaded cycling towards high work rates, where it 
reached a plateau, with the exception of one patient with diabetes and four controls. 
Each subject attained the highest %∆[HHb] value (i.e., 100%) at peak exercise. 
%∆[HHb] at moderate work rates tended to be higher in men with diabetes than in 
controls, but no significant differences between the groups were observed for 
%∆[HHb] at any work rate. Q̇VL rose significantly in both groups from unloaded cycling 
towards high work rates; in detail, Q̇VL was similar between the groups at submaximal 
work rates but lower in men with diabetes than in controls at peak exercise (0.19 ± 
0.02 vs. 0.22 ± 0.02, respectively, P = 0.042). 
Peak Q̇VL correlated positively with peak Q̇ in controls (r = 0.74, P = 0.008) but not 
in men with diabetes (r = 0.27, P = 0.281). In addition, HbA1c tended to correlate 
inversely with peak Q̇VL in men with diabetes (Figure 16C).  
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Figure 15 Pulmonary and cardiovascular responses to maximal incremental cycling (Study III). 
Pulmonary O2 uptake (V̇O2) (A), arterial O2 content (CaO2) (B), end-diastolic volume index 
(EDVi) (C), stroke volume index (SVi) (D), heart rate (HR) (E), cardiac output index (Q̇i) (F), 
systemic vascular resistance index (SVRi) (G), and systemic arterial-venous O2 difference 
(C(a-v)O2) (H). White triangles (Δ) = men with type 1 diabetes (n = 7), black triangles (▲) = 
controls (n = 10). Presented work rates include seated rest, unloaded cycling, work rates 
performed by each subject, and mean peak work rate. * Significant (P < 0.05) difference 
between men with type 1 diabetes and controls. 
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Figure 16 Associations between glycosylated hemoglobin A1c (HbA1c) and stroke volume index (SVi) (A), 
HbA1c and cardiac output index (Q̇i) (B), and HbA1c and local microvascular blood flow in the 
vastus lateralis muscle (Q̇VL) (C) in men with type 1 diabetes (Study III). 
 
 
 
 
 
Figure 17 NIRS recordings from leg muscle (m. vastus lateralis) during maximal incremental cycling 
(Study III). Normalized relative concentration changes in deoxygenated hemoglobin 
(%∆[HHb]) (A) and microvascular blood flow (Q̇VL) (B) as a function of work rate. White 
triangles (Δ) = men with type 1 diabetes (n = 7), black triangles (▲) = controls (n = 10). 
Presented work rates include seated rest, unloaded cycling, work rates performed by each 
subject, and mean peak work rate. * Significant (P < 0.05) difference between men with type 
1 diabetes and controls, ‡ Significantly (P < 0.01) different from unloaded cycling, § 
Significantly (P < 0.001) different from unloaded cycling. 
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6.2.4 EFFECTS OF EXERCISE TRAINING ON RESPONSES TO CPET IN MEN 
WITH VERSUS WITHOUT TYPE 1 DIABETES (STUDY IV) 
 
Table 8 shows that in Study IV 1) exercise training was similar in the two training 
groups in terms of frequency, duration, energy expenditure, modes, and intensity; 2) 
training was on average composed of 3-4 endurance training sessions and one 
resistance training session per week; 3) average training intensity was moderate (463); 
and 4) no progression in training was observed within the two training groups. 
At baseline before the training intervention, work rates as well as pulmonary and 
cardiovascular responses at peak exercise, including V̇O2peak (L/min: P = 0.451; 
mL/min/kg: P = 0.974; mL/min/kg FFM: P = 0.120), were similar between men with 
type 1 diabetes and healthy controls (P > 0.05), apart from peak systolic arterial blood 
pressure, which was higher in men with diabetes (Table 9). Training elevated peak 
work rates and V̇O2peak in both groups. Particularly, V̇O2peak (mL/min/kg FFM) rose 
10% ± 7% in men with diabetes (ES = 1.4, large, P = 0.004) and 8% ± 9% in controls 
(ES = 0.89, moderate, P = 0.045). In addition, peak O2 pulsei increased 10% ± 11% in 
men with diabetes (ES = 0.91, moderate, P = 0.032) and 11% ± 10% in controls (ES = 
1.1, moderate, P = 0.018). Group×Time interactions were not significant for any peak 
responses, whereas MAP at peak exercise was overall higher in men with diabetes (P = 
0.016 for the Group effect). 
In men with diabetes, the magnitude of training-induced changes in work rates or 
pulmonary or cardiovascular responses at peak exercise had no associations with 
different characteristics of exercise training (P > 0.05) (variables in Tables 8 and 9 
were examined). By contrast, the associations were consistent in healthy controls: 
percentual change (∆) in peak work rate (W) vs. frequency (r = 0.77, P =0.027), ∆peak 
work rate (W) vs. duration (r = 0.78, P = 0.022), ∆peak work rate (W/kg FFM) vs. 
duration (r = 0.71, P = 0.048), ∆peak O2 pulse vs. endurance training frequency (r = 
0.83, P = 0.043), ∆peak O2 pulse vs. duration (r = 0.72, P = 0.044). The training-
elicited changes in work rates or pulmonary or cardiovascular responses were not 
significantly associated with baseline V̇O2peak (both groups), baseline HbA1c (men with 
diabetes), training-induced change in HbA1c (men with diabetes), or diabetes duration 
(men with diabetes) (P > 0.05). 
At baseline, leg muscle %∆[HHb] and ∆[HHb] at any given work rate were similar 
in men with diabetes and controls (P > 0.05) (Figure 18). Figures 18A-B show that 
training decreased %∆[HHb] at submaximal work rates in controls but not in men with 
diabetes, and one significant Group×Time interaction was observed for %∆[HHb] at 
80 W. Within-group changes and Group×Time interaction for %∆[HHb] at peak 
exercise were not significant (P > 0.05). Figures 18C-D demonstrate that training 
increased ∆[HHb] at peak exercise in controls (ES = 0.48, small, P = 0.039) but not in 
men with diabetes, while significant and borderline significant Group×Time 
interactions were observed for ∆[HHb] at 160 W and peak exercise, respectively. 
Reference group had higher V̇O2peak at baseline (54 ± 10 mL/min/kg FFM) than 
men with diabetes (P = 0.024). V̇O2peak did not change (+3% ± 6%, P = 0.245), no 
within-group changes in peak work rates or pulmonary or cardiovascular responses 
were observed, and no evident changes in %∆[HHb] or ∆[HHb] were seen at any work 
rate in Reference group (P > 0.05). Based on the Reference group data, a typical 
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percentage error for V̇O2peak (mL/min/kg FFM) was 2.9% ± 3.1% (451). Overall, both 
these CPET data as well as the earlier presented data on anthropometry, hematology, 
and spirometry reflect the repeatibility of the methods employed in this study. 
 
 
Table 8 Exercise training performed per month by the training groups during the intervention in Study 
IV. 
 
 T1D (n = 8) Controls (n = 8) P 
Total volume    
   Frequency (training sessions/month) 16 ± 4 18 ± 4 0.454 
   Duration (h:min/month) 16:58 ± 6:07 16:52 ± 4:39 0.967 
   Energy expenditure (kcal/month) 7759 ± 4540 7762 ± 3812 0.462 
Mode    
   Endurance training frequency (sessions/month) 13 ± 4 15 ± 6 a 0.317 
   Resistance training frequency (sessions/month) 3 ± 1  3 ± 3 a 0.927 
Intensity    
   Mean heart rate (bpm) 122 ± 12 122 ± 6 0.994 
   Mean heart rate (% of HRR) 57 ± 5 55 ± 8 0.553 
Progression    
   The 1st third of the intervention:    
   Energy expenditure (kcal/month) b 
 
7749 ± 4583 
 
7206 ± 2179 
 
0.529 
   The 2nd third of the intervention:   
   Energy expenditure (kcal/month) b 
 
6975 ± 3935 
 
8592 ± 5396 
 
0.401 
   The 3rd third of the intervention:   
   Energy expenditure (kcal/month) b 
 
8610 ± 5637 
 
7342 ± 4408 
 
0.753 
Data are means ± SD. T1D, men with type 1 diabetes; HRR, heart rate reserve. 
a n = 6 (two subjects in Controls did not report their exercise modes), b Nonnormally distributed data: 
Nonparametric Mann-Whitney U test is used to compare the groups. 
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Table 9 Effects of the training intervention on work rates and pulmonary and cardiovascular responses 
at peak exercise in Study IV. 
 
 T1D (n = 8)  Controls (n = 8)  
 Baseline Post  Baseline Post P for Group×Time a 
Work rate (W) b 237 ± 34 254 ± 27*  255 ± 17 282 ± 36* - 
Work rate (W/kg FFM) 3.5 ± 0.4 3.9 ± 0.5**  3.8 ± 0.3 4.1 ± 0.4* 0.977 
V̇O2 (L/min) 3.04 ± 0.60 3.27 ± 0.53*  3.22 ± 0.24 3.53 ± 0.46* 0.567 
V̇O2 (mL/min/kg) 38 ± 4 41 ± 3**  38 ± 4 41 ± 5* 0.916 
V̇O2 (mL/min/kg FFM) 45 ± 5 49 ± 6**  48 ± 3 52 ± 5* 0.677 
V̇E (L/min) 130 ± 33 131 ± 31  143 ± 26 146 ± 27 0.750 
SpO2 (%) 96 ± 1 c 97 ± 2 c  95 ± 2 95 ± 2 0.502 
CaO2 (mL O2/L blood) 186 ± 10 c 196 ± 13 c **  185 ± 4 c 190 ± 5 c 0.366 
HR (bpm) 175 ± 11 173 ± 9  184 ± 12 180 ± 13 0.634 
O2 pulse (mL/beat) 18 ± 4 19 ± 3  18 ± 1 20 ± 2** 0.361 
O2 pulsei (mL/beat/kg FFM) 0.26 ± 0.03 0.28 ± 0.03*  0.26 ± 0.02 0.29 ± 0.03* 0.880 
SAP (mmHg) 216 ± 16 d † 217 ± 26 d  193 ± 15 c † 197 ± 23 b, c - 
DAP (mmHg) 113 ± 36 d 101 ± 24 d  100 ± 15 c 80 ± 22 c ** 0.707 
MAP (mmHg) † 147 ± 26 d 140 ± 10 d  131 ± 11 c 119 ± 16 c * 0.758 
Data are means ± SD. T1D, men with type 1 diabetes; SAP, systolic arterial blood pressure; DAP, diastolic 
arterial blood pressure. For other abbreviations, see the Abbreviations section. 
a Between-group difference in change from baseline to post is evaluated with Group (T1D vs. Controls) as a 
between-subjects factor and Time (Baseline, Post) as a within-subject factor; b Nonnormally distributed data: 
Nonparametric tests are used to compare the groups (Mann-Whitney U) and Baseline vs. Post (Wilcoxon 
signed-rank), and use of repeated-measures ANOVA is inappropriate; c n = 7; d n = 6. 
* Significantly (P < 0.05) different from Baseline, ** Significantly (P < 0.01) different from Baseline, † Significant 
(P < 0.05) difference between T1D and Controls. 
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Figure 18 NIRS recordings from leg muscle (m. vastus lateralis) during maximal incremental cycling 
(Study IV). Normalized relative (%∆[HHb]) and relative (∆[HHb]) concentration changes in 
deoxygenated hemoglobin as a function of work rate in men with type 1 diabetes (T1D) (A, C; 
squares; n = 8) and controls (B, D; circles; n = 8) at Baseline (white plots) and after the 1-year 
training intervention (= Post; black plots). Presented work rates include unloaded cycling, work 
rates accomplished by all subjects, and mean peak work rate. * Significant (P < 0.05) within-
group difference between Baseline and Post, ** Significant (P < 0.01) within-group difference 
between Baseline and Post. 
 
 
6.3 STATISTICAL POWER 
 
In Study II, post hoc calculation provided statistical power of 84.5% (two-tailed test) 
or 90.8% (one-tailed test) (alpha <5%) to detect the between-group difference in 
V̇O2peak (40 ± 6 vs. 46 ± 5 mL/min/kg FFM in PCOS women vs. controls) (466). 
Similarly, post hoc calculation in Study III provided statistical power of 87.1% (two-
tailed test) or 92.6% (one-tailed test) (alpha <5%) to detect the difference in V̇O2peak 
(47 ± 5 vs. 56 ± 7 mL/min/kg FFM in men with type 1 diabetes vs. controls) (466). 
 98 
In Study IV, post hoc calculation demonstrated that at least six subjects per training 
group were needed to obtain statistical power of 80% for the observed training-induced 
change in V̇O2peak (∆V̇O2peak = +9% ± +8% in a pooled population [i.e., all 16 trained 
men included in the eventual analyses], two-tailed alpha <5%) (467). 
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7 DISCUSSION 
This thesis comprises four original studies examining integrated components of O2 
delivery and utilization during acute dynamic exercise in both healthy individuals and 
individuals with PCOS or type 1 diabetes. The adaptations induced by long-term 
exercise training have also been evaluated in individuals with type 1 diabetes and 
compared with those in individuals without diabetes. 
In conclusion, while integrated data on local and whole-body responses to maximal 
incremental treadmill exercise in healthy adults were provided by Study I, performing 
maximal incremental cycling exercise revealed early signs of cardiovascular 
dysfunction related to PCOS and type 1 diabetes in Studies II and III, respectively. 
Moreover, long-term adherence to exercise training was particularly found to induce 
similar improvements in cardiorespiratory fitness in adults with and without type 1 
diabetes in Study IV. However, according to the results of Study IV, long-term exercise 
training as such resulted in deficient adaptations of active muscle microvasculature 
and was not able to improve glycemic control in individuals with type 1 diabetes. 
The following Sections 7.1-7.4 explore the details and implications of the findings 
of Studies I-IV and particularly do so from a perspective of the integrated pathway for 
O2 from the atmosphere to the mitochondria. Section 7.5 provides a methodological 
discussion of the thesis, and Section 8 summarizes the main conclusions of the study 
overall. Section 9 eventually discusses future directions. 
 
 
7.1 LOCAL TISSUE-SPECIFIC IMBALANCE BETWEEN OXYGEN 
DELIVERY AND UTILIZATION AS PART OF WHOLE-BODY 
RESPONSE TO ACUTE DYNAMIC EXERCISE (STUDY I) 
 
Study I was the first study to simultaneously examine alveolar gas exchange and local 
O2 delivery and utilization within active muscle, less active muscle, and cerebral tissues 
during maximal incremental treadmill exercise. As tHb-mass of the study subjects was 
also determined, the setting of Study I overall provided a possibility to interpret 
integrated coupling of some key adjustments of whole-body systemic O2 delivery and 
local tissue-specific imbalance between O2 delivery and utilization during acute 
dynamic exercise. Regarding the NIRS data of Study I (as well as those of Studies III 
and IV), it is notable that while local tissue (de)oxygenation depends on SpO2, tissue 
blood volume and flow, and metabolic demand of a tissue of interest, SpO2 remained 
relatively constantly between 95% and 100% at submaximal intensities and averaged 
no less than 93% (i.e., reflecting mild-to-moderate EIAH) at peak exercise. This 
suggests that any changes observed in the NIRS data mainly resulted from alterations 
in tissue blood volume and flow and in local tissue-specific O2 extraction and 
utilization. The findings of Study I are mainly applicable to healthy, relatively fit adult 
men. 
Leg muscle (de)oxygenation patterns observed in Study I are in accordance with 
previous studies that have investigated incremental treadmill exercise (468,469): At 
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the onset of baseline walking, ∆[HHb] decreased below and TSI increased above 
standing levels. These immediate onset responses reflect the expulsion of pooling 
venous blood towards the heart as a result of the activated muscle pump (238,460). 
Subsequently at speeds of ≥8 km/h, ∆[HHb] and TSI gradually increased and 
decreased, respectively, with the increases in locomotion speed, active muscle O2 
demand, and active muscle imbalance between O2 delivery and utilization. A plateau 
of ∆[HHb] near peak exercise was observed in 11 of 22 subjects. Parallel to ∆[HHb] 
and TSI responses, after decreasing at the onset of exercise due to the muscle pump 
activation, ∆[tHb] increased at speeds of ≥8 km/h, reflecting increased leg muscle 
blood volume. However, ∆[tHb] decreased at high intensities (≥12 km/h) in agreement 
with previous findings (468), likely primarily reflecting sympathetically mediated 
vasoconstriction within the active muscle microvasculature. In this regard, it is of 
critical importance to realize that ∆[tHb] is not an estimate of blood flow but just local 
blood volume; hence, the observed decrease in leg ∆[tHb] at high intensities does not 
directly oppose the findings of earlier reports (175-177) or Study III, according to which 
active muscle microvascular blood flow actually seems to accelerate near peak cycling 
exercise. 
When it comes to NIPs observed in active leg muscle, two main findings emerged: 
First, the observed NIPs coincided with AT and/or RC, and second, both NIPLegAT and 
NIPLegRC were manifested only in nine subjects. After the publication of Study I, several 
studies (182-184) have reported a consistent temporal coincidence of the onset of 
active muscle ∆[HHb] plateau and RC during maximal incremental cycling. This 
coincidence has been suggested to be evidence of a whole-body “metabolic boundary 
partitioning heavy from very heavy exercise domains”, the detection of which with 
NIRS technology might be of valuable practical importance (183,184). Simply put, 
these findings together with our results concerning leg NIPs would imply that 
metabolic changes within active muscle tissue are coupled with pulmonary function 
during incremental exercise. However, Boone et al. (470) have very recently concluded 
in their extensive review that despite a consistent correlation between active muscle 
∆[HHb] plateau and RC, relatively large intra- and interindividual variability 
characterizes the findings in the field. As an example, our finding of NIPLegAT and 
NIPLegRC manifesting in only nine of the 22 subjects demonstrates this variability. Thus, 
it is currently unclear whether active muscle and whole-body responses to acute 
dynamic exercise are mechanistically linked and whether local (e.g., leg NIPs) and 
whole-body (e.g., RC) thresholds can be interpreted interchangeably (470). 
Arm muscle (de)oxygenation profile was initiated similarly to the above-described 
leg muscle pattern: ∆[HHb] decreased below and TSI increased above standing levels 
at the onset of baseline walking likely due to arm movements and the concomitantly 
activated muscle pump. Thereafter, at speeds of ≥8 km/h, ∆[HHb] and TSI first 
increased and decreased, respectively, in a moderate manner, which was followed by 
accelerated changes during more strenuous exercise. These findings are consistent 
with previous findings made during incremental cycling (236). Interestingly, the extent 
of exercise-induced deoxygenation was much greater in arm muscle than in leg muscle 
or cerebral tissue, which likely highlights whole-body blood flow redistribution during 
acute dynamic exercise: at high exercise intensities, sympathetically mediated 
vasoconstriction diminishes blood flow in less active muscles (143,144) so that local O2 
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extraction in such tissues needs to increase to guarantee their adequate O2 utilization 
(41). 
As regards NIPs observed in arm muscle, NIPArmAT coincided with AT but was 
evident only in six subjects, suggesting that arm muscle deoxygenation is hardly 
associated with pulmonary function at low exercise intensities. At higher intensities, 
NIPArmRC was observed later than RC. Moreover, a NIP reflecting accelerating arm 
deoxygenation was observed in 10 subjects during the last two minutes of exercise, and 
an accelerated rise of V̇E occurred in nine of those 10 subjects ~one minute before the 
deoxygenation acceleration. Ogata et al. (237) have accordingly observed that the 
magnitude of decrease in O2 delivery to less active muscle is coupled to the magnitude 
of increase in hyperventilation during incremental cycling. Moreover, coupling 
between inactive arm muscle blood flow and respiratory muscle fatigue near peak 
cycling exercise has also been reported after the publication of Study I (144). Such 
associations have been suggested to be due to metabolite accumulation resulting from 
increased anaerobic metabolism and provoking both hyperventilation and decrease in 
O2 delivery to less active muscle (237), likely as a result of increased sympathetic 
outflow (144). On a larger scale, these findings takes us back to one of the two 
fundamental physiological challenges faced during acute dynamic exercise: as 
appropriate maintenance of MAP is always needed, sufficient blood flow to working 
locomotor but also respiratory muscles is guaranteed at the expense of blood flow and 
O2 delivery to less active tissues (22,41,42). 
Cerebral oxygenation response to maximal incremental treadmill exercise, reflected 
by cerebral TSI curve, was predictably rather similar to that observed previously during 
cycling (212): TSI increased from low intensities to the speed of 11 km/h and then 
started declining towards peak exercise. Meanwhile, ∆[HHb] increased exponentially 
along with running speed up to peak exercise after a short initial plateau, indicating an 
accelerating imbalance between prefrontal O2 delivery and utilization. 
Cerebral deoxygenation, reflecting the above-mentioned cerebral O2 imbalance, 
particularly accelerated after RC, demonstrated by NIPCerRC, which followed RC. This 
finding has been repeated by Racinais et al. (471) after the publication of Study I. 
PETCO2 (i.e., a surrogate for PaCO2) began decreasing at RC due to hyperventilation 
as expected (60,64). While decreasing PaCO2 is generally known to induce cerebral 
vasoconstriction (213), we observed no evidence of prefrontal vasoconstriction as 
∆[tHb] just plateaued at high intensities. However, this does not indicate that cerebral 
blood flow would not have decreased in our subjects at high intensities: In fact, it has 
been shown that when cerebral blood flow and ∆[tHb] are measured simultaneously 
during incremental exercise, the former decreases while the latter remains elevated 
near peak exercise, which is likely due to a dominant contribution of increasing 
∆[HHb] to the ∆[tHb] signal (472). Collectively, earlier studies have reported cerebral 
∆[tHb] remaining elevated in trained individuals at peak exercise (212), whereas 
Bhambhani et al. (242) have shown a post-RC decrease in cerebral blood volume (i.e., 
∆[tHb]) in less fit individuals. As discussed earlier in Section 2.1.2.3, this 
interindividual variability of ∆[tHb] levels at peak exercise may at least partly be 
explained by lower chemosensitivity and lower submaximal V̇E of trained individuals, 
which attenuate PaCO2 reduction at high intensities, thus resulting in less cerebral 
vasoconstriction (214). 
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Regarding tHb-mass and its links with the CPET data of Study I, we observed that 
a 1 g change in tHb-mass was associated with a 3.6 mL/min change in V̇O2peak, 
according with previous literature (129). tHb-mass also correlated with the extent of 
exercise-induced leg muscle deoxygenation (i.e., exercise-induced change in ∆[HHb] 
from baseline walking to peak exercise). In other words, based on Equation 11, tHb-
mass correlated with the extent of exercise-induced increase in optical density of leg 
muscle ∆[HHb], as other variables of Equation 11 remain constant during any 
experiment period. Since an increase in tHb-mass is a well-known adaptation to 
endurance training (287), the described correlation is simply explained by associations 
between tHb-mass and local endurance training adaptations taking place in active 
muscles. First, structural vascular adaptations such as capillary proliferation (291) and 
luminal enlargement of arterioles (293) increase intramuscular surface for O2 diffusion 
and shorten diffusion distance. This leads to longer mean blood transit time (102), 
during which more O2 can be extracted (290) and diffused from the microvasculature 
to the active myocytes. Local active muscle O2 extraction may also be enhanced by 
training-induced decreases in blood flow heterogeneity (290). Second, endurance 
training also increases the oxidative capacity of the skeletal musculature via increases 
in mitochondrial content (296,473) and activities of mitochondrial oxidative enzymes 
(296,298). These vascular and mitochondrial adaptations together enable the 
attainment of higher exercise-induced increase in optical density of leg muscle 
∆[HHb]. Herewith, rather than having any independent contribution to the extent of 
exercise-induced leg muscle deoxygenation, tHb-mass simply reflects overall training 
adaptations and is thus strongly associated also with the vascular and mitochondrial 
adaptations. This hypothesis is supported by the finding that no associations between 
tHb-mass and the extent of deoxygenation were observed in arm muscle or cerebral 
tissue; adaptations to endurance training in these tissues are not as obvious as they are 
in active skeletal musculature. 
Overall, Study I describes in healthy adult men how local imbalance between O2 
delivery and utilization in different tissues seems to be physiologically linked to 
alveolar gas exchange (i.e., whole-body) responses to acute treadmill exercise. 
Importantly, the findings closely resembled those observed previously in cycling 
protocols. However, the existing evidence of associations between local tissue-specific 
(de)oxygenation and whole-body exercise responses is overall somewhat variable 
(470). It therefore remains to be confirmed whether local and whole-body adjustments 
are mechanistically linked and whether local (i.e., NIPs) and whole-body (e.g., AT and 
RC) thresholds can be interpreted interchangeably (470). However, the findings of 
Study I for their part form a base for the following discussions of Studies II-IV, which 
examine integrated adjustments to acute dynamic exercise from a viewpoint of disease. 
 
 
7.2 ALTERATIONS IN PERIPHERAL RATHER THAN SYSTEMIC 
ADJUSTMENTS TO ACUTE DYNAMIC EXERCISE IN PCOS 
(STUDY II) 
 
No study before Study II has examined cardiac pump function during acute dynamic 
exercise in women with PCOS. Besides monitoring cardiac pump function, we also 
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determined subjects’ [Hb], measured SpO2, and hence, estimated CaO2 along with 
alveolar gas exchange measurements during our maximal incremental cycling 
protocol. This enabled us to draw integrated (albeit only whole-body data-based) 
conclusions regarding potential early defects in organ systems responsible for O2 
delivery and utilization in overweight and obese PCOS women. The findings of Study 
II can mainly be applied to adult women with PCOS and excess weight but without 
clinically overt cardiovascular disease. In addition, hyperandrogenism did not have a 
major effect on the findings since PCOS women overall had relatively low androgen 
levels, and only 27% (4/15) of them had diagnostic signs of hyperandrogenism. 
We observed 13% lower V̇O2peak in PCOS women than in controls, while HOMA-IR 
did not differ significantly between the groups. An Italian research group has 
previously reported even 48-63% lower V̇O2peak in overweight and obese women with 
PCOS than in age- and BMI-matched healthy women (31-33). Notably, while being 
normoglycemic, PCOS women in those studies have had almost two times higher 
fasting insulin level, hence much higher HOMA-IR, and therefore, a markedly worse 
metabolic profile than PCOS women in our study (31). Two smaller studies (34,35) 
have observed that if exhibiting a similar IR profile, obese women with PCOS might 
also have similar V̇O2peak to that of age- and BMI-matched women without PCOS. As 
the magnitude of IR has also been shown to have a strong inverse association with 
V̇O2peak in PCOS women (31), IR has been suggested to be the leading 
pathophysiological feature affecting V̇O2peak in this patient group. However, V̇O2peak 
has been scaled to body weight in all of these five studies (31-35). This dismisses body 
composition and may introduce a bias against overweight and obese women (456), as 
discussed later in Section 7.5. A negative correlation between FFM-adjusted V̇O2peak 
and HOMA-IR did not reach statistical significance in our study. Instead, when V̇O2peak 
was scaled to body weight, the correlation between V̇O2peak and HOMA-IR in all 
subjects turned out to be significant. Taken together, it seems that the magnitude of IR 
is likely linked to V̇O2peak in overweight and obese women with PCOS but the link 
becomes weaker when the confounding influence of adipose tissue is taken into 
account. This suggests that some pathophysiological features in addition to IR also 
have a significant effect on V̇O2peak in women with PCOS. It must be highlighted, 
however, that such a concluding suggestion carries the caveat of IR being interpreted 
by HOMA-IR in previous studies (31,34,35) as well as in our Study II; when Stepto et 
al. (314) using the “gold standard” hyperinsulinemic-euglycemic clamp method 
reported that PCOS involves intrinsic syndrome-specific IR compared with well-
matched women without PCOS, they did not observe a significant between-group 
difference in HOMA-IR. 
Behind the reduced V̇O2peak, we observed both reduced C(a-v)O2 and a steeper 
∆Q̇/∆V̇O2 slope in PCOS women when compared to controls. C(a-v)O2 also tended to 
be lower in PCOS women than in controls throughout the incremental exercise until 
reaching the significant difference at peak exercise. While SpO2 and CaO2 were 
similarly maintained in the groups throughout the exercise, PvO2 and CvO2 at peak 
exercise must have been higher in PCOS women than in controls after first tending to 
be higher at submaximal intensities. These findings together indicate that PCOS 
women exhibited a pronounced response of Q̇ to increasing O2 utilization from the very 
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beginning of incremental exercise to compensate for alterations in peripheral 
adjustments to exercise. 
Why would PvO2 and CvO2 be higher in PCOS women than in controls during acute 
dynamic exercise, thereby leading to the reduced V̇O2peak? While this question cannot 
be answered by Study II, the answer(s) must lie in derangements of peripheral O2 
delivery and/or utilization. Herewith, the possible answers can be hypothesized in light 
of the integrated pathway for O2. First, endothelial dysfunction, which is an intrinsic 
feature of PCOS (332), has been shown to correlate with reduced exercise capacity in 
women (474). In disease, such a correlation may be due to impaired active muscle 
blood flow during exercise, resulting from reduced bioavailability of NO (333). In fact, 
particularly NO-mediated microvascular vasodilatator dysfunction has recently been 
observed in PCOS (35). In addition, exercise training has been shown to enhance NO-
mediated endothelial function with a parallel improvement in V̇O2peak in obese women 
with PCOS (35). Whether endothelial dysfunction is associated with IR status in PCOS 
remains to be elucidated (332), but endothelial dysfunction and IR do have a well-
acknowledged reciprocal relationship in several disease states (334). Second, exercise-
induced blood flow redistribution may also be pathologically affected by the autonomic 
nervous system dysfunction that is characteristic of PCOS: as sympathetic nerve 
activity has been concluded to be increased in PCOS (336), this might theoretically lead 
to inappropriate distribution of blood flow during exercise so that less active regions 
such as splanchnic regions and less active muscles would receive unnecessarily high 
amounts of flowing blood at the expense of active muscle blood flow. To demonstrate 
pronounced sympathetic outflow, Tekin et al. (335) reported an exaggerated systolic 
blood pressure response to maximal exercise in PCOS women. Contrarily, no such 
exaggeration was evident in our study, but MAP and SVRi were similar between women 
with and without PCOS. This suggests that vascular conductance at the whole-body 
level was not decreased in PCOS women. However, we cannot draw conclusions 
concerning exercise-induced redistribution of blood flow between active muscles and 
less active tissues, because local active muscle blood flow differs considerably from 
systemic circulatory responses during incremental exercise (175). Third and last, but 
not least, in conditions in which there are defects in mitochondrial oxidative 
metabolism, such as in specific myopathies, the findings of reduced V̇O2peak, reduced 
C(a-v)O2, and a pronounced ∆Q̇/∆V̇O2 slope resemble our findings in PCOS women 
(196,197). As already mentioned in Section 2.2.4.1, defects in skeletal muscle insulin 
signaling pathways (317,318) and expression of genes involved in mitochondrial 
oxidative metabolism (319) have been observed in women with PCOS and pronounced 
IR. When present, such mitochondrial dysfunction could potentially reduce 
responsiveness to substrate and O2 utilization within the skeletal musculature, which 
is evident in diabetes-related insulin-resistant metabolic derangements (337). 
However, evidence of potential mitochondrial dysfunction in PCOS is highly 
controversial since intact gene expression (338) and function (339,340) of skeletal 
muscle mitochondria have also been found in women with the syndrome. Therefore, it 
is unclear whether any mitochondrial defect could reduce O2 utilization and thus 
increase CvO2 during exercise in PCOS women in the present study. 
In terms of systemic O2 delivery, alveolar gas exchange hardly sets any limitation as 
SpO2 and CaO2 were similarly maintained in women with and without PCOS 
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throughout the incremental exercise. Furthermore, after exhibiting the pronounced 
response of Q̇ to increasing O2 demand, PCOS women ended up at similar peak levels 
of Q̇ and Q̇i when compared with controls. We also calculated CPO (and CPOi), which 
particularly conveys the hydraulic power of the heart by relating changes in systemic 
blood flow and afterload (454); no differences between PCOS women and controls were 
observed for CPO or CPOi at peak exercise. While cardiac pump function during 
exercise in women with PCOS has never before been estimated, let alone measured, 
previous case-control echocardiographic studies have reported both diastolic (324-
326) and systolic (326,327) dysfunction as well as normal cardiac pump function (328-
330) at rest in women with PCOS. Moreover, there may be an inverse association 
between cardiac function and the severity of IR in PCOS since associations between 
cardiac dysfunction and IR have been observed in women with PCOS (324-327). 
Accordingly, Rees et al. (329) recently reported that diastolic dysfunction is linked to 
IR in overweight and obese women, but is not further contributed by PCOS itself. Thus, 
our finding of similar cardiac function at peak exercise in PCOS women and controls 
might be due to rather similar (and relatively low) HOMA-IR in the groups. These data 
overall indicate that while cardiac pump function has its vital role in the integrated 
pathway for O2 (23-30), the cardiovascular system’s total ability to generate 
appropriate convective blood flow during increasing O2 demand was not further 
diminished in PCOS women. In conclusion, our findings suggest that PCOS per se does 
not contribute to limitations of systemic O2 delivery during exercise. 
Two previous paragraphs can be distilled into Figure 19, which illustrates four 
different possibilities of how the observed reduction of V̇O2peak in PCOS women can be 
explained in light of the integrated model of V̇O2peak (see Section 2.1.3.2). Higher peak 
PvO2 and CvO2 can lead to reduced V̇O2peak in PCOS women via reduced muscle O2 
diffusional capacity (Figure 19A) or reduced mitochondrial metabolic capacity to 
utilize O2 (Figure 19B). In addition, it is possible that both the peripheral derangements 
are present in PCOS, but either reduced diffusional capacity (Figure 19C) or reduced 
metabolic capacity (Figure 19D) finally determines the level of the V̇O2peak reduction. 
It is of note that no limitation of systemic O2 delivery during exercise was observed in 
PCOS women, as already discussed. 
In summary, the findings of Study II revealed reduced V̇O2peak, reduced peak C(a-
v)O2, and a steeper ∆Q̇/∆V̇O2 slope in overweight and obese PCOS women relative to 
well-matched control women without PCOS. In parallel, similar cardiac function at 
peak exercise was observed in the two groups, while CaO2 was also similarly 
maintained in the groups. These observations indicate that PCOS per se is linked to 
alterations in peripheral adjustments to exercise rather than to limitations of systemic 
O2 delivery in overweight and obese women. From a clinical point of view, these 
findings provide important information. First, reduced V̇O2peak can be regarded as an 
independent early sign of overall cardiovascular dysfunction, and hence, have a 
negative impact on the prognosis of women with PCOS in terms of their cardiovascular 
morbidity (268,269). Second, such a reduction of exercise capacity/tolerance and the 
suggested peripheral derangements may indirectly further worsen the cardiovascular 
prognosis as well as the overall health of women with PCOS; they may hypothetically 
decrease adherence to regular exercise, which is highly recommended to be an essential 
part of healthy lifestyle of PCOS women, particularly in overweight and obese 
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individuals (308,309). Third, the pronounced ∆Q̇/∆V̇O2 slope in PCOS women reflects 
pronounced exercise-induced stress on the heart, which may theoretically predispose 
women with PCOS to an increased risk of adverse cardiac events during exercise in the 
long term. 
 
 
 
 
Figure 19 Different possibilities of how the observed reduction of peak pulmonary O2 uptake (V̇O2peak; 
black circles [●]) in PCOS women can be explained in light of the integrated plots of V̇O2 
against partial pressure of muscle venous O2 (PvO2). Notably, no limitation of systemic O2 
delivery during exercise was observed in PCOS women. Instead, higher PvO2, reflecting 
higher venous O2 content, at peak exercise and hence lower V̇O2peak in PCOS women can be 
due to reduced muscle O2 diffusional capacity (A), reduced mitochondrial metabolic capacity 
to utilize O2 (B), or their combinations so that either reduced diffusional capacity (C) or 
reduced metabolic capacity (D) eventually determines the level of the V̇O2peak reduction in 
these women. White circles (○) reflect how reduced metabolic capacity (C) or reduced 
diffusional capacity (D) may be present in PCOS, without determining V̇O2peak. 
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7.3 BOTH SYSTEMIC AND PERIPHERAL CARDIOVASCULAR 
IMPAIRMENTS ARE MANIFESTED DURING ACUTE 
DYNAMIC EXERCISE IN TYPE 1 DIABETES (STUDY III) 
 
The novelty of Study III resided in the simultaneous examination of both systemic and 
peripheral mechanisms contributing to V̇O2 response to acute dynamic exercise in 
patients with type 1 diabetes. Not only were the PhysioFlow method and NIRS 
employed to estimate cardiac pump function and active muscle responses during 
maximal incremental cycling, respectively, but also BV was measured by the CO-
rebreathing method to examine its associations with cardiac responses to incremental 
exercise. This integrated setting provided a possibility to identify and specify potential 
early signs of cardiovascular dysfunction induced by type 1 diabetes. The results of 
Study III are primarily applicable to physically active adult men with relatively well-
controlled type 1 diabetes and no clinically overt micro- or macrovascular 
complications. 
Our finding of 16% lower V̇O2peak in men with diabetes than in controls is rather 
consistent with the ~20% lower V̇O2peak reported previously in adults with type 1 
diabetes (236,375-378). However, the finding disagrees with studies (379-386) that 
have observed similar V̇O2peak in adults with and without type 1 diabetes. As already 
extensively discussed in Section 2.3.4.1, such a discrepancy is likely due to the effect of 
glycemic control on the integrated entity of V̇O2peak: adults with type 1 diabetes are 
likely capable of attaining V̇O2peak similar to that of healthy adults, but this most likely 
depends on them maintaining good glycemic control. To at least weakly support this 
conclusion originally presented by Baldi and Hofman (36), a relatively high albeit 
statistically nonsignificant negative correlation coefficient between V̇O2peak and HbA1c 
(i.e., r = -0.54) was observed in men with diabetes in our study. 
Systemic O2 delivery may decrease V̇O2peak in type 1 diabetes due to impairments of 
both pulmonary (370,378,382,389) and cardiac (371,372,385,389) function. In 
addition, reduced blood O2 carrying capacity may impair systemic O2 delivery and 
hence V̇O2peak in type 1 diabetes (376). In Study III, the levels of SpO2 and CaO2 were 
well maintained in men with and without diabetes throughout the incremental 
exercise, suggesting that pulmonary function had no limiting effect on V̇O2peak. As 
regards cardiac function, earlier studies have demonstrated reduced SV and Q̇ in type 
1 diabetes patients during both submaximal (371,372) and maximal (385,389) exercise. 
Accordingly, we also observed lower SVi and lower Q̇i at peak exercise in men with 
diabetes, indicating decreased cardiac performance. In addition, both peak SVi and 
peak Q̇i correlated inversely with HbA1c. The latter supports previous studies 
(371,384,385) that have reported associations between glycemic control and cardiac 
performance during exercise in type 1 diabetes as well as large registry studies (18,368) 
reporting pronounced heart failure risk in type 1 diabetes patients with poorer glycemic 
control. 
Reduced SV and subsequently diminished overall cardiac function in diabetes are 
primarily due to diastolic, but possibly also systolic (particularly at later stages of the 
disease), dysfunction (15,16). While the overall pathogenesis of this diabetic 
cardiomyopathy phenomenon is poorly understood, the mechanisms behind the 
diabetes-specific diastolic dysfunction include impairments of isovolumic relaxation, 
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ventricular filling/preload, and ventricular compliance (15,16). In Study III, mean 
EDVi in men with diabetes was 9% lower at rest and on average 10% lower during 
exercise than in controls, agreeing with previous findings in adolescents with type 1 
diabetes (371). However, the between-group differences in EDVi failed to reach 
statistical significance, which is discussed later in this section. Reduced diastolic 
function, associated with reduced BV, has previously been observed in adults with type 
2 diabetes (392). Regarding BV, before hypothesizing about the contribution of 
reduced BV to decreased cardiac performance in diabetes, it must be noted here that 
specific mechanisms of diabetes-related reduction of BV are not only beyond the scope 
of this thesis but also largely unknown, and, in fact, reduced BV in patients with 
diabetes remains to be confirmed by larger population studies. However, we did 
observe a 9% lower BV scaled to FFM in men with diabetes than in controls, which is 
congruent with a previous finding from our laboratory (376). Thus, because BV also 
correlated positively with peak values of EDV, SV, and Q̇, it is physiologically justified 
(86,289) to suggest that lower BV reduces reserves of ventricular preload, SV, and Q̇ in 
type 1 diabetes. This emphasis on the reduced preload is further supported by our 
finding of similar peak EDV/BV and peak SV/BV ratios in men with and without 
diabetes. However, no association between HbA1c and BV scaled to FFM was observed 
in men with diabetes. This accords with our previous finding (376) and indicates that 
other more hyperglycemia-related components of diastolic function and SV (e.g., 
impaired ventricular relaxation and/or compliance) were also present in men with 
diabetes and led to the strong inverse associations between HbA1c and cardiac 
performance. Strict interpretation of the data of Study III would suggest that the 
combination of nonsignificantly reduced peak EDVi but significantly reduced peak SVi 
implies impaired peak systolic function in men with diabetes. However, peak EF was 
rather similar between the study groups and no evidence of reduced systolic function 
in men with diabetes was provided. 
As mentioned above, the between-group differences in EDVi failed to reach 
statistical significance both at rest and during exercise. This may partly be due to the 
“derived nature” of the PhysioFlow method, but likely results mainly from diastolic 
dysfunction being evident only in ~30% of otherwise healthy type 1 diabetes adults 
(366,367); these two issues, combined with the relatively small sample size of Study 
III, probably led to the relatively high SD of the observed EDVi values. To interpret the 
missed statistical significance further, it must be remembered that the amount of 
diastolic filling is affected by HR (83). Reduced peak HR has occasionally been 
reported in type 1 diabetes (370,372,391) and is one component of reduced cardiac 
reserve in individuals with diabetes (396,397). Reduced peak HR might be explained 
by hypoglycemia-related reduction of β-adrenoceptor sensitivity (394) and be 
pronounced in patients with diabetes-related autonomic neuropathy (391). In Study 
III, no patient with diabetes had previous evidence of neuropathy. However, it is of 
note that only two patients with diabetes, but six controls, attained age-predicted HR 
(475) at peak exercise, leading to a statistically nonsignificant 6 bpm lower peak HR in 
men with diabetes. 
Reduced Q̇VL, independent of Q̇, was observed in men with diabetes at peak exercise. 
Previously, reduced leg blood flow, independent of Q̇, has been observed in patients 
with type 2 diabetes during submaximal exercise (476). In Study III, men with diabetes 
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also had higher SVRi and tended to have higher systolic arterial blood pressure at peak 
exercise than controls. It is well known that type 1 diabetes is characterized by vascular 
dysfunction manifested as endothelial dysfunction (399), reduced arterial compliance 
(374,400,401), decreased capillary-to-muscle fiber ratio (402,403), and impaired 
microvascular muscle blood flow and O2 diffusional capacity (403-405). Based on the 
combination of these previously reported derangements and our present findings, it 
can be suggested that in men with type 1 diabetes, peripheral vascular dysfunction 
independently limited blood flow and O2 delivery to the active skeletal musculature at 
peak exercise. Importantly, peak Q̇VL tended to correlate inversely with HbA1c in men 
with diabetes and may thus depend on glycemic control. 
Although peak blood flow, and thus, peripheral O2 delivery to active muscles were 
limited in men with diabetes, the C(a-v)O2 response was similar in men with and 
without diabetes throughout the exercise. This is congruent with previous findings in 
adolescents (372) and adult women (384) with type 1 diabetes and indicates that O2 
extraction was not limited at the whole-body level for men with diabetes. The 
combination of reduced peak Q̇VL but preserved peak C(a-v)O2 in men with diabetes 
might be explained by exaggerated fractional O2 extraction from microvascular blood 
flow; reductions of microvascular muscle blood flow (404) and microvascular O2 
partial pressure (477) have been observed in type 1 diabetes rats at rest and suggest 
that fractional O2 extraction from the adjacent blood flow could be higher in active 
muscles of men with diabetes. In addition, as a sign of slower V̇O2 kinetics, before 
attaining a similar steady-state level, microvascular O2 partial pressure has been 
observed to fall more rapidly and to far lower levels during 3-min electrical muscle 
stimulation in rats with type 1 diabetes than in healthy rats (477). These findings 
suggest that if fractional O2 extraction from the adjacent blood flow was higher in men 
with diabetes in our present study, it conceivably was so at rest and immediately after 
each transition from the previous work rate to the next one but not after attaining 
steady state. As we used a step incremental CPET protocol, which enables attaining 
steady state (up to AT) or at least getting close to steady state (after AT) at each 
submaximal work rate (452), it can be concluded that fractional O2 extraction was 
likely similar in the study groups during the last 30 s of each work rate. Thus, diabetes 
hardly affected the method used to quantify Q̇VL at submaximal work rates. If diabetes 
affected the method at peak exercise (i.e., if fractional O2 extraction was higher in men 
with diabetes because of not attaining steady state before volitional exhaustion), it only 
led to underestimating of the between-group difference in peak Q̇VL, not to incorrect 
conclusions. 
As was the case with Study II, all of the above-discussed findings of Study III can 
eventually be interpreted and summarized in light of the integrated model of V̇O2peak 
(see Section 2.1.3.2). Such an interpretation is illustrated by Figure 20 and relies on 
the assumption that peak PvO2 in men with and without diabetes was rather similar at 
peak exercise. In this context, Figure 20 shows how lower V̇O2peak in men with type 1 
diabetes is due to both reduced O2 delivery to active muscles and reduced muscle O2 
diffusional capacity. The latter may at least partly be reflected by the observed 
reduction of peak Q̇VL in men with diabetes, but may also include some other 
unidentified factors such as lower subsarcolemmal mitochondrial content (303). 
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In conclusion, Study III showed that both systemic and peripheral cardiovascular 
impairments were manifested in physically active adult men with type 1 diabetes 
during maximal incremental cycling and led to lower V̇O2peak than in well-matched 
healthy men without any diabetes. Systemically, lower BV has potential to reduce 
capacities of ventricular preload, SV, and Q̇, thereby limiting O2 delivery in individuals 
with diabetes. Peripherally, peak microvascular blood flow within active skeletal 
muscles was observed to be independently reduced in men with diabetes, thus further 
contributing to their reduced V̇O2peak. Importantly, systemic and probably also 
peripheral limitations seem to be associated with HbA1c in type 1 diabetes patients. 
While the early development of cardiac dysfunction in type 1 diabetes has already been 
shown to have significant clinical importance (18), the findings of Study III also have 
clinical importance in many ways and share many similarities with the implications of 
the findings of Study II. First, reduced V̇O2peak independently weakens the prognosis 
of patients with type 1 diabetes in terms of their cardiovascular health (19). Second, 
this reduction of exercise capacity/tolerance may indirectly further worsen the 
cardiovascular prognosis as well as the overall health of type 1 diabetes patients since 
it may hypothetically decrease adherence to regular exercise, which is recommended 
for all patients with the disease (39). In this context of promoting overall health, any 
additional cardiovascular limitation to exercise tolerance is problematic since type 1 
diabetes itself already creates a barrier to physical activity via potential glycemic 
imbalance (478). Third, the observed associations between O2 delivery and HbA1c 
highlight the importance of maintaining good glycemic control. 
 
 
 
Figure 20 Reduced peak pulmonary O2 uptake (V̇O2peak; black circles [●]) in men with type 1 diabetes 
(T1D) explained in light of the integrated plots of V̇O2 against partial pressure of muscle 
venous O2 (PvO2). It is first of note that peak PvO2 in the groups is rather similar reflecting the 
postulate according to which the study groups attained rather similar level of venous O2 
content at peak exercise. In this context, lower V̇O2peak in men with type 1 diabetes is due to 
both reduced O2 delivery to active muscles (arrow 1) and reduced muscle O2 diffusional 
capacity (arrow 2). Apart from the observed reduction of active muscle microvascular blood 
flow at peak exercise, other derangements contributing to reduced diffusional capacity in men 
with type 1 diabetes could not be specified. The white circle (○) reflects how reduced O2 
delivery to active muscles for its part decreases V̇O2peak in men with type 1 diabetes. 
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7.4 EFFECTS OF LONG-TERM EXERCISE TRAINING ON 
RESPONSES TO ACUTE DYNAMIC EXERCISE AND 
GLYCEMIC CONTROL IN TYPE 1 DIABETES (STUDY IV) 
 
Performing laboratory experiments before and after one year of individualized exercise 
training intervention made Study IV the first study to examine training-induced 
adaptations after such a long training period in patients with type 1 diabetes. 
Previously, different cardiovascular and -respiratory adaptations as well as glycemic 
control adaptations induced by training interventions of only six weeks to five months 
have been studied in this patient group (see Table 2). Simultaneous monitoring of 
alveolar gas exchange, SpO2, HR (and thus also peak O2 pulse), as well as continuous 
wave NIRS data during CPET enabled examination of training adaptations from an 
integrated viewpoint with a focus again particularly on different components of O2 
delivery and utilization but also glycemic control. Chiefly, the observations of Study IV 
can be applied to nonathlete adult men with rather well-controlled type 1 diabetes and 
without signs of clinically overt micro- or macrovascular disease. 
The existing evidence on the effects of exercise training on V̇O2peak, glycemic 
control, and thus cardiovascular morbidity in type 1 diabetes has been presented in 
depth in Section 2.3.4.2 and Table 2. Aerobic training interventions of six weeks to five 
months have consistently resulted in 5-27% increases in V̇O2peak in type 1 diabetes 
patients (407-414,432-439). Moreover, three (411,435,436) of those intervention 
studies have compared the extent of training-induced increases in V̇O2peak between 
individuals with and without type 1 diabetes and observed no differences in V̇O2peak 
improvements between the groups. Accordingly, Study IV also showed that V̇O2peak 
increased similarly in men with (+10%) and without (+8%) type 1 diabetes after long-
term adherence to regular exercise training. In light of vast epidemiological evidence 
(19,275), this similar improvement of V̇O2peak in the groups for its part suggests that 
exercise training reduces a risk of cardiovascular complications to a similar extent 
whether one has type 1 diabetes or not. Regarding glycemic control, it has remained 
uncertain whether physical activity has any beneficial influence on HbA1c in type 1 
diabetes (416-421). The findings of Study IV support the data of several earlier short-
term intervention studies (407-410,412-414,433,436-439) and a meta-analysis (421) 
according to which such a glycemic benefit does not exist; HbA1c did not decrease in 
men with diabetes, although the duration of the training intervention was as long as 
one year. This finding further questions whether physical activity has potential benefits 
regarding the occurrence of micro- and macrovascular complications in type 1 diabetes 
since the magnitude of hyperglycemia is known to be a major risk factor for 
cardiovascular disease in type 1 diabetes (18,354,365,368). Regarding the unchanged 
HbA1c, it has been suggested that training-induced reduction of daily insulin 
requirements could partly contribute to the finding (415). This might also be the case 
in Study IV, as a daily dose of basal insulin decreased in men with diabetes as a result 
of the intervention. However, Study IV is a small study and certainly does not provide 
any “end-point data” regarding cardiovascular morbidity. Its findings still accord with 
previous literature and simply indicate that, in adults with type 1 diabetes, 
recreational-like training seems to have a similar influence on V̇O2peak to that in 
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individuals without any diabetes, and a reduction of HbA1c is not a prerequisite for or 
a consequence of an increase in V̇O2peak. 
Regarding different components of V̇O2peak, endurance-type exercise training has 
been shown to improve cardiac pump function in animal models of type 1 diabetes 
(440,441). However, human studies examining training effects on cardiac pump 
function or, on the whole, systemic O2 delivery in type 1 diabetes are sparse. In this 
context, only a single finding of a 10% increase in peak O2 pulse (i.e., a surrogate for 
peak SV (20,123)) has been observed after three months of aerobic training in type 1 
diabetes adults (412). Meanwhile, data on type 2 diabetes patients have shown both 
training-induced improvements (442,443) and no improvements (444,445) in 
myocardial function when assessed by echocardiography parameters. Peak O2 pulsei 
rose in a similar manner in men with (+10%) and without (+11%) type 1 diabetes in 
Study IV. This indirectly suggests a similar improvement in SV, and thus, cardiac pump 
function in the groups (20,123). However, it must be noted that changes in different 
components of peak C(a-v)O2 also affect changes in peak O2 pulse (see Equation 7); in 
this regard, no statistically significant differences in adaptations of peak SpO2, [Hb], 
and therefore, peak CaO2 were observed between the groups in Study IV, whereas CvO2 
was not measured. Thus, acknowledging both the highly surrogate nature of peak O2 
pulse and also its inability to separate diastolic and systolic components of cardiac 
function, the data of Study IV suggest an equivalent net effect of the 1-year training 
intervention on peak systemic O2 delivery in men with and without type 1 diabetes. 
While the integrated nature of V̇O2peak makes V̇O2peak depend also on peripheral O2 
delivery and utilization, two findings of Study IV reflect peripheral vascular defects 
characteristic of type 1 diabetes (374,399-405). First, at peak exercise, MAP was 
pronounced in men with diabetes (i.e., significant Group effect), whereas the 
components of Q̇ (HR and SV estimated roughly by O2 pulse) were similar in men with 
diabetes and healthy men. This suggests higher peak SVR in men with diabetes, hence 
consistent with the findings of Study III. Second, we observed that leg muscle 
%∆[HHb] at submaximal work rates decreased in controls but not in men with 
diabetes, whereas ∆[HHb] at peak exercise increased in controls but not in men with 
diabetes. These NIRS findings agree well with each other and can be interpreted as 
follows: ∆[HHb] at peak exercise increased in controls due to enhanced local 
microvascular O2 extraction capacity, which resulted from previously summarized 
skeletal muscle (i.e., vascular and mitochondrial) adaptations to endurance training 
(see Section 2.1.4.2). This rise in peak ∆[HHb] was for its part reflected by decreases 
in submaximal %∆[HHb], which simply describes local O2 extraction in relation to 
maximal extraction capacity. The training-induced increase in peak ∆[HHb] has 
previously been reported by both cross-sectional (182) and longitudinal (302) studies. 
However, it is a novel finding that such enhancement of local microvascular O2 
extraction capacity was totally absent in men with diabetes. While we have no data to 
explain this in more detail, it can be postulated that the finding must result from 
unidentified diabetes-related maladaptations regarding active muscle O2 delivery and 
utilization. Previously, animal (402) and short-term training intervention (436) 
studies have showed that training-induced capillary proliferation is deficient in type 1 
diabetes patients relative to individuals without diabetes. Thus, it is plausible that the 
longer 1-year training intervention of Study IV also led to such a deficient angiogenic 
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adaptation in men with diabetes, and thereby, to their unchanged muscle 
microvascular O2 extraction. Theoretically, both deficient muscle fiber type 
transformation (from type IIb to IIa or even from IIa to I) and/or unaltered enzymatic 
mitochondrial capacity for oxidative metabolism could also explain the retained level 
of O2 extraction (299). However, while neither of these two possible maladaptations 
can be interpreted by Study IV, at least the latter is highly unlikely since even poorly 
controlled type 1 diabetes patients have displayed a normal training response in 
mitochondrial enzyme activities (435,436). In any case, however, any maladaptations 
at the muscle level in men with diabetes were not sufficiently severe to prevent further 
improvements in exercise capacity (i.e., in peak work rate and V̇O2peak). 
Individually collected training data enabled the examination of associations 
between the characteristics (i.e., dose) and the outcomes (i.e., response) of training: 
While training dose was consistently associated with observed training responses in 
healthy men (e.g., the higher the training volume, the greater the increase in peak work 
rate), no such dose-response associations were evident in men with diabetes. This may 
highlight the need for greater individualization of exercise prescription in type 1 
diabetes (39), although it is noteworthy that the intervention as such was beneficial 
also for men with diabetes despite the lack of obvious dose-response associations. 
To sum up, one-year adherence to exercise training, on average consisting of 3-4 
weekly endurance training sessions and one resistance training session performed at 
moderate intensity and for approximately one hour at a time, led to similar increases 
in V̇O2peak in well-matched adult men with and without type 1 diabetes. This similarity 
was accompanied by equivalent improvements in peak O2 pulse. On the contrary, 
training enhanced NIRS-derived active muscle microvascular O2 extraction at peak 
exercise in controls but not at all in men with diabetes. Meanwhile, training led to no 
reduction of HbA1c in men with diabetes. These findings provide novel evidence of 
clinical importance. First, the similar increases in V̇O2peak and peak O2 pulse suggest 
that an equivalent long-term dose of exercise training reduces an overall risk for 
cardiovascular complications (19,275) and improves cardiac pump function (20,123), 
respectively, to a similar extent in adult men with and without type 1 diabetes. Second, 
however, the lack of improvements in active muscle microvascular O2 extraction in 
men with type 1 diabetes suggests that even long-term training, to this extent, does not 
induce significant adaptations regarding active muscle microvascular O2 delivery and 
utilization in men with diabetes. This maladaptation might be due to deficient capillary 
proliferation and may also be linked to contradictory evidence according to which 
physical activity either is (423) or is not (424) protective against microvascular 
complications in type 1 diabetes. Particularly in this context, it is important to note that 
while improved glycemic control has strongly been proved to decrease the risk of 
microvascular complications (354), even long-term training does not seem to reduce 
HbA1c in type 1 diabetes. Importantly, the lack of associations between training dose 
and responses in men with diabetes may highlight the need for better individualization 
of exercise regimens in type 1 diabetes (39).  
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7.5 METHODOLOGICAL STRENGTHS AND LIMITATIONS 
 
Methodological strengths of this thesis include the use of the various setting of 
noninvasive methods, enabling the examination of O2 delivery and utilization during 
acute dynamic exercise from an integrated viewpoint. Furthermore, matching the 
subject groups (i.e., PCOS women vs. controls [Study II] and men with type 1 diabetes 
vs. controls [Studies III and IV]) carefully for age, anthropometry, LTPA (Studies II 
and III), and baseline V̇O2peak (Study IV) is a strength, minimizing the potential 
confounding effect of these factors on between-group comparisons. Hence, any 
observed between-group differences in Studies II-IV likely reflect disease-related 
differences between healthy individuals and those with PCOS or type 1 diabetes. 
The main methodological limitation of all four original studies is the small number 
of participants, which means that the main results of this thesis overall must be verified 
by further studies with larger populations. This should be done, although the post hoc 
statistical power calculations presented in Section 6.3 naturally indicate that the 
magnitudes of the attained statistical power were adequate. The use of a single 
question to obtain a measure of LTPA is also a methodological limitation. In this 
regard, it is notable that the criterion validity of a single-item measure against more 
quantitative accelerometry has suggested that a single question is a valid method to 
screen physical activity in both men and women (479,480). However, it must be 
acknowledged that more detailed physical activity questionnaires and/or objective 
measuring of physical activity (e.g., accelerometries) are more accurate ways to 
quantify LTPA. While the in-depth discourse of Sections 7.1-7.4 also include some 
methodological discussion, the following paragraphs discuss a few more 
methodological considerations study by study. 
In Study I, the most important methodological detail is perhaps that all of the 
results were interpreted in light of the strict criteria used for NIP determination (see 
Section 5.1.5.3); for instance, seven NIPs in leg muscle were concluded to reflect  
oxygenation (i.e., ∆[O2Hb] ↑, ∆[HHb] ↓, and TSI ↑), although more detailed inspection 
of the data does show that leg muscle ∆[HHb] actually reached “some kind of” plateau 
around RC in 11 subjects. However, the results of Study I can overall be physiologically 
reasonably interpreted and are in accordance with literature published both before and 
after Study I (see Section 7.1). Thus, the criteria used for NIP determination can be 
regarded as appropriate for the aims of Study I. Another methodological note 
concerning this study is that during the treadmill exercise interindividual variability in 
anthropometry as well as different locomotion strategies (e.g., stride frequency, stride 
length) certainly affect muscle recruitment patterns, levels of muscle work, and hence, 
local O2 delivery and utilization responses. Furthermore, not only the NIRS data of 
Study I but also those of Studies III and IV carry the caveat that only the biceps brachii 
(Study I) and the vastus lateralis (Studies I, III, and IV) muscles were under 
examination, while spatial heterogeneity of local O2 delivery and utilization within and 
between muscle groups is well acknowledged (185,186,194). 
In Study II, V̇O2peak scaled to FFM was lower in PCOS women than in controls, 
whereas V̇O2peak expressed as L/min did not differ between the groups, which may raise 
a question as to whether or not V̇O2peak was truly different between the two well-
matched groups. The contribution of adipose tissue to O2 utilization has been shown 
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to be negligible and independent of V̇O2peak (481). Instead, V̇O2peak expressed as L/min 
follows a linear function of FFM (455,456). In addition, Krachler et al. (456) recently 
demonstrated how scaling V̇O2peak data collected during cycling to FFM introduces a 
much smaller bias against overweight and obese women than quantifying V̇O2peak in a 
more traditional manner (i.e., L/min, mL/min/kg body weight), although cycling is not 
a weight-bearing exercise mode. Thus, in Study II involving overweight and obese 
women, V̇O2 was appropriately scaled to FFM to avoid ignoring any differences in body 
size and composition between PCOS women and controls. The superiority of using this 
FFM approach is due to the apparently good ability of FFM to reflect the amount of 
active skeletal muscle mass, which is mainly responsible for O2 utilization during acute 
dynamic exercise; a magnetic resonance imaging study by Abe et al. (482) 
demonstrated strong positive associations both between FFM and total skeletal muscle 
mass and also between FFM and lower leg skeletal muscle mass in normal-weight 
women. Although it is not known whether such studies have been conducted in 
overweight or obese individuals, the above-mentioned findings of Krachler et al. (456) 
strongly suggest that FFM likely reflects the amount of active muscle mass well also in 
individuals with excess weight. One limitation of Study II is the use of feasible HOMA-
IR as a method to assess IR; using an intravenous frequently sampled glucose tolerance 
test or a euglycemic-hyperinsulinemic clamp technique would have provided a more 
sensitive and in-depth assessment of insulin sensitivity. 
The primary methodological limitation of Study III is the use of the assumed values 
of muscle (a-v)O2 (55,461) when estimating Q̇VL. Accepting this limitation, the actual 
patterns of Q̇VL should remain similar to those presented here in Figure 17B unless 
large deviations existed between the actual muscle (a-v)O2 and the published values 
(55,461) used. 
As already mentioned, the comparatively long 1-year duration of the training 
intervention is the main strength and novelty of Study IV. In addition, Study IV is also 
the first longitudinal study to examine the effect of exercise training on active muscle 
deoxygenation profiles in individuals with diabetes. As a shortcoming of Study IV, 
interpreting its findings in light of the integrated model of V̇O2peak was hindered by SV 
and Q̇ not being measured or even estimated by PhysioFlow. Moreover, the allocation 
of the subjects to the training groups was performed in a nonrandom fashion, which 
can also be regarded as a limitation. Such a nonrandom allocation was due to the 
substantial burden on subjects imposed by the relatively long-term intervention, 
including intensive collecting of individual exercise data. While it is acknowledged that 
a randomized design would have been necessary to preclude selection bias, the 
nonrandom allocation hardly had any effect on comparisons between the training 
groups. Lack of consistent progression in training of the training groups may also be 
regarded as a limitation. However, more often than not, such lack of progression is 
certainly characteristic of recreational-like training. Hence, the completed training 
intervention likely reflected real-world circumstances, which was one purpose of Study 
IV. Moreover, the completed training can truly be regarded as “exercise training” 
rather than “habitual exercise” since the subjects changed their physical activity habits, 
and thereby, improved their exercise capacity and cardiorespiratory fitness by ~10%, 
which would hardly have happened if they had just kept on exercising in a similar 
fashion as before the intervention. 
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8 SUMMARY AND CONCLUSIONS 
This study entity examined O2 delivery and utilization during acute dynamic exercise 
in both healthy individuals and individuals with PCOS or type 1 diabetes. Acute 
dynamic exercise was thus used as a tool to identify early signs of cardiovascular 
dysfunction in PCOS and type 1 diabetes. Whether long-term exercise training 
alleviates such early signs related to type 1 diabetes was also assessed. Importantly, all 
of the findings were approached from the perspective of the integrated pathway for O2 
from the atmosphere to the mitochondria. In summary, individuals with PCOS or type 
1 diabetes but without clinically overt cardiovascular disease were characterized by 
early signs of cardiovascular dysfunction, eventually reflected as reduced V̇O2peak. 
Furthermore, long-term adherence to exercise training was partially but not fully able 
to alleviate the early signs of cardiovascular dysfunction associated with type 1 
diabetes. 
 
The main conclusions of the four original studies are specifically as follows: 
 
I Local imbalance between O2 delivery and utilization within active leg 
muscle, less active arm muscle, and cerebral tissues was integrated with 
alveolar gas exchange (i.e., whole-body) responses to maximal 
incremental treadmill exercise in healthy adult men similarly to what has 
previously been reported during maximal incremental cycling. 
 
II In comparison with overweight and obese women without PCOS, reduced 
V̇O2peak, reduced peak C(a-v)O2, and a pronounced ∆Q̇/∆V̇O2 slope but 
otherwise intact systemic O2 delivery were observed in overweight and 
obese PCOS women during maximal incremental cycling. These findings 
indicate that PCOS per se is linked to alterations in peripheral adjustments 
to acute dynamic exercise rather than to limitations of systemic O2 delivery 
in overweight and obese women. 
 
III In comparison with healthy men, reduced peak cardiac pump function, 
being associated with reduced BV, and independently deteriorated peak 
microvascular blood flow within active muscle were observed during 
maximal incremental cycling in adult men with type 1 diabetes. Thus, O2 
delivery is limited both systemically and peripherally during acute 
dynamic exercise in type 1 diabetes, which is further reflected as reduced 
V̇O2peak in this patient group. Importantly, the findings of Study III also 
suggest that both systemic and peripheral limitations are associated with 
glycemic control. 
 
IV The long-term (1-year) individualized exercise training intervention 
improved V̇O2peak and peak O2 pulse similarly in adult men with and 
without type 1 diabetes. By contrast, training had no effect on NIRS-
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derived local active muscle O2 extraction or HbA1c in men with type 1 
diabetes. These findings suggest that adherence to regular exercise 
improves cardiorespiratory fitness, probably cardiac pump function, and 
hence, the overall prognosis of cardiovascular morbidity in type 1 diabetes 
to the same extent as it does in individuals without diabetes. Instead, 
regular exercise, at least to the extent in Study IV, is unable to alleviate 
disease-related defects within active muscle microvasculature or to 
improve glycemic control in this patient group. Importantly, consistent 
associations between training dose and responses were observed in 
healthy men, but not in men with diabetes, highlighting the need for 
greater individualization of exercise prescription in type 1 diabetes. 
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9 FUTURE PERSPECTIVES 
The conclusions summarized in Section 8  provide a basis for future multi-disciplinary 
research to identify more detailed mechanisms underlying the observed early disease-
specific signs of cardiovascular dysfunction. Moreover, while V̇O2peak itself is known to 
be a strong predictor of cardiovascular health (19), detailing the clinical significance of 
the present findings further is also warranted. Examples of large and intriguing 
questions that remain to be answered include the following: What are the defects 
reducing peripheral O2 delivery and/or utilization within active muscle tissue of 
women with PCOS and excess weight? How does the magnitude of IR relate to such 
unidentified PCOS-specific peripheral defects? Can these unidentified PCOS-related 
defects in the periphery be alleviated by chronic exercise training? What are the 
mechanisms that make chronic hyperglycemia lead to such an early development of 
cardiac dysfunction in type 1 diabetes? Can chronic adherence to exercise training 
really reverse or even delay the early development of diabetes-related cardiac 
dysfunction that has recently been shown to have significant clinical importance in 
type 1 diabetes (18)? What features in exercise training could improve microvascular 
dysfunction and/or HbA1c in type 1 diabetes? 
In addition to answering the open scientific questions exemplified above, all 
exercise scientists and clinicians are encouraged to approach any observed responses 
to acute dynamic exercise from the integrated perspective highlighted here instead of 
attempting to answer overly simplified questions like “what single factor limits exercise 
capacity or V̇O2peak?”. Such an integrated approach enables identification of specific 
mechanisms underlying pulmonary and/or cardiovascular dysfunction as well as 
exercise intolerance in terms of a single disease or a single person. This is vital when 
prescribing effective, health-promoting, and safe exercise training to any population or 
individual.  
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win. 
 
 
 
 
After some long days, 
 
Antti-Pekka Rissanen 
Helsinki, April 2017 
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APPENDICES 
APPENDIX 1 SCALING OF THE FIGURES PLOTTED FOR NIP   
DETERMINATION (SEE SECTION 5.1.5.3) 
 
- Figure plotting performed by Microsoft Office Excel 2007 (Microsoft 
Corporation, Redmond, WA, USA). 
- Worksheet zoom level: 100%. 
- Figure titling: Title (e.g., Leg ∆[HHb]) above each figure with bolded Calibri 
font size 18. 
- Figure sizes: 
o Width: 15 intact columns 
o Height: 20 intact rows 
- Figure axes: 
o Leg ∆[HHb] vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Leg ∆[HHb]): height 30 μmol/L 
o Leg ∆[O2Hb] vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Leg ∆[O2Hb]): height 35 μmol/L 
o Leg TSI vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Leg TSI): height 70% (from 20% to 90%) 
o Arm ∆[HHb] vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Arm ∆[HHb]): height 50 μmol/L 
o Arm ∆[O2Hb] vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Arm ∆[O2Hb]): height 55 μmol/L 
o Arm TSI vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Arm TSI): height 90% (from 0% to 90%) 
o Cerebral ∆[HHb] vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Cerebral ∆[HHb]): height 12 μmol/L 
o Cerebral ∆[O2Hb] vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Cerebral ∆[O2Hb]): height 30 μmol/L 
o Cerebral TSI vs. Time 
? x-axis (Time): width 2500 s 
? y-axis (Cerebral TSI): height 55% (from 40% to 95%) 
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